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SUMMARY 
 
MicroRNAs (miRNAs) are a conserved class of small non-coding RNA genes with 19 
to 25 nucleotides in length that are found in all higher eukaryotes as well as some 
DNA viruses. MiRNAs have been elucidated to exert important regulatory functions in 
many biological and pathological processes, by imperfect base pairing to the 3’ 
untranslated region (UTR) of target mRNAs, leading to translational repression or 
mRNA degradation. In the recent years, the rapid development of next generation 
sequencing (NGS) technologies has tremendously enhanced the identification of 
novel miRNA genes as well as the profiling of miRNA expression levels. In this study, 
NGS method has been applied to two different gammaherpesviruses (γ-herpesviruses) 
associated models: Epstein-Barr virus (EBV)-infected nasopharyngeal carcinoma 
(NPC) in human and murine gammaherpesvirus 68 (MHV-68)-infected cell lines from 
mouse. As a result, two novel miRNA precursors from EBV and six novel miRNA 
precursors from MHV-68 have been successfully identified and characterized. In 
addition, the completion of MHV-68 miRNA set has revealed a unique viral tRNA 
(vtRNA)-miRNA-miRNA structure in MHV-68 genome. Furthermore, expression levels 
of the viral miRNAs suggest a distinct pattern during different stages of the viral life 
cycle. On the other hand, the profiling of cellular miRNAs also defined a number of 
miRNAs that have been dysregulated in EBV-positive NPC tissues compared to 
healthy control tissues, and in MHV-68-infected compared to non-infected NIH 3T3 
murine fibroblasts. Among them, miR-15 and miR-16 were upregulated upon EBV or 
MHV-68 infection. The tumor suppressor gene BRCA1 has been revealed to be the 
repressed target protein of miR-15/16 in both models, implying an interesting role of 
miRNAs in the pathogenesis of γ-herpesviruses. Meanwhile, to facilitate the analysis 
of NGS data, an automated software was designed and developed. Additional 
information gained during the analysis processes revealed the possible 
mis-annotations existing in the miRNA registry database, suggesting that the 
definition and characterization of novel miRNA genes has to be performed with much 
more caution. 
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1.  INTRODUCTION 
1.1   MiRNA Genes 
1.1.1 MiRNAs and Ago proteins 
MicroRNAs (miRNAs) are a conserved class of small non-coding RNAs of 
approximately 19 to 25 nucleotides in length, identified from various organisms during 
the recent two decades. MiRNA genes are normally transcribed by RNA polymerase II 
or III as primary transcripts (Borchert et al., 2006; Lee et al., 2004), which are further 
processed into stem-loop structured precursors (pre-miRNA), mainly by the nuclear 
microprocessor complex containing the RNase III Drosha (Lee et al., 2003) and its 
cofactor DGCR8 (Gregory et al., 2004). Pre-miRNAs are then transported by the 
export receptor exportin-5 into the cytoplasm (Lund et al., 2004; Yi et al., 2003), where 
the RNase III Dicer cleaves off the loop of the hairpin, thus creating a short 
double-stranded RNA (Bernstein et al., 2001; Hammond et al., 2000) (Figure 1.1). 
Such intermediates are subsequently unwound, and one strand, referred to as the 
mature miRNA, is loaded into the RNA-induced-silencing-complexes (RISCs) 
(Hutvagner and Zamore, 2002; Mourelatos et al., 2002), while the other strand, 
referred to as miRNA*, is degraded (Khvorova et al., 2003; Schwarz et al., 2003). 
The key players of RISCs in miRNA pathway are members of the Argonaute (Ago) 
protein family (Meister and Tuschl, 2004). Ago genes vary in their numbers among 
species, and can be sub-grouped according to the sequence similarities into Ago and 
Piwi subfamilies (Peters and Meister, 2007). In human, Ago subfamily consists of 
hAgo1-4, which are approximately 100kDa, ubiquitously expressed, and mainly 
function in miRNA pathway. Further studies revealed that, hAgo2, distinct from the 
other three members, possesses endogenous cleavage activity in its catalytic domain, 
thus is able to cleave the fully complementary sequences guided by artificial short 
interfere RNAs (siRNAs) or miRNAs (Liu et al., 2004; Meister et al., 2004b). All four 
hAgo proteins are capable of loading miRNAs and guiding them to the mRNA of target 
proteins. In common cases, miRNAs interact with the target sites in the 3’ 
untranslated region (UTR) of the mRNAs by partial complementarity. It is believed that 
nucleotides 2-8 of the miRNA, referred to as the seed sequence, is important for the 
miRNA-mRNA interaction (Lewis et al., 2005; Rajewsky, 2006). The complementarity 
of seed sequences is the basic idea behind most of the target prediction algorithms 
that are widely used for miRNA target identification. Whether there is any 
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Figure 1.1 Model of miRNA-guided post-transcriptional regulation of gene expression.
Primary miRNA transcripts are processed to miRNA precursors by Drosha in the nucleus. The 
miRNA precursors are then transported into cytoplasm by exportin-5, and further processed by 
Dicer (DCR-1) to the double-stranded RNAs. The strand of mature miRNA is loaded in to 
RNA-induced-silencing-complexes (RISCs). Argonaute (Ago) proteins, the key players of 
RISCs, guide the miRNA to the 3’ UTR of its target mRNA by partial complementarity. The 
expression of target mRNA will be downregulated by different mechanisms. Translation of 
target mRNA is repressed either at initiation or post-initiation stages. The stability of target
mRNAs can be also affected, by activating the decapping and deadenylation complexes, 
leading to mRNA degradation. (modified from (Meister and Tuschl, 2004)) 
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preference of the four hAgo for distinct miRNA or mRNA species association remains 
unclear.  
The expression of target proteins will subsequently be downregulated through 
different mechanisms (Figure 1.1). In animals, miRNAs were reported to repress the 
translational initiation step by interfering with the recognition of the 7-methyl 
guanosine (m7GpppG) cap structure on the mRNAs (Mathonnet et al., 2007; Pillai et 
al., 2005; Thermann and Hentze, 2007). The suppression effect was also observed at 
the post-initiation stage of translation, because miRNAs were found to repress the 
translation-initiated mRNAs by causing ribosomes to exit prematurely from the 
associated mRNAs (Olsen and Ambros, 1999; Petersen et al., 2006). MiRNAs were 
demonstrated to affect the stability of their mRNA targets as well. Deadenylation of the 
poly(A) tail followed by decapping of the m7GpppG cap leads to the degradation of 
target mRNAs (Behm-Ansmant et al., 2006; Wu et al., 2006). The mRNAs targeted by 
miRNAs were illustrated to be localized in processing bodies (P-bodies) in the 
cytoplasm (Liu et al., 2005; Sen and Blau, 2005). The decapping complex (consisting 
of DCP1 and DCP2), required for the mRNA decay inside P-bodies, was revealed to 
be crucial for miRNA-mediated gene silencing (Rehwinkel et al., 2005). GW182 
proteins are the major proteins found in P-bodies, stabilizing the integrity of P-bodies. 
The physical interaction between GW182 and Ago proteins suggested the functional 
link between the cytoplasmic P-bodies and the ability of miRNAs to suppress the 
target mRNAs (Liu et al., 2005; Rehwinkel et al., 2005). The identification and 
characterization of the other RISC components promote the clarification of the whole 
picture of miRNA silencing pathway (Hock et al., 2007; Meister et al., 2005; 
Weinmann et al., 2009).  
 
1.1.2 Identification of miRNA genes and miRNA database 
The small regulatory RNA genes was first identified in Caenorhabditis elegans, and 
described as small temporal RNA (stRNA) by the labs of Ambros and Ruvkun (Lee et 
al., 1993; Wightman et al., 1993). StRNA lin-4 was found important in developmental 
timing by regulating lin-14 mRNA by imperfect base pairing in the 3’ UTR. It was not 
until seven years later that the second stRNA let-7 was discovered in C. elegans 
(Pasquinelli et al., 2000; Reinhart et al., 2000; Slack et al., 2000). Shortly thereafter, 
the small regulatory RNAs were identified to be an abundantly expressed gene class 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001; Reinhart et al., 
2000), and termed as microRNAs (miRNAs). The explosive development of miRNA 
studies soon expanded into the fields of animals, plants, as well as viruses 
  INTRODUCTION 
4 
 
(Lagos-Quintana et al., 2003; Lagos-Quintana et al., 2002; Llave et al., 2002; Pfeffer 
et al., 2004; Reinhart et al., 2002). The identification and characterization of miRNA 
genes from various organisms revealed their feature of evolutionary conservation, 
and their regulatory functions involved in different biological pathways. 
The identification work of novel miRNAs was first carried out by genetic screening 
method, classical small RNA cloning, and sometimes with the assistance of miRNA 
prediction programs (Zhang et al., 2006). This resulted in the discovery of hundreds of 
miRNA genes in the genomes of many model organisms. During the recent few years, 
however, the advent of Next Generation Sequencing (NGS) technologies, which is 
capable of producing large numbers of short sequences at low cost (Metzker, 2010) 
turned out to be an advanced methodology for miRNA identification. Highly improved 
sensitivity of NGS technologies has led to the characterization of formerly 
undetectable, low abundant miRNA genes (Landgraf et al., 2007). 
The rapid identification of new miRNA genes led to the basic need of a public 
database as a reliable storage pool for the up-to-date miRNA sequences, with rational 
rules for nomenclature and useful annotations of sequence characteristics. Although 
several databases emerged at similar time, one of them, the miRBase (Griffiths-Jones, 
2004; Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008), has gradually become 
the most popularly referred database in the literature and in miRNA field. Launched by 
The Wellcome Trust Sanger Institute in 2003, miRBase contained only 506 miRNA 
entries from six organisms when accessible for the first time. Keeping with the 
accelerating pace in miRNA studies, miRBase was also expanding rapidly by 
accepting the registration of novel miRNA genes from publications. The newest 15th 
version of miRBase was just released in April of 2010, with 14197 entries from more 
than 100 organisms, and it’s still growing. 
 
1.1.3 MiRNAs and cancers 
The identification and characterization of miRNA genes has revealed a so far 
unrecognized complexity of gene networks which are important for development, as 
well as other physiological and pathological processes. MiRNAs-guided gene 
regulation was found to be involved in diverse diseases, ranging from the nervous 
system and the cardiovascular system, to the immune system (Latronico and 
Condorelli, 2009; Lodish et al., 2008; Schratt, 2009). Cancers, being one of the 
biggest challenges to the world, are also demonstrated to be associated with miRNA 
dysregulation (Croce, 2009). 
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During the studies of miRNA functions in tumorigenesis, miRNA profiling has become 
a new focus to systemically explore differentially expressed miRNAs (Barbarotto et al., 
2008; Cummins and Velculescu, 2006). The distinct patterns of cellular miRNA 
expression levels are not only useful for disease diagnosis, staging, progression, 
prognosis and response to treatment, but also suggest a list of dysregulated miRNA 
genes that may contribute to the epigenetic regulation of oncogenetic pathway (Lee 
and Dutta, 2009). The alterations in the expression of miRNA genes can be caused by 
various mechanisms, including genomic deletions, amplifications or mutations of 
miRNA loci, epigenetic silencing such as DNA methylation or the dysregulation of 
transcription factors that target specific miRNAs and posttranscriptional modification 
of the miRNA sequences (Croce, 2009). Much effort has been devoted to figure out 
the significant targets of the miRNAs that are responsible for the tumorigenesis as 
well. The overexpressed miRNA genes, often referred to as oncomirs (Cho, 2007; He 
et al., 2005), are frequently found to downregulate tumour suppressor genes, while 
the underexpressed miRNAs lead to the reduced suppression of oncogenes (Croce, 
2009; Kent and Mendell, 2006; Lee and Dutta, 2009). 
Progress in the clarification of miRNA functions also shed light on the research of 
novel cancer therapies. The overexpressed miRNA genes become a new group of 
candidates to be targeted, probably by using antisense miRNA inhibitors, known as 
antagomirs (Kasinski and Slack, 2010; Trang et al., 2008). Furthermore, the 
application of the artificial siRNAs have been discussed and studied for a long time, 
seeking an optimized way to target the upregulated oncogenes (Ashihara et al., 2010). 
However, huge obstacles remain in both methodologies of developing the efficient 
and non-toxic administration approaches (Whitehead et al., 2009), and restraining the 
off-target side-effects (Jackson and Linsley, 2010). 
 
1.2   Gammaherpesvirus and MiRNAs 
1.2.1 Epstein-Barr Virus and Murine Herpesvirus 68 
The herpesvirus family (Herpesviridae) constitutes the large enveloped 
double-stranded DNA viruses, which are divided into three subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae, according to their 
host and tissue specificities, together with their replication characteristics (McGeoch, 
1989). A hallmark of herpesviruses is their ability to establish and maintain the latent 
stages during the infection, wherein the virus genome circularizes and persists as an 
episome, and only very limited viral gene expression takes place (Garcia-Blanco and 
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Cullen, 1991). Epstein-Barr Virus (EBV) and Murine Gammaherpesvirus 68 (MHV-68), 
two model gammaherpesviruses (γ-herpesviruses) respectively infecting human and 
mouse, will be further discussed in the following paragraphs. 
Epstein-Barr Virus was named after its two discoverers when identified from the 
Burkitt’s lymphoma cells more than 40 years ago (Epstein and Barr, 1965; Epstein et 
al., 1965). It is also called Human Herpesvirus 4 (HHV-4). B cells are the main site of 
EBV infection where the latency is maintained (Young and Rickinson, 2004). However, 
EBV is also able to infect some other cell types, such as epithelial cells, mesenchymal 
cells and T cells, mostly evidenced by its association with various diseases (Kutok 
and Wang, 2006). Despite the fact that more than ninety percent of human population 
is infected with EBV since childhood, mostly in a benign and uneventful status, a 
spectrum of diseases varying from tumors (Young and Murray, 2003) to autoimmune 
diseases (Niller et al., 2008), were found to be significantly related with EBV, though 
most of the mechanisms remain to be elucidated. Nasopharyngeal Carcinoma (NPC), 
which occurs in the epithelial lining of the nasopharynx, was constantly detected to be 
infected by EBV (Wei and Sham, 2005). This malignancy has specifically high 
incidence in the area of South East Asia (Busson et al., 2004). The involvement of 
EBV in the transformation and development of NPC has been actively studied to seek 
for novel therapeutic strategies. 
MHV-68 is another popular topic in the γ-herpesvirus studies. Isolated from the murine 
host in 1980 (Blaskovic et al., 1980; Svobodova et al., 1982), it soon attracted much 
interest. Due to the species-specificity of the γ-herpesviruses, pathogenetic studies of 
human infections are restricted. The discovery of the mouse γ-herpesvirus MHV-68 
allows to investigate γ-herpesvirus infection in a small animal model (Simas and 
Efstathiou, 1998). B cells are also the main site wherein MHV-68 resides in its latent 
stage (Sunil-Chandra et al., 1992). In addition, MHV-68 readily establishes, unlike 
EBV, productive infections in a variety of cell lines and thus facilitates the examination 
of de novo lytic infections. Further studies in MHV-68 genome revealed a unique 
region, where eight so-called virus tRNAs (vtRNAs) are located. These vtRNA 
sequences were identified more than ten years ago with their characteristics of the 
homology to the classical A/B box tRNAs (Bowden et al., 1997). These sequences 
were observed to be posttranscriptionally modified as normal tRNAs, however, they 
were never detected to be actually amino-acetylated, and their functions still remain 
unknown. 
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1.2.2 Identification of miRNAs in gammaherpesviruses 
After the miRNA genes had been identified from a number of animals and plants, the 
biologists began to wonder, whether the small-sized, compact viral genome is able to 
encode miRNA genes as well. The first viral miRNA genes were characterized in EBV 
infected B cell lymphomas, though a mutant strain with genomic deletion was utilized 
and the number of EBV miRNA genes was underestimated (Pfeffer et al., 2004). Later 
on, miRNA studies were expanded to different herpesviruses and other dsDNA 
viruses. So far, more than 200 viral miRNA genes have been identified, and they are 
believed to employ the cellular machineries during miRNA processing and functioning 
pathways (Skalsky and Cullen, 2010) (Table 1.1). 
Before the study of this thesis, 23 miRNA genes had been found in EBV, clustering in 
two regions in the genome, BHRF1 and BART regions (Cai et al., 2006; Grundhoff et 
al., 2006; Pfeffer et al., 2004). The BHRF1 miRNAs were detected exclusively during 
the latency III-infected lymphoblasts and induced lytic replication (Cai et al., 2006; 
Xing and Kieff, 2007), while the BART miRNAs were expressed at high levels in 
latently infected epithelial cells and at lower, albeit detectable, levels in B cells (Cai et 
al., 2006; Kim do et al., 2007). In MHV-68, nine miRNA genes had been identified in 
Table 1.1  Numbers of miRNA precursors in herpesviruses. 
Virus Family Virus Host Number of 
pre-miRNAsa 
α-herpesviruses 
HSV-1 (Herpes simplex virus 1) human 16 
HSV-2 (Herpes simplex virus 2) human 18 
MDV-1 (Marek’s disease virus type 1) avian 14 
MDV-2 (Marek’s disease virus type 2) avian 18 
HVT (Herpes virus of turkeys) avian 17 
ILTV (Infectious laryngotracheitis virus) avian 7 
β-herpesviruses 
hCMV (Human cytomegalovirus) human 11 
mCMV (Mouse cytomegalovirus) mouse 18 
γ-herpesviruses 
EBV (Epstein Barr virus) human 23 
rLCV (Rhesus lymphocryptovirus) primate 36 
KSHV (Kaposi sarcoma-associated herpesvirus) human 13 
RRV (Rhesus monkey rhadinovirus) primate 7 
MHV-68 (Mouse Gammaherpesvirus 68) mouse 9 
 
a. Numbers of viral miRNA precursors are according to the newest release v15.0 from 
miRBase. 
b. The table is modified from (Skalsky and Cullen, 2010) 
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the first 6 kilo base-pair (kbp) of the genome, where the eight vtRNA genes are also 
located (Pfeffer et al., 2005). MiRNA studies has been carried out in more than ten 
species of herpesviruses infecting human, mouse, primate and avian, while many of 
them were characterized as miRNA clusters (Boss et al., 2009). Interestingly, distinct 
from the observation in the open reading frames (ORFs) of γ-herpesvirus genomes, 
there is not much conservation found among the identified miRNA genes within the 
γ-herpesvirus family. Only a couple of EBV miRNA genes from both BHRF1 and 
BART clusters show homology to the miRNA genes from Rhesus lymphocryptovirus 
in the primates (Cai et al., 2006; Walz et al., 2010; Yao et al., 2007). 
 
1.2.3 MiRNA functions in gammaherpesvirus infection 
Upon the identification of the significant number of miRNA genes from 
γ-herpesviruses, people have also been making the effort to clarify the roles of viral 
miRNAs during virus infection, replication, and possible pathogenetic processes. 
Some studies revealed that several viral miRNAs were able to target their own mRNA 
transcripts. Ebv-mir-BART2 was shown to downregulate the viral DNA polymerase 
BALF5 (Barth et al., 2008). Other three EBV miRNAs were illustrated to synergistically 
fine-tune the level of the transforming viral latent membrane protein LMP1, so as to 
promote cancer development in NPC (Lo et al., 2007). 
On the other hand, viral miRNAs also suppress the cellular proteins involved in 
various pathways. PUMA, the p53 up-regulated modulator of apoptosis, was 
demonstrated to be targeted by ebv-mir-BART5 in NPC tissues, suggesting a novel 
therapeutic strategy by depleting ebv-mir-BART5 to further sensitize cancer cells in 
response to the proapoptotic reagents (Choy et al., 2008). The miRNAs of BHRF1 
cluster, expressed during latency III, were found to be inversely correlated with levels 
of a cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC (Xia 
et al., 2008). However, compared to the numbers of identified viral miRNAs, the 
validated targets are few (Cullen, 2009). 
Moreover, the changes of cellular miRNAs were examined during the viral infection, 
too. The above mentioned EBV protein LMP1 was shown to induce the level of 
mir-146a through NF-kappa B pathway, thus forms a negative feedback loop to 
modulate the intensity and/or duration of the interferon response (Cameron et al., 
2008b). The oncomir mir-155 was also revealed to be transactivated by LMP1 (Gatto 
et al., 2008; Rahadiani et al., 2008). A few studies have attempted to systematically 
study the cellular miRNA levels in the EBV-infected B lymphomas by microarrays, and 
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suggested a list of cellular miRNAs that have been dysregulated (Cameron et al., 
2008a; Godshalk et al., 2008) 
Nevertheless, miRNA functions in γ-herpesvirus infection have just emerged as an 
important piece in the puzzle of pathogenesis of γ-herpesviruses-related diseases. 
Further studies on viral miRNAs and their targets, as well as the cellular miRNA 
response will promote the development of novel and efficient therapies. 
 
1.3   Next Generation Sequencing and MiRNA Study 
1.3.1 Advent of next generation sequencing 
Automated Sanger Sequencing had been established and applied as the fundamental 
technology to determine DNA sequences in biological studies during the past few 
decades including the break-through accomplishment of the finished-grade human 
genome sequences (2004). However, the dominant position of this classical 
sequencing technology has been challenged over the past five years, whereas 
several revolutionary technologies became broadly available, and elevated genome 
sequencing to next generation. 
Next Generation Sequencing (NGS) technologies, named after the reference of 
Automated Sanger Sequencing as the ‘first-generation’ (Metzker, 2005), constitute 
various advanced strategies in template preparation, sequencing, imaging and data 
analysis, and produce enormous volumes of data in a rapid and inexpensive way. 
Several platforms are currently available on the market, with different features in 
strategic design and data production, leading to the diversities in applications 
(Metzker, 2010). The 454 Sequencing from Roche and the Solexa Sequencing from 
Illumina are the two most popularly applied technologies in the literature, and were 
also utilized in the studies of this thesis, so the basic principles behind the two 
technologies will be explained in further detail. 
 
1.3.2 Working principles of 454 sequencing 
454 Life Sciences, initially founded by Jonathan Rothberg, latterly acquired by Roche 
Diagnostics, released the first next-generation DNA sequencer on the market in 2005 
(Margulies et al., 2005). Its great potential in biological studies was soon 
demonstrated by the Neanderthal Genome Project (Green et al., 2006; Noonan et al., 
2006), followed by the rapidly expanding applications in various fields.  
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Figure 1.2  Working principles of 454 sequencing. (A). Sample amplification is carried out 
by emulsion PCR. A reaction mixture consisting of an oil-aqueous emulsion is created to 
encapsulate bead-DNA complexes into single aqueous droplets. PCR amplification is 
performed within these droplets to create beads containing several thousand copies of the 
same template sequence. (B). Pyrosequencing signal is generated from individual bead in 
PicoTiterPlate wells. DNA-amplified beads are deposited into individual PicoTiterPlate (PTP) 
wells. Additional beads, coupled with sulfurylase and luciferase, are added. As shown in the 
examples, a single type of 2’-deoxyribonucleoside triphosphate (dNTP)—cytosine—is flowing 
across the PTP wells. The fiber-optic slide is directly attached to a high-resolution
charge-coupled device (CCD) camera, which allows detecting the light generated from each 
PTP well undergoing the pyrosequencing reaction. (C). An exemplar diagram of 454 
sequencing result is shown. The light generated by the enzymatic cascade is recorded as a 
series of peaks called a flowgram. The output of DNA sequences is interpreted by the number 
of continuous identical nucleotides in proportion to the height of corresponding signal peaks. 
PPi, inorganic pyrophosphate. (modified from (Metzker, 2010)) 
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454 Sequencing is a large-scale parallel sequencing system. It has fundamentally 
upgraded the capacity of sequencing by the invention of multiplexing the samples by 
emulsion-based PCR (Dressman et al., 2003; Ghadessy et al., 2001; Tawfik and 
Griffiths, 1998). During the template preparation, the single-stranded DNA (ssDNA) 
library is immobilized onto specifically designed DNA Capture Beads, so that each 
bead carries only one unique ssDNA fragment. The bead-bound library is then 
emulsified with amplification reagents in a water-in-oil mixture, resulting in 
microreactors containing only one bead with one unique sample fragment. The 
amplification within the microreactors produces several million copies of each 
fragment bound to the individual bead (Margulies et al., 2005) (Figure 1.2 A).  
The sequencing principle of 454 technology is based on the pyrosequencing method, 
that is, to detect the released pyrophosphate (PPi) during DNA synthesis through a 
cascade of enzymatic reactions, in the form of visible light that is proportional to the 
number of incorporated nucleotides. The newly developed pyrosequencing 
technology emerged as a competitive substitution of the traditional dideoxy chain 
termination technology, with its advantages to sequence at high throughput but low 
cost (Ronaghi et al., 1996; Ronaghi et al., 1998). 454 technology employs the typical 
solid-phase pyrosequencing, immobilizing DNA on beads within a three-enzyme 
system including exo- DNA polymerase, ATP sulfurylase and Luciferase (Margulies et 
al., 2005). 
Moreover, the incorporated design of a PicoTiterPlate device enables the 
simultaneous sequencing of the multiplexed DNA samples, by allowing only one bead 
per well throughout the process of sequencing (Leamon et al., 2003). As a result, a 
unique but enriched chemiluminescent signal is generated from each template strand 
and recorded by the charge-coupled device (CCD) camera within the instrument 
(Figure 1.2 B). These signals will be subsequently interpreted into sequence 
information (Margulies et al., 2005) (Figure 1.2 C). 
The up-to-date 454 Sequencing machine is able to produce 1 million reads with the 
average length of 400 bases within 10 hours (http://www.454.com). The ability of 
producing the longest read length among all available NGS machines highlighted its 
applications in the de novo assemblies of small-size genomes, e.g. from bacteria and 
insects. Its short running time also encourages its utility in the other projects such as 
epigenetics and transcriptome studies (Metzker, 2010). However, the high error rates 
in the homopolymer repeats derived from the detection of non-linear light response 
raise the problems and limitations during the result interpretation. 
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1.3.3 Working principles of Solexa sequencing 
Solexa was the name of the company that has commercialized the NGS machine 
called Genome Analyser (GA) in 2006 and was later acquired by Illumina. The 
working principles behind Solexa Sequencing technology are fundamentally different 
from 454 Sequencing, leading to the distinct features in produced results. 
During template multiplexing preparation, high-density forward and reverse primers 
are covalently attached onto a planar, optically transparent surface, where the ssDNA 
sample fragments are bridge-amplified to form clusters (Bentley et al., 2008; Fedurco 
et al., 2006) (Figure 1.3 A). The sequencing strategy utilized by Solexa GA platform is 
called four-colour Cyclic Reversible Termination (CRT) (Metzker, 2010) (Figure 1.3 B 
and C). CRT is a cyclic method that comprises nucleotide incorporation, fluorescence 
imaging and cleavage (Metzker, 2005). The key feature of terminating DNA synthesis 
after the addition of a single nucleotide in CRT is realized by the application of 
3’-blocked reversible terminators in Solexa Sequencing. Before cleaving and washing 
of blocking group and fluorescent dye, the four colours are detected by total internal 
reflection fluorescence (TIRF) imaging using two lasers with ultra-high resolution 
(Bentley et al., 2008) (Figure 1.3 D). In addition, the sample slide can be partitioned 
into eight channels, allowing simultaneous analysis of independent samples. 
The Illumina/Solexa GA platform is currently dominating the NGS market (Metzker, 
2010). The astonishing ability to produce nearly 2 GB sequence information per day 
(http://www.illumina.com/systems/genome_analyzer.ilmn) has largely promoted its 
diverse applications. However, the short read length of 75 bases and the most 
frequent error of substitutions has raised the problems during its utility in de novo 
genome sequencing.  
 
1.3.4 Small RNA sequencing by NGS 
The production of enormous amount of low-cost short reads makes the NGS 
platforms very powerful in many applications. Among them, NGS was soon employed 
for small RNA sequencing since the length limitations in NGS can be ideally ignored 
when only very short pieces of sequences are desired. The sequencing of small RNA 
libraries was therefore performed in diverse organisms and cell conditions, largely 
promoting the studies in miRNA field (Morozova et al., 2009). 
The sample preparation of small RNA sequencing involves one more step of reverse 
transcription, comparing to the DNA samples. In short, the extracted RNA is first 
size-fractionated according to the length desired, normally by polyacrylamide gel 
electrophoresis (PAGE). Then, the small RNAs are ligated with 5’ and 3’ adaptors, 
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Figure 1.3  Working principles of Solexa sequencing. (A). Sample amplification is 
carried out by solid-phase bridge amplification. The single-stranded, single molecule 
template is initially primed and extended by hybridizing to the primers immobilized on a solid 
support, e.g., the glass slide. The bridge amplification of the immobilized template is 
performed with the immediately adjacent primers to form clusters. (B). The four-colour cyclic 
reversible termination (CRT) method is used during the sequencing procedures. All four 
nucleotides, labeled with a different dye, are incorporated into the DNA sequences of the 
solid-phase-amplified template clusters. Following imaging, a cleavage step removes the 
fluorescent dyes and generates the 3’-OH group using the reducing agent 
tris(2-carboxyethy)phosphine (TCEP) for the next reaction cycle. (C). The chemical structure 
of the modified nucleotide used in Solexa sequencing is depicted. Solexa sequencing uses 
3’-O-azidomethy as the blocking group in the reversible terminator chemistry, as denoted by 
the red chemical structure. This group, attached to the 3’-oxygen of the 2’-deoxyribose sugar, 
is cleavable. The arrow indicates the site of cleavage separating the fluorophore from the 
nucleotide. The blue chemical structure denotes the residual linker structures that are 
attached to the base and accumulate with subsequent cycles. (D). The exemplar four-colour 
images are shown. The highlighted (circled) colour points are the sequencing data from two 
clonally amplified templates, and interpreted as below. (modified from (Metzker 2010)) 
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while there might be slightly modified strategies of using different DNA and RNA 
adaptors. The small RNAs are subsequently reverse transcribed with the universal 
primer to the 3’ adaptor to build the cDNA library, before the regular sample 
multiplexing PCR and automated sequencing steps are conducted (Berninger et al., 
2008). 
Among the huge numbers of reads produced by NGS, people found that, not only the 
sequence information of the small RNAs could be retrieved, but also the quantification 
information of individual small RNA was reserved, represented by the abundance of 
the reads in the library (Wang et al., 2009b). Therefore, NGS soon gained the 
advantage over the classical small RNA cloning with its less hand-on work, less 
sample amount demanded, but much more sequence information produced. 
Meanwhile, NGS of small RNAs also became a competitive substitute of miRNA 
microarrays, for the reason that the design of the microarrays excludes the 
information from the unknown sequences, while NGS technologies generates data 
with integrity (Sharma and Vogel, 2009). 
Nevertheless, NGS technologies applied in small RNA sequencing have some 
inherent problems, mostly derived from the sample preparation stage. The adaptor 
ligation, reverse transcription and PCR multiplexing all might introduce the bias of the 
effectively detectable sequences into the final result (Metzker, 2010). Consequently, 
the idea of direct RNA sequencing without the need to convert RNA into cDNA is also 
being actively carried out by some companies (Ozsolak et al., 2009), and will likely 
join the competition of NGS technologies in near future. 
 
1.3.5 Analysis tools for NGS data 
The emergence of the revolutionary NGS technologies first excited people with its 
huge set of data, which, however, turned out to be a big challenge soon after. The 
enormous amount of the short sequences demanded a more efficient annotation 
strategy, comparing to the process of traditional sequencing data. Different problems 
arose during the analysis of the diverse NGS applications, especially the de novo 
assembly and the fast reference alignment, and people have been seeking the 
optimized solutions with much effort (McPherson, 2009). 
The analysis tools for NGS data have been developed by the platform-designing 
companies, as well as many laboratories and service companies. However, there are 
not many tools publicly available so far. In the field of small RNA sequencing, some of 
the data processing programs became available during the recent two years 
(Fahlgren et al., 2009; Friedlander et al., 2008; Hackenberg et al., 2009; Pantano et 
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al., 2010; Wang et al., 2009a). Most of them were released as interactive web-servers, 
some of which also provided stand-alone versions. The main strategies employed by 
these programs have subtle differences. Some of them, e.g., miRanalyzer and 
SeqBuster, first align all the sequences to the whole genome, annotate the sequences 
according to the genome loci, and directly predict the novel miRNA genes by folding 
the flanking sequences of the un-annotated sequences (Hackenberg et al., 2009; 
Pantano et al., 2010). The other programs, like miRExpress, usually annotate the 
sequences according to the established miRNA databases at first, as one solution to 
accelerate the whole process (Berninger et al., 2008; Wang et al., 2009a). Apart from 
the miRNA frequency data as the outcome in common, some programs provide 
additional information from novel miRNA gene candidates to frequent miRNA variants. 
Nevertheless, none of these programs has become a well-established popular tool in 
the RNA community. Many aspects still need to be improved, such as the flexibility of 
the applied genomes and databases, the simplicity in the result format, and the 
friendliness of the interface. 
 
1.4   Aim of the Thesis 
The advent of NGS in miRNA field promoted many labs to re-visit miRNA expressions 
in many physiological and pathological processes. The application of NGS in small 
RNA studies allows a detailed identification of all miRNA gene candidates in the 
genomes of various species. Furthermore, it provides the information of miRNA 
expression profiles. Here, NGS was employed to analyze EBV and MHV-68 infected 
cells. This was the first time that NGS was utilized for miRNA studies in 
γ-herpesviruses so far. The aim of the study in this thesis is, first, to identify and 
validate potential novel miRNA genes from these viral genomes by NGS technologies; 
second, to study cellular miRNA profiles upon virus infection, and third to characterize 
the interesting miRNA target genes that might contribute to the physiological and 
pathological processes during virus infection. To facilitate the analysis of NGS data, 
an automated software was designed and developed, which can be further utilized for 
other NGS data. Additional information gained during the analysis processes revealed 
the possible mis-annotations existing in the miRNA registry database, suggesting that 
the definition and characterization of novel miRNA genes has to be performed with 
much more caution. 
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2.  RESULT 
2.1  NGS Data Processing Software 
The enormous amount of the read sequences produced by NGS technologies 
demands an automated tool for analysis, for the reason that manual analyzing 
procedures are no more possible to handle the huge data set. To fully employ the 
sequencing ability, the barcode system was designed so that different samples can be 
pooled and sequenced at the same time. Barcode is the sample-specific tag of a few 
nucleotides in the adaptor sequence. After converting the sequencing signal to the 
nucleo-base sequence, the raw data generated from NGS usually include additional 
information, e.g., barcodes, 5’ and 3’ adaptors, which have to be first processed 
before the actual sequences are extracted for analysis (Figure 2.1). The recognition of 
barcode sequences helps to sort the read sequences from different samples. During 
sequences annotation, the miRNA gene information constitutes the most significant 
result of the small RNA libraries, while the annotation to other non-coding RNAs 
(ncRNAs) and genomic sequences reserves the information of degradation products 
and novel miRNA candidates. The sequences of novel miRNA candidates are further 
1. Sort reads according to BARCODE 
2. Remove adaptors from 5-prime and 3-prime 
3. Count frequencies of unique sequences 
4. Annotate sequences according to miRBase 
5. Annotate sequences according other non-coding RNA databases and genomic information 
6. Retrieve flanking genomic sequences of potential novel miRNA and fold by mFOLD 
Figure 2.1  Flow chart of NGS data analysis procedures. The step-by-step procedures 
to process NGS data from raw sequences to final gene annotations and frequency counting 
are depicted here. All the sequencing data studied in this thesis are analyzed based on this 
process. 
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analyzed by retrieving flanking genomic sequences and folding by RNA folding 
program mFOLD (Zuker, 2003) (Figure 2.1). Based on these working procedures, an 
automated software was designed and developed for the analysis of all NGS data 
involved in this thesis. 
There was no software available for analysis of NGS data of small RNA libraries when 
this project began. It was urged to develop an analysis tool, not only capable of 
handling the data set step by step as basic functions, but also able to provide 
interactive platforms so that the results can be produced in the way of interest. To this 
purpose, an interactive software has been developed by using BASIC language of 
RealBasic (https://www.realsoftware.com). Step 1 to Step 5 of the working procedures 
in Figure 2.1 can be realized by the software, with much flexibility, as all functions 
shown in the software main window (Figure 2.2 A). There are many interactive input 
windows in the different functions of the software, where the genomes of interest, the 
barcodes, and the parameters during annotations can be assigned (Figure 2.2 B to D). 
 
  
  
 
Figure 2.2 Interactive platforms of developed software for NGS data analysis. (A). Main 
window of the software is shown. The main functions of the software are described on the 
interactive buttons. (B). The input window for the construction of desired miRNA database is 
shown. The genome names of interest can be added to the list in the window. (C). The input 
window for barcode sorting is shown. The barcodes can be added to the list in the window. 
(D). The parameter window for annotation is shown. Different parameters can be assigned as 
desired. 
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The sequence annotation is carried out on the basis of direct alignment, while the 
sequence information, gene annotation and mismatch number are all reserved for 
further analysis. The main function of the software is to annotate NGS data by miRNA 
gene information from miRBase. A result data set with all miRNA count numbers is 
automatically generated. Furthermore, the information of miRNA hairpin sequences, 
other ncRNAs and genomic sequences, can be produced as desired.  
The development of this software has largely facilitated the analysis of small RNA 
NGS data. 
 
2.2  Analysis of Small RNA Libraries from EBV-infected NPC 
Samples 
The small RNA cloning and NGS approach was first applied to the Nasopharyngeal 
Carcinoma (NPC) samples. NPC cells are known to be constantly associated with 
Epstein-Barr Virus (EBV) (Wei and Sham, 2005). Before this study, EBV genome was 
elucidated to harbor 23 miRNA genes, clustered in BHRF1 and BART regions (Cai et 
al., 2006; Grundhoff et al., 2006; Pfeffer et al., 2005). To explore the roles of EBV 
miRNAs as well as cellular miRNAs in NPC pathogenesis, 454 sequencing 
technology was utilized to study NPC samples together with control tissues. 
 
2.2.1 Small RNA cloning and sequencing from NPC and control samples 
Small RNAs were cloned and sequenced from EBV-positive NPC samples as well as 
control tissues (GEO number GSE14738). Biopsies were taken from the nasopharynx 
Table 2.1  Sequence distribution of small RNA libraries from NPC samples. 
 NPC-1 Control-1 NPC-2 Control-2 
Total reads 25223 16249 22636 19052 
Mapped to human genome 21668 1874 13445 3330 
Mapped to EBV genome 1014 34 1217 0 
Reads of known miRNAs 20019 1269 5980 1445 
Human miRNAs 19262 1242 4889 1445 
EBV miRNAs 757 27 1085 0 
Reads of human ncRNAs 2317 616 8412 1843 
human rRNAs 1294 462 7185 1456 
human tRNAs 156 90 392 117 
human other ncRNAs 867 64 835 270 
 
  RESULT 
19 
 
in an area where there was clinical evidence of tumor, and control tissues were taken 
from clinically normal mucosa from the opposite side of the nasopharynx of the same 
patient. In total, four samples were generated from two patients.  
Altogether, 25,223 sequence reads were obtained for NPC sample 1 (NPC-1) and 
22,636 reads were obtained for NPC sample 2 (NPC-2) that were further grouped 
according to their origins (Table 2.1). For control tissues, there were 16,249 (Control-1) 
and 19,052 (Control-2) sequences generated. Interestingly, only in the NPC tissue, it 
was possible to map 50% of the sequences to the human or the EBV genome. The 
libraries obtained from control tissues contained only a minor portion of human- or 
EBV-derived sequences. The majority of the sequences were derived from bacterial 
genomes, probably due to the bacterial flora in the throat of the patients or the 
contamination of the samples. About 20,000 sequences of NPC-1 and about 6,000 
sequences of NPC-2 were identified as known cellular or viral miRNAs. Notably, the 
libraries from NPC-2 and Control-2 contained significant numbers of other ncRNAs, 
which may indicate sample-specific lower RNA quality (Table 2.1). 
 
2.2.2 Identification of novel EBV miRNA genes 
Then, the data sets were analyzed for novel miRNA candidates. First, the sequences 
that match the EBV genome but have not yet been annotated functionally were 
investigated. Three different small RNAs were found derived from two individual 
Figure 2.3 Schematic locations of putative novel EBV miRNAs in BART miRNA cluster 
of EBV genome. Each box with an arrow indicates an EBV miRNA precursor and its 
transcription direction. The putative new miRNA precursors are depicted in red. The numbers 
in the boxes represent the names of the BART miRNAs. The genomic localization of the 
BHRF1 and BART clusters are indicated schematically in the double-stranded episome. oriP, 
origin of replication. 
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precursors that fold into hairpins and originate from the EBV BART region (Figure 2.3, 
Table 2.2). These miRNA candidates were named as ebv-mir-BART21 and 
ebv-mir-BART22 according to the submission to the miRBase. Interestingly, 
ebv-mir-BART21 is conserved in Rhesus lymphocryptovirus, a common model 
system in the primates for EBV infection (Table 2.2). Furthermore, the star sequences 
from ebv-mir-BART4 and ebv-mir-BART5, which have not been reported in the 
miRBase before, were also detected in NPC samples, suggesting that some viral star 
miRNAs might be functional as well (Table 2.3).  
 
Table 2.2  Novel candidate miRNAs of novel precursors identified from NPC
samples. 
 
 
 
a. Names of the putative new miRNA sequences are according to the submission to miRBase 
(http://www.mirbase.org). 
b. RNA secondary structure prediction and free energy calculation have been done using mFOLD
version 3.2. The miRNA sequences are underlined. Due to the characteristics of 454 sequencing, 
the putative miRNA sequences might extend to the additional “A” at the end. The actual size of the
stem-loop has not been experimentally determined. 
c. The genomic locations of EBV miRNAs are referring to the positions in EBV genome (GenBank 
accession number AJ507799).  
d. rLCV, Rhesus lymphocryptovirus. 
 
 
Table 2.3  Numbers of novel EBV miRNA reads in the libraries. 
Name Sequence 
Reads in libraries 
NPC-1 Control-1 NPC-2 Control-2 
ebv-mir-BART21-5P UCACUAGUGAAGGCAACUAACa 26 1 9 0 
ebv-mir-BART21-3P CUAGUUGUGCCCACUGGUGUUUa 10 1 6 0 
ebv-mir-BART22 UUACAAAGUCAUGGUCUAGUAGU 201 1 80 0 
ebv-mir-BART4* CACAUCACGUAGGCACCAGGUGU 6 0 9 0 
ebv-mir-BART5* GUGGGCCGCUGUUCACCUa 0 0 1 0 
 
a. Due to the characteristics of 454 sequencing, the putative miRNA sequences might have additional 
“A” at the end. 
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2.2.3 Identification of novel human miRNA genes 
In addition, efforts were also made in order to find novel human miRNAs, by analyzing 
the pool of unknown sequences which match the human genome. Indeed, three new 
miRNA genes were identified. Two of them were annotated as hsa-mir-1301 and 
hsa-mir-1307, while this work was in progress. The third one was named as 
hsa-mir-2110 according to the submission to the miRBase (Table 2.4). Hsa-mir-1301 
is located in an intergenic region, whereas hsa-mir-1307 and hsa-mir-2110 reside in 
the 5’ UTRs of protein coding genes (Table 2.4). Additionally, six unidentified miRNA 
star sequences that derive from known miRNA genes and have not been cloned 
before were also found in the libraries (Table 2.5). 
Table 2.4  Novel candidate human miRNAs of novel precursors identified from NPC
samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Names of the putative new miRNA sequences are according to the submission to miRBase 
(http://www.mirbase.org). 
b. RNA secondary structure prediction and free energy calculation have been done using mFOLD
version 3.2. The miRNA sequences are underlined. Due to the characteristics of 454 sequencing, 
the putative miRNA sequences might extend to the additional “A” at the end. The actual size of the 
stem-loop has not been experimentally determined. 
c. The genomic locations of human miRNAs are referring to the positions in human chromosomes 
according to the assembly from GenBank. 
d. mmu, Mus musculus (mouse); ptr, Pan troglodytes (chimpanzee); mml, Macara mulatta (monkey). 
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2.2.4 Validation of novel EBV miRNAs 
In order to further validate the expression of the novel miRNA candidates, Northern 
blotting was performed in the EBV-positive cell lines Jijoye, EREB2.5, C666.1, and 
BL41/B95.8 as well as the EBV-negative B cell line BL41 (Figure 2.2). Probes specific 
to the two arms of ebv-mir-BART21 as well as ebv-mir-BART22 were readily 
Figure 2.4  Expression analysis of novel EBV miRNAs by Northern blotting. (A). Total 
RNAs from EBV-positive Jijoye (lane 1) and BL41/B95.8 (lane 2) cells and EBV-negative 
BL41 cells (lane 3) were blotted onto nylon membranes and hybridized with probes 
complementary to hsa-mir-16, ebv-mir-BART1-5p, ebv-mir-BART4-5p, ebv-mir- BART21-5p, 
ebv-mir-BART21-3p, and ebv-mir-BART22. Novel EBV miRNAs are highlighted in red. (B).
Total RNAs from BL41 (lane 1), Jijoye (lane 2), EREB2.5 (lane3), and C666.1 (lane 4) cells 
were blotted onto a nylon membrane and hybridized with probes complementary to 
ebv-mir-BART21-5p and ebv-mir-BART22. 
 
Table 2.5  Numbers of novel human miRNA reads in the libraries. 
 
Name Sequence 
Reads in libraries 
NPC-1 Control-1 NPC-2 Control-2 
hsa-mir-1301 UUGCAGCUGCCUGGGAGUGa 15 1 5 0 
hsa-mir-1307 ACUCGGCGUGGCGUCGGUCGUGG 22 8 79 22 
hsa-mir-2110 UUGGGGAAACGGCCGCUGAGUGa 3 1 2 3 
hsa-mir-103-2* AGCUUCUUUACAGUGCUGCCUUG 12 1 15 1 
hsa-mir-205* GAUUUCAGUGGAGUGAAGUUCa 15 3 9 5 
hsa-mir-196b* UCGACAGCACGACACUGCCUUCa 0 1 0 0 
hsa-mir-224* AAAAUGGUGCCCUAGUGACUACa 0 0 2 0 
hsa-mir-365-2* AGGGACUUUCAGGGGCAGCUGU 0 0 1 0 
hsa-mir-449b* CAGCCACAACUACCCUGCCACU 1 0 0 0 
 
a. Due to the characteristics of 454 sequencing, the putative miRNA sequences might have 
additional “A” at the end. 
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detectable in Jijoye, EREB2.5, and C666.1 cells, whereas no signal was observed in 
BL41/B95.8 and BL41 cells. Notably, the BL41/B95.8 cell line carries a deletion within 
the BART region where the two novel miRNAs are located (Figure 2.3). The C666.1 
cell line originated from an NPC, and its miRNA pattern closely resembles the EBV 
miRNA pattern in NPC tissues. It is therefore a model cell line for NPC pathogenesis 
(Cheung et al., 1999). 
To further confirm the existence of the new EBV miRNAs in NPC samples, six 
undifferentiated NPC samples and one control tissue were taken to measure the 
expression levels of novel miRNAs. HEK 293 cells served as a negative control 
(Figure 2.5). Since the amount of extracted RNA from the tissues was very low, the 
RNAs were polyadenylated and reverse transcribed (Hurteau et al., 2006), generating 
cDNA from miRNA suitable for qRT-PCR validation. GAPDH mRNA was taken for 
normalization. The background signal from the control tissue sample was set to 1 for 
calculation. On that basis, all six NPC samples gave strong signals for one known 
EBV miRNA (ebv-mir-BART1-5p) and three new EBV miRNAs (ebv-mir-BART21-5p, 
ebv-mir-BART21-3p, and ebv-mir-BART22) tested, indicating that the new EBV 
miRNAs can be detected in a number of NPC samples.
Figure 2.5 Verification of novel EBV miRNA expressions in several NPC samples by 
qRT-PCR. Total RNA was extracted from six undifferentiated NPC samples (1# to 6#), one
tumor negative control tissue samples (neg. control) and HEK cells. Equal amount of RNA was 
polyadenylated and reverse transcribed using an oligo dT-adaptor primer as described 
(Hurteau et al., 2006). One known EBV miRNA (ebv-mir-BART1-5p) and three new EBV 
miRNAs (ebv-mir-BART21-5p, ebv-mir-BART21-3p, ebv-mir-BART22) levels were measured 
with normalization to GAPDH mRNA level. The result from the negative control tissue was set 
as 1. Data is shown in logarithm scale.  
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2.2.5 MiRNA expression analysis suggests an NPC-specific miRNA signature 
MiRNA expression analyses revealed distinct miRNA signatures for different types of 
tumors (Calin and Croce, 2006). In order to establish a miRNA expression profile 
characteristic for NPCs, the viral and cellular miRNAs compositions were examined in 
detail in the individual library from NPC or control tissues. 
Generally, about 5% of the NPC-1 and 19% of the NPC-2 miRNAs were identified as 
EBV miRNAs, indicating that viral miRNAs are highly expressed in NPCs (Figure 2.6). 
Notably, small numbers of EBV miRNAs were present in Control-1 as well, which 
might be due to a minor contamination of the control tissue with tumor tissue (Table 
2.1). 
Figure 2.6  MiRNA composition in NPC samples. Schematic representation of cellular and 
EBV-derived miRNA fractions in NPC tissue samples is shown. 
 
Figure 2.7 Relative abundance of EBV miRNAs in the NPC-1 and NPC-2 libraries.
Individual read numbers are presented as percentages of the total miRNA reads in the 
libraries. 
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Among the EBV miRNAs, high levels of ebv-mir-BART1, ebv-mir-BART4, ebv-mir- 
BART6, ebv-mir-BART7, ebv-mir-BART11, ebv-mir-BART12, and ebv-mir-BART19 as 
well as the new EBV miRNAs ebv-mir-BART21 and ebv-mir-BART22 were found in 
both NPC libraries. Interestingly, no EBV miRNA from the BHRF1 cluster was 
detected in the libraries, suggesting that miRNAs from this region might not be 
involved in NPC pathogenesis (Figure 2.7). 
The most abundant human miRNAs are presented in Figure 2.8. The 20 most 
frequently cloned miRNAs were similar between NPC and control tissues (Appendix 
Table I). However, hsa-mir-320, hsa-mir-17-5p, and hsa-mir-652 were less frequent in 
the libraries from the NPCs than in those from control tissues, suggesting that these 
miRNAs might be downregulated in NPC tissue. On the other hand, the read numbers 
for hsa-mir-23a/b (both miRNAs were indistinguishable in our sequencing data sets), 
hsa-mir-200c, and hsa-mir-27a/b were significantly increased in the NPC tumor 
samples, suggesting specific upregulation of these miRNAs. Consistent with the 
cloning data, hsa-mir-23a/b and hsa-mir-27a/b were known to be processed from the 
same primary transcript. 
Figure 2.8  Cellular miRNA expressions in NPC and control tissue. Cellular miRNAs 
hsa-mir-23a/b, hsa-mir-200c, and hsa-mir-27a/b are upregulated in NPC tissues. 
Hsa-mir-320, hsa-mir-17-5p, and hsa-mir-652 are more abundant in small RNA libraries from 
control tissue samples. The criteria for miRNA selection were a 1.8-fold change in both 
patients and at least 1% abundance in two of the four samples. MiRNA read numbers are 
shown as percentages of the total miRNA reads in the libraries. 
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2.2.6 Misregulated miRNAs hsa-mir-15a and hsa-mir-16 inhibit expression of 
tumor suppressor BRCA1 
Next, the potential targets of the miRNAs that are mis-expressed in the two NPC 
libraries were analyzed. In both NPC samples, expressions of hsa-mir-15a and 
hsa-mir-16, which are derived from one primary transcript, were upregulated (Figure 
2.9). Indeed, bioinformatic predictions identified target sites for hsa-mir-15a and 
hsa-mir-16 in the 3’UTR of the tumor suppressor BRCA1 (Breast Cancer 1) (Figure 
2.10 A). Therefore, high levels of hsa-mir-15a and has-mir-16 may lead to low levels 
of BRCA1, resulting in low tumor suppressor activity and tumor growth in NPC cells.  
In order to analyze the effects of hsa-mir-15a and hsa-mir-16 on BRCA1 expression, 
the BRCA1 3’ UTR was fused to a firefly-renilla dual luciferase reporter. The reporter 
plasmid was transfected into HEK 293 cells together with 2’-O-Methylated (2’OMe-) 
antisense inhibitors against endogenous hsa-mir-15a or hsa-mir-16 (Meister et al., 
2004a). Indeed, luciferase expression was elevated when endogenous hsa-mir-15a 
or hsa-mir-16 was inhibited, suggesting that BRCA1 is regulated by hsa-mir-15a and 
hsa-mir-16 (Figure 2.10 B). 
To further validate a functional interaction of the miRNA pathway with the BRCA1 
mRNA, the binding of Ago proteins to the BRCA1 mRNA was investigated. It was 
shown that miRNA target mRNAs can be immunoprecipitated and identified using 
antibodies against Ago proteins (Beitzinger et al., 2007; Easow et al., 2007; 
Hendrickson et al., 2008; Karginov et al., 2007). Endogenous Ago1 and Ago2 
complexes were immunoprecipitated from a HEK 293 cell lysate by using Ago1- and 
Ago2-specific antibodies, and co-immunoprecipitated mRNAs were analyzed by 
qRT-PCR. As shown in Figure 2.10 C, BRCA1 mRNA was coimmunoprecipitated with 
 
Figure 2.9 Expressions of hsa-mir-15a and hsa-mir-16 are upregulated in two NPC 
samples compared to healthy tissues. MiRNA read numbers are shown as percentages of 
the total miRNA reads in the libraries. 
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Figure 2.10  Hsa-mir-15a and hsa-mir-16 target BRCA1 mRNA. (A) Putative binding sites 
of hsa-mir-15a and hsa-mir-16 in the BRCA1 3’UTR predicted by Miranda (John et al., 2004). 
(B). A firefly luciferase reporter fused to the BRCA1 3’UTR was cotransfected with 2’OMe-
antisense inhibitors against hsa-mir-15a or hsa-mir-16 into HEK 293 cells. Firefly luciferase 
expression was measured after 48 h and normalized to Renilla luciferase expression. (C).
Ago1- and Ago2-containing complexes were immunoprecipitated by monoclonal antibodies 
from HEK 293 cell lysates transfected with miRNA inhibitors as indicated. RNAs were 
extracted and reverse transcribed from immunoprecipitated Ago1/2 complexes. BRCA1
mRNA incorporated into Ago1/2 complexes was measured by qRT-PCR and normalized to the 
GAPDH mRNA level. (D). Total RNA was extracted and reverse transcribed from HEK 293 
cells transfected with miRNA inhibitors as indicated. BRCA1 mRNA levels were quantified by 
qRT-PCR and normalized to GAPDH mRNA levels. (E). Analysis of BRCA1 protein levels by 
Western blotting. Lysates of MCF-7 cells transfected with 2’OMe- antisense inhibitors to 
hsa-mir-15a and hsa-mir-16 (lane 1) or to ebv-mir-BHRF1-1 as a control (lane 2) were 
transferred to nitrocellulose membranes and analyzed by Western blotting using anti-BRCA1
antibodies. 
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anti-Ago1 and anti-Ago2 monoclonal antibodies. Moreover, the BRCA1 mRNA was 
released from Ago protein complexes when 2’OMe- inhibitors complementary to 
hsa-mir-15a or hsa-mir-16, which interrupt miRNA-mRNA interactions, were 
transfected, indicating that BRCA1 is targeted by the miRNA pathway. 
Finally, BRCA1 mRNA as well as protein levels were measured in the presence or 
absence of hsa-mir-15a or hsa-mir-16 inhibitor. MiRNAs suppress target protein 
synthesis either by induction of target mRNA degradation or translational repression. 
The qRT-PCR reveals that, endogenous BRCA1 mRNA was robustly increased when 
hsa-mir-15a or hsa-mir-16 was inhibited (Figure 2.10 D). Notably, inhibition of 
hsa-let-7a, a miRNA that does not target BRCA1, led to a decrease of BRCA1 mRNA 
levels, which was most likely due to unrelated, secondary hsa-let-7a effects. 
Consistent with the mRNA expression data, an increase in BRCA1 protein levels was 
also observed when hsa-mir-15a and hsa-mir-16 were inhibited (Figure 2.10 E).  
In summary, the data suggest that hsa-mir-15a and hsa-mir-16 are upregulated in 
NPC samples and target the tumor suppressor BRCA1. 
 
2.2.7 Summary of results from NGS data in NPC samples 
Taken together, 454 sequencing in two pairs of NPC samples with corresponding 
control tissues has identified two novel EBV and three novel human miRNA genes, 
together with a number of previously unidentified EBV and human star miRNAs. The 
miRNA composition has suggested a unique expression signature of NPC samples 
compared to healthy tissues. Among the dysregulated miRNAs, hsa-mir-15a and 
hsa-mir-16 were shown to be elevated in both NPC samples, and they were revealed 
to target the tumor suppressor BRCA1 at both mRNA and protein levels. 
 
2.3  Analysis of Small RNA Libraries from MHV-68 infected 
Cell Lines 
Next, the small RNA cloning and NGS approach were employed in MHV-68 infected 
cell lines, of which the viral miRNAs had not been well characterized. Nine miRNA 
genes had been so far identified in MHV-68 genome (Pfeffer et al., 2005). 454 
sequencing technology was utilized in this miRNA study of MHV-68 infected cell lines 
compared to control cell lines, to investigate whether there were more novel MHV-68 
miRNA genes, and to study miRNA profiles in differentially treated cell lines, so as to 
explore the roles of MHV-68 and cellular miRNAs during viral infection and life cycle. 
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2.3.1 Small RNA cloning and sequencing of MHV-68 infected cells 
In order to validate the expression of known and to identify novel MHV-68 miRNAs, 
murine fibroblast NIH 3T3 cells were infected with MHV-68, which results in lytic 
replication (sample NIH 3T3+). Uninfected NIH 3T3 cells served as negative control 
(sample NIH 3T3-). In addition, S11 cells, the B lymphoma cell line persistently 
infected with MHV-68, were also analysed. S11 cells were either left untreated 
(sample S11-) or were treated with TPA (12-O-tetradecanoylphorbol-13-acetate) to 
induce the lytic cycle (sample S11+). Small RNAs were extracted and sequenced 
using 454 sequencing technology. 59922 reads were obtained from NIH 3T3-, 54135 
reads from NIH 3T3+, 43035 reads from S11- and 60704 reads from S11+ after 
barcode sorting (GEO number GSE22938). After removal of the adapter sequences, 
more than 99% of the remaining reads are longer than 15 nt, which were taken for the 
subsequent analysis (Table 2.6). 
After thorough analysis of the reads against both MHV-68 and mouse genomes, it 
was found that the majority of reads are miRNA sequences, while there was a minor 
portion derived from degradation products of other nc RNAs (Table 2.6 and Figure 
2.11), indicating good quality of the small RNA libraries. Accordingly, no MHV-68 
sequence was found in the NIH 3T3- sample. Nearly 10% of the reads in both the 
S11- and S11+ libraries were MHV-68 sequences, i.e. much more than the 0.5% in 
MHV-68 infected NIH 3T3 cells (Figure 2.11). 
Table 2.6  Sequence distribution of small RNA libraries from MHV-68 infected cell 
lines. 
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2.3.2 Identification of novel MHV-68 miRNA genes 
By analyzing the pool of MHV-68 sequences from the small RNA libraries, a 
considerable number of reads did not match to known mature MHV-68 miRNAs in 
miRBase v14.0. However, among them, about half of the sequences matched to 
known miRNA hairpins, and were thus characterized as novel star miRNAs (Table 2.6 
and Table 2.7). The remaining MHV-68 sequences were analyzed using the 
secondary structure prediction program mFOLD by extracting the flanking sequences 
from MHV-68 genome. In this way, six novel MHV-68 miRNA genes (termed 
mghv-mir-M1-10 to mghv-mir-M1-15), which give rise to 11 mature miRNAs in total, 
were identified (Table 2.7). Mghv-mir-M1-11 is a perfectly matched hairpin, but has 
only very low read numbers from both arms. The other five hairpins show common 
imperfect miRNA folding structure, and are biased in generating the mature miRNAs 
from the 3-prime arm (Table 2.7 and Table 2.8). 
Figure 2.11 Comprehensive analysis of small RNA libraries by 454 sequencing 
constructed from NIH 3T3 and S11 cells. Schemes show the abundance of MHV-68 and 
murine sequences (mmu) as the percentage of read numbers in NIH 3T3 and S11 small RNA 
libraries by 454 sequencing. 
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Table 2.7  MiRNA read numbers of known and novel viral precursors from MHV-68 
infected samples. 
 
 
Namea Sequence 
Number of reads in the libraries 
NIH 3T3+ S11- S11+ 
mghv-mir-M1-1 UAGAAAUGGCCGUACUUCCUUU 35 1168 1572 
mghv-mir-M1-1* AGGAAGUGGGUCCAACUU 0 2 0 
mghv-mir-M1-2 CAGACCCCCUCUCCCCCUCUUU 1 36 71 
mghv-mir-M1-2-5p AGAGGGGGAGUGUGUGGUCUGUb 19 149 225 
mghv-mir-M1-3 GAGGUGAGCAGGAGUUGCGCUU 7 29 42 
mghv-mir-M1-3* AGCGAACCUCUGCUCACUGCCC 0 9 15 
mghv-mir-M1-4 UCGAGGAGCACGUGUUAUUCUA 0 23 29 
mghv-mir-M1-4* AGAUAGCAUGUGCCGUCCUCUUU 0 6 7 
mghv-mir-M1-5 AGAGUUGAGAUCGGGUCGUCUC 8 144 275 
mghv-mir-M1-5* AGGCAAACCCGAGCUCCUCCUU 29 28 84 
mghv-mir-M1-6 UGAAACUGUGUGAGGUGGUUUU 1 38 101 
mghv-mir-M1-6* CAACCACCUCCCACAAUUUCAGb 0 22 28 
mghv-mir-M1-7-5p AAAGGUGGAGGUGCGGUAACCU 11 140 231 
mghv-mir-M1-7-3p GAUAUCGCGCCCACCUUUAUU 12 306 510 
mghv-mir-M1-8 AGCACUCACUGGGGGUUUGGUC 61 679 977 
mghv-mir-M1-8* UGACCAACCCUAAGUGAGUUUU 7 154 177 
mghv-mir-M1-9 UCACAUUUGCCUGGACCUUUUU 58 674 617 
mghv-mir-M1-10 UGAUUACACGGAAGGUUCUUUU 5 62 90 
mghv-mir-M1-10* UUAAGAACCCUCAGUGCAAUCb 1 20 12 
mghv-mir-M1-11-5p AGCUGUCAGGGGUUACAUGb 0 0 1 
mghv-mir-M1-11-3p UGUAACCCCUGACAGCUGUC 0 1 0 
mghv-mir-M1-12 UUUGGUGUGGGAGUCCUACCCCUUU 4 76 103 
mghv-mir-M1-12* AAGGGUACUCUCAUCACCAAUGUb 0 1 2 
mghv-mir-M1-13 UAUCUCAUGUGAGCUCUUCUUU 8 254 276 
mghv-mir-M1-13* UGGGAAGAGUCUGUUGAGUGGC 0 1 4 
mghv-mir-M1-14 UGCUACAGCGUGCAGAACGUUU 2 74 78 
mghv-mir-M1-14* CCCGUUCUGGAUGCUGUGGGACb 3 7 8 
mghv-mir-M1-15 AGCUACCCGCGUGGCCGGAGUGUUU 0 0 2 
 
 
a. The definition of miRNAs and star miRNAs of a precursor is according to the relative abundance of 
the reads of both arms. Names in black are the known miRNAs. Names in red are the novel star 
miRNAs of known precursors. Names in blue are the novel miRNAs of novel precursors. 
b. Due to the characteristics of 454 sequencing, the putative miRNA sequences might extend to the 
additional “A” at the end.  
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Table 2.8  Novel candidate MHV-68 miRNAs of novel precursors identified from 
MHV-68 infected samples. 
 
 
 
 
a. Names of the putative new miRNA sequences are according to the submission to miRBase 
(http://www.mirbase.org). The definition of miRNAs and star miRNAs of a precursor is according to 
the relative abundance of the reads of both arms (See Table 2.7). 
b. RNA secondary structure prediction and free energy calculation have been done using mFOLD
version 3.2. The miRNA sequences are underlined. Due to the characteristics of 454 sequencing, 
the putative miRNA sequences might extend to the additional “A” at the end. The actual size of the 
stem-loop has not been experimentally determined. 
c. The genomic locations of MHV-68 miRNAs are referring to the positions in MHV-68 genome 
(GenBank accession number NC_001826.2).  
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Furthermore, the seed homology of the known and newly identified MHV-68 miRNAs 
was investigated by comparing to the miRNAs from mouse and other herpesviruses, 
since both Kaposi's sarcoma-associated herpesvirus (KSHV) and Marek's disease 
virus (MDV) have been reported to encode the functional orthologs of the oncogenic 
mir-155 (Skalsky et al., 2007; Zhao et al., 2009). Intriguingly, mghv-mir-M1-4 shows 
the same seed sequence as mmu-mir-151-5p, which has been revealed to be an 
important oncogenic factor during tumor invasion and metastasis (Ding et al., 2010) 
(Figure 2.12 A). On the other hand, mghv-mir-M1-9 and newly identified 
mghv-mir-M1-14 have the seed homology with two miRNAs from KSHV and MDV 
(Figure 2.12 B and C). This information suggests that miRNAs from different viruses 
or even mouse may regulate similar target mRNAs. 
 
2.3.3 Genomic organization of novel MHV-68 miRNAs 
Interestingly, like the already known nine MHV-68 miRNAs, all six novel miRNA genes 
are situated within the first 6 kbp at the left end of the MHV-68 genome and are 
located closely to the eight vtRNAs, except for mghv-mir-M1-11 (Figure 2.13).  
 
Figure 2.12 Seed sequence homology among MHV-68 miRNAs and murine or other 
herpesvirus miRNAs. The alignment of three MHV-68 miRNA sequences and murine or 
other herpesvirus miRNA sequences is shown. 
 
Figure 2.13 MHV-68 miRNAs are located directly after vtRNA sequences. Genomic 
locations of MHV-68 miRNAs are shown, modified from (Pfeffer et al., 2005). The first 6 kbp of 
the MHV-68 genome are depicted. Black triangles represent the 8 vtRNA sequences. M1 to 
M9 (in red) are the known MHV-68 miRNA precursors. M10 to M15 (in blue) are the 6 novel 
MHV-68 miRNA genes identified in this paper. ORF: open reading frame; TR: terminal repeat. 
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Figure 2.14  Unique vtRNA-miRNA-miRNA structures in MHV-68 genome. RNA folding 
structures of 8 vtRNA sequences and their subsequent miRNAs are shown. Sequences in 
green are the predicted anticodons of the vtRNA sequences (Bowden et al., 1997). 
Sequences in red are the known MHV-68 miRNAs. Sequences in yellow are the novel star 
miRNAs of known precursors. Sequences in blue are the novel miRNAs of novel MHV-68 
miRNA precursors. The genomic locations of the sequences are annotated aside. 
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The novel MHV-68 miRNAs are positioned either immediately following the known 
miRNAs (Figure 2.14 A and E), or between the vtRNAs and known miRNAs (Figure 
2.14 F and H). The vtRNA-miRNA-miRNA structure is common for six of the eight 
vtRNAs. There is only one miRNA hairpin structure following vtRNA3 and vtRNA7, 
and the other stretch was neither able to form a hairpin according to mFOLD (Figure 
2.14 C and G), nor was any corresponding read found from the libraries. Furthermore, 
these specifically structured RNA sequences of approximately 200 nt in length all start 
with the conserved A/B box promoter for RNA polymerase III in the vtRNAs, and end 
with a poly(U) sequence which serves as the terminus for RNA polymerase III, 
implying that the vtRNA-miRNA-miRNA sequences are transcribed as a long primary 
transcript and are then processed further into mature miRNAs. 
 
2.3.4 Validation of the novel MHV-68 miRNA expression 
To further validate the existence of the novel MHV-68 miRNAs, Northern blotting was 
performed with RNAs isolated from S11 cells. RNAs were extracted from either total 
cell lysates or from lysates after immunoprecipitation (IP) with a monoclonal 
anti-mouse Ago2 antibody. As the negative control, immunoprecipitation were 
performed using an isotype-matched control antibody (anti-BrDU). Probes against the 
abundant mghv-mir-M1-10, mghv-mir-M1-12 and mghv-mir-M1-14 were well 
Figure 2.15  Validation of novel MHV-68 miRNAs. (A). Northern blot validation of novel 
MHV-68 miRNAs. RNAs were extracted from total S11 cell lysates (lane 1), anti-BrDU control 
IP (lane 2), and anti-mAgo2 immunoprecipitation (IP) using monoclonal antibody 6F4 (lane 3), 
and blotted onto a nylon membrane. Probes complementary to known or novel MHV-68 
miRNAs were labelled and used for detection. Novel MHV-68 miRNAs are highlighted in blue. 
(B). Stem-loop qRT-PCR validation of the novel MHV-68 miRNA mghv-mir-M1-13. RNA was 
extracted from total cell lysates of S11 cells and from infected or uninfected Ag-8 cells. The 
latter served as a negative control. The samples were subjected to stem loop qRT-PCR as 
described in materials and methods. Data shown are means + SD of triplicate experiments. As 
positive controsl, the expressions of mghv-mir-M1-1 and cellular miRNA mmu-mir-191 are also 
shown. 
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detectable not only in total cell lysates but also in the anti-mAgo2 
co-immunoprecipitated samples (Figure 2.15 A), indicating that the novel MHV-68 
miRNAs, like cellular and already known MHV-68 miRNAs, are efficiently associating 
with functional RISC complexes. Only a very weak signal could be detected from the 
probe against mghv-mir-M1-13 (data not shown). However, the expression of 
mghv-mir-M1-13 was shown by a more sensitive stem-loop qRT-PCR (Figure 2.15 B) 
in both S11 cells and in Ag-8 myeloma cells 48 hours after infection with MHV-68. No 
MHV-68 miRNAs were detectable in uninfected Ag-8 cells, while the cellular miRNA 
mmu-mir-191 was detected in all three samples. 
Since MHV-68 miRNAs derive from unusual precursors, it was interesting to 
investigate whether the MHV-68 miRNAs employ the same miRNA processing 
machinery as cellular miRNAs. To this end, Dicer-deficient mouse embryonic 
fibroblasts (Dicer-/- MEF) were infected with MHV-68 and miRNA generation was 
monitored. Two independently derived Dicer-/- MEF clones were tested. Compared to 
wildtype MEFs (Dicer+/+), Dicer-/- MEFs were not able to produce mature cellular or 
MHV-68 miRNAs (Figure 2.16). Thus, MHV-68 miRNAs are processed by a 
Dicer-dependent pathway. 
 
Figure 2.16  MHV-68 miRNAs are generated in a Dicer-dependent pathway. MHV-68 
miRNA generation in MHV-68 infected Dicer-/- MEFs was monitored. Two independent clones 
of Dicer-/- MEFs (lane 2 and lane 4) were infected with MHV-68 in parallel with wildtype 
controls (lane 1 and lane 3). Total RNAs were extracted and blotted onto a nylon membrane. 
Probes complementary to mghv-mir-M1-1 and mmu-mir-21 were labelled and used for 
detection. Probing against tRNA-Met served as a loading control. 
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2.3.5 Cellular miRNA profiles in NIH 3T3 and S11 cells 
Apart from the MHV-68 sequences, the majority of reads in the sequencing libraries 
were murine miRNA sequences. Annotating these sequences by miRBase v14.0, a 
significant number of reads derived from the other arm of known murine miRNA 
hairpins were found. Altogether, 61 novel murine star miRNAs were identified and 
registered (Table 2.9).  
Table 2.9  Sequences and read numbers of murine novel star miRNAs in the 
sequencing libraries. 
 
Namea Sequence 
Number of reads in the libraries 
NIH3T3- NIH3T3+ S11- S11+ 
mmu-let-7a-2* CUGUACAGCCUCCUAGCUUUC 1 1 1 0 
mmu-let-7e* CUAUACGGCCUCCUAGCUUUCC 7 15 0 0 
mmu-let-7f-2* CUAUACAGUCUACUGUCUUUC 6 2 5 5 
mmu-mir-100* ACAAGCUUGUGUCUAAUAGGUAU 1 1 0 0 
mmu-mir-103-1* GGCUUCUUUACAGUGCUGCCUUG 0 5 0 0 
mmu-mir-103-2* AGCUUCUUUACAGUGCUGCCUUG 16 7 3 6 
mmu-mir-107* AGCUUCUUUACAGUGUUGCCUUG 2 2 0 1 
mmu-mir-132* AACCGUGGCUUUCGAUUGUUAC 0 0 1 1 
mmu-mir-134* CUGUGGGCCACCUAGUCACCb 2 5 0 0 
mmu-mir-143* GGUGCAGUGCUGCAUCUCUGG 7 2 0 0 
mmu-mir-152* UAGGUUCUGUGAUACACUCCGACU 1 0 0 0 
mmu-mir-155* CUCCUACCUGUUAGCAUUAACb 0 0 3 6 
mmu-mir-16-2* ACCAAUAUUAUUGUGCUGCUUUb 27 24 16 24 
mmu-mir-181b-1* CUCACUGAACAAUGAAUGCb 2 0 0 0 
mmu-mir-181c* ACCAUCGACCGUUGAGUGGACC 5 1 0 0 
mmu-mir-182* GUGGUUCUAGACUUGCCAACUb 0 2 0 0 
mmu-mir-190* ACUAUAUAUCAAGCAUAUUCCUb 1 0 0 0 
mmu-mir-1948* AUAUGAGUAUUCUGCCUAAAU 1 0 0 1 
mmu-mir-195* CCAAUAUUGGCUGUGCUGCUCCb 0 1 0 0 
mmu-mir-196a-1* CAACGACAUCAAACCACCUGAU 0 2 0 0 
mmu-mir-196b* UCGACAGCACGACACUGCCUUCb 1 0 0 0 
mmu-mir-1981* CAUCUAACCCUGGCCUUUGACb 1 2 0 0 
mmu-mir-19b-1* AGUUUUGCAGGUUUGCAUCCAGC 2 1 0 0 
mmu-mir-210* AGCCACUGCCCACCGCACACUG 7 1 0 0 
mmu-mir-217* CAUCAGUUCCUAAUGCAUUGCCU 0 1 0 0 
mmu-mir-221* ACCUGGCAUACAAUGUAGAUUUCUGU 8 6 0 0 
mmu-mir-222* UCAGUAGCCAGUGUAGAUCCU 1 1 0 0 
mmu-mir-23a* GGGGUUCCUGGGGAUGGGAUUU 0 0 3 0 
mmu-mir-25* AGGCGGAGACUUGGGCAAUUGC 0 2 0 0 
mmu-mir-26a-2* CCUGUUCUUGAUUACUUGUUUC 1 1 0 0 
mmu-mir-29b-2* CUGGUUUCACAUGGUGGCUUAGAUU 0 0 1 0 
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Table 2.9 (continue)  Sequences and read numbers of murine novel star miRNAs in 
the sequencing libraries. 
 
Namea Sequence 
Number of reads in the libraries 
NIH3T3- NIH3T3+ S11- S11+ 
mmu-mir-301a* GCUCUGACUUUAUUGCACUACU 1 0 0 0 
mmu-mir-30d* CUUUCAGUCAGAUGUUUGCUGC 7 2 0 1 
mmu-mir-32* CAAUUUAGUGUGUGUGAUAUU 2 0 0 1 
mmu-mir-329* AGAGGUUUUCUGGGUCUCUGUU 0 1 0 0 
mmu-mir-34a* AAUCAGCAAGUAUACUGCCCUb 11 2 22 33 
mmu-mir-350* AAAGUGCAUGCGCUUUGGGb 2 0 0 0 
mmu-mir-351* GGUCAAGAGGCGCCUGGGAAC 2 6 0 0 
mmu-mir-361* UCCCCCAGGUGUGAUUCUGAUUUGU 1 2 2 2 
mmu-mir-370* CAGGUCACGUCUCUGCAGUUb 0 2 0 0 
mmu-mir-379* UAUGUAACAUGGUCCACUAACU 2 1 0 0 
mmu-mir-410* AGGUUGUCUGUGAUGAGUUCG 1 0 0 0 
mmu-mir-466h-3p UACGCACGCACACACACACb 1 2 0 0 
mmu-mir-466i-5p UGUGUGUGUGUGUGUGUGUG 0 0 2 3 
mmu-mir-466l-5p UUGUGUGUACAUGUACAUGUAUb 1 0 0 0 
mmu-mir-493* UUGUACAUGGUAGGCUUUCb 1 0 0 0 
mmu-mir-497* CAAACCACACUGUGGUGUUAGb 1 0 0 0 
mmu-mir-500* AAUCCUUGCUAUCUGGGUGCUUAGU 0 0 0 1 
mmu-mir-543* AAGUUGCCCGCGUGUUUUUCG 1 0 0 0 
mmu-mir-652* CAACCCUAGGAGGGGGUGCCAUUCb 3 0 2 0 
mmu-mir-664* CUGGCUGGGGAAAAUGACUGGb 1 4 0 0 
mmu-mir-669a-1* ACAUAACAUACACACACACGUAUb 22 6 0 0 
mmu-mir-669d* UAUACAUACACACCCAUAUACb 1 0 0 0 
mmu-mir-669f-5p AGUUGUGUGUGCAUGUGCAUGUGU 7 1 0 0 
mmu-mir-670* UUUCCUCAUAUCCAUUCAGGAGUGU 0 3 0 0 
mmu-mir-677* GAAGCCAGAUGCCGUUCCUGAGAAGG 0 0 0 2 
mmu-mir-700* UAAGGCUCCUUCCUGUGCUUGCb 2 1 0 0 
mmu-mir-805* AUUAUAUGUCUUUCAAGUUCUUAG 0 1 0 0 
mmu-mir-92a-1* AGGUUGGGAUUUGUCGCAAUGCU 1 1 0 0 
mmu-mir-96* CAAUCAUGUGUAGUGCCAAUAU 1 0 0 0 
mmu-mir-98* CUAUACAACUUACUACUUUCCU 9 1 0 0 
 
a. The definition of miRNAs and star miRNAs of a precursor is according to the relative abundance of 
the reads of both arms (Appendix II). 
b. Due to the characteristics of 454 sequencing, the putative miRNA sequences might extend to the 
additional “A” at the end.  
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Figure 2.17 Cellular miRNA profiling of uninfected 
or MHV-68 infected NIH 3T3 cells and of untreated 
or TPA-treated S11 cells. Cellular miRNA levels 
were calculated and compared in the four small RNA
libraries. MHV-68 infected vs. non-infected NIH 3T3
are depicted in heatmap (A). TPA-treated vs. 
untreated S11 are depicted in the heatmap (B). 
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The read numbers of annotated murine miRNAs in the libraries suggested unique 
miRNA expression signatures of NIH 3T3 and S11 cells (Appendix Table II). NIH 3T3- 
and NIH 3T3+ cells showed distinct patterns of cellular miRNA expression levels, 
suggesting that miRNAs may play a role in the cellular response to MHV-68 infection 
(Figure 2.17 A). The cellular miRNA expression profile was also analysed in 
TPA-induced versus non-induced S11 cells. The changes after TPA induction were 
only subtle (Figure 2.17 B). 
Among the abundantly expressed cellular miRNAs in NIH 3T3 cells, mmu-mir-16 and 
mmu-mir-15b, which belong to the same miRNA family, were found to be highly 
upregulated after MHV-68 infection. This upregulation was further confirmed by 
Northern blotting (Figure 2.18 A). Mghv-mir-M1-1 was, as expected, only present in 
NIH 3T3+ cells, and tRNA-Met served as loading control.  
In the study of cellular miRNA profiles in EBV-infected NPC samples, it has been 
shown that hsa-mir-15a and hsa-mir-16 are upregulated in EBV-positive 
nasopharyngeal carcinoma (Figure 2.9). The tumour suppressor gene BRCA1 was 
found to be one of the targets that are regulated by miR-15/16 (Figure 2.10). 
Therefore, the question whether the upregulation of mmu-mir-16 and mmu-mir-15b 
after MHV-68 infection might also lead to downregulation of BRCA1 in the MHV-68 
Figure 2.18 miR-15/16 upregulation was observed in MHV-68 infected NIH 3T3 cells. (A).
Northern blot validation of cellular miRNAs upregulated after infection of NIH 3T3 cells. Total 
RNAs were extracted from uninfected (lane 1) or MHV-68 infected NIH 3T3 cells (lane 2). 
RNAs were blotted onto a nylon membrane and detected by labelled probes complementary 
to mmu-mir-16, mmu-mir-15b and mghv-mir-M1-1. Probing against tRNA-Met served as a 
loading control. (B). Downregulation of BRCA1 in MHV-68 infected NIH 3T3 cells. To analyse 
the expression of BRCA1, RNA was isolated from uninfected and MHV-68 infected NIH 3T3
cells 48h after infection and subjected to qRT-PCR using primers specific for BRCA1 and 18S 
RNA. Data shown are means + SD of triplicate determinations. 
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model system was further investigated. As shown in Figure 2.18 B, BRCA1 
expression was indeed reduced when NIH 3T3 cells were infected with MHV-68, 
compared to uninfected cells, suggesting that miR-15/16 upregulation and the 
subsequent BRCA1 downregulation might be a common feature of γ-herpesvirus 
infection.  
 
2.3.6 Summary of results from NGS data in MHV-68 infected cells 
In summary, 454 sequencing has been carried out in two pairs of model cell lines, i.e. 
the MHV-68 infected versus non-infected NIH 3T3 cells and TPA-treated versus 
untreated S11 cells. Six novel MHV-68 miRNA genes, generating 11 mature miRNAs 
in total, were identified and validated. Furthermore, the accomplishment of the 
MHV-68 miRNA set revealed a unique vtRNA-miRNA-miRNA structure in MHV-68 
genome. On the other hand, these RNA polymerase III promoter driven transcripts still 
employ a Dicer-dependent pathway in the biogenesis of MHV-68 miRNAs. Moreover, 
the analysis of cellular miRNAs in the small RNA sequencing libraries has suggested 
the expression signature of NIH 3T3 and S11, after the treatment of MHV-68 infection 
and TPA induction, respectively. The MHV-68 infection in NIH 3T3 cells led to the 
upregulation of mmu-mir-15b and mmu-mir-16, and the downregulation of BRCA1 
expression, which was similar to the consequences of EBV infection in NPC samples, 
implying a common effect of γ-herpesvirus infection. 
 
 
2.4  Mis-annotation of MicroRNA Genes in miRBase 
By using miRBase as the reference database in our miRNA studies, we found that 
some miRNA sequences of interest turned out to be the pieces of the other 
non-coding RNAs (ncRNAs). Therefore, we set out to systematically check all the 
murine and human miRNA sequences in the database for the mis-annotation. To 
better distinguish between the mis-annotated miRNAs and the alternatively generated 
miRNAs from the other ncRNAs, the small RNA libraries by Solexa sequencing 
accessible through the GEO database, provided by Babiarz et al. in the study of 
Dgcr8 and Dicer dependency in the production of small RNAs (Babiarz et al., 2008), 
were re-analysed. Surprisingly, the study elucidated that, a considerable number of 
miRNA genes might have been mis-annotated in the current version of miRBase. 
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2.4.1 Examination of murine miRNA genes 
To systematically analyze the known miRNA genes, the newest version (v15.0) of 
miRBase, which was just released in April 2010, was downloaded. The most 
commonly used murine and human miRNA sequences were extracted for a close 
examination. These miRNA sequences were compared with the other ncRNA gene 
sequences, including ribosomal RNA (rRNA) genes (Benson et al., 2008), transfer 
RNA (tRNA) genes (Chan and Lowe, 2009), small nuclear and small nucleolar RNA 
(snRNA and snoRNA) genes (Szymanski et al., 2003) and the mitochondrial genome 
sequence (Benson et al., 2008). Since at least snoRNA and tRNA sequences have 
been reported to produce miRNAs in an alternative pathway (Babiarz et al., 2008; 
Ender et al., 2008), the finding that some miRNA sequences fully matched to the other 
ncRNAs was not sufficient to define that these miRNA sequences have been 
mis-annotated. 
Babiarz et al. have generated the small RNA libraries from wildtype, Dicer1 knockout 
and Dgcr8 knockout mouse embryonic stem cells (wt, Dicer1-/-, Dgcr8-/- mESCs) for 
Solexa sequencing, to study the dependency of these two processor proteins in the 
production of small RNAs (Babiarz et al., 2008). These libraries were ideal to 
distinguish the small RNA sequences as miRNAs or the degradation pieces of 
ncRNAs. Dicer dependency was considered as an important criteria to define a 
miRNA gene annotation (Ambros et al., 2003). To the knowledge known so far, the 
Dgcr8-containing microprocessors could be bypassed in the production of miRNAs 
from mirtrons (miRNAs produced from intron sequences), snoRNAs and tRNAs, but 
Dicer is dependent in the processing of all miRNAs, only with the exception of mir-451, 
according to the recent report that, its conserved short hairpin is specifically cleaved 
by Ago2 (Cifuentes et al., 2010). 
For this purpose, Solexa sequencing data of these three libraries were retrieved 
through the publicly accessible GEO database (GEO number GSE20384), and 
re-analyzed using the reference of miRBase v15.0. Since it was noticed that, in the 
large amount of reads produced by Solexa sequencing, the read with errors of 
nucleotide substitution tend to accumulate especially in the highly abundant reads, 
the reads with one mismatch in the hit to miRNA sequences were also reserved, in 
addition to the fully matched reads for further analysis (Appendix Table III and IV). 
As expected, 325 murine miRNA genes (mature miRNA and its star miRNA, or same 
mature miRNA from different precursors, was counted as one miRNA gene) showed 
nice dependencies on both Dicer1 and Dgcr8, characterized by that, the read 
numbers of these miRNAs were much more in the wt mESCs libraries than in the  
  RESULT 
43 
 
 
Table 2.10 Read numbers of mentioned murine miRNA entries in three small RNA 
libraries. 
 
miRNAa 
wt Dicer1-/- Dgcr8-/- 
mismatch0b mismatch1b mismatch0 mismatch1 mismatch0 mismatch1 
mmu-mir-451 111 11 127 4 115 21 
mmu-mir-590-3p 0 0 0 0 0 0 
mmu-mir-590-5p 0 0 0 0 0 0 
mmu-mir-664 14 0 1 0 171 21 
mmu-mir-685 13 3 53 2 16 2 
mmu-mir-689 19 1 33 11 25 7 
mmu-mir-696 2 1 1 1 4 2 
mmu-mir-712 5 1 1 0 12 1 
mmu-mir-712* 658 66 40 3 306 18 
mmu-mir-714 3 1 12 0 3 0 
mmu-mir-715 4 2 2 0 2 0 
mmu-mir-720 861 118 1440 83 1975 196 
mmu-mir-1274a 67 575 305 1659 196 1678 
mmu-mir-1937a 273 38 872 67 877 94 
mmu-mir-1937b 25 2 192 21 175 23 
mmu-mir-1937c 1 2 0 1 2 4 
mmu-mir-1944 343 31 657 30 867 67 
mmu-mir-1957 0 75 0 270 0 355 
mmu-mir-1959 116 143 169 261 221 355 
mmu-mir-1971 0 5 0 0 1 254 
mmu-mir-1981 37 3 0 0 2770 110 
mmu-mir-2132 90 31 256 62 536 147 
mmu-mir-2133 41 11 334 46 232 47 
mmu-mir-2134 27 3 12 3 40 6 
mmu-mir-2135 514 110 304 37 501 79 
mmu-mir-2138 827 133 1091 95 1172 196 
mmu-mir-2140 71 8 49 1 77 7 
mmu-mir-2141 1257 164 1174 68 1779 152 
mmu-mir-2142 8946 1125 12243 1268 14705 1808 
mmu-mir-2143 662 120 3721 214 3199 275 
mmu-mir-2144 532 77 777 61 995 120 
mmu-mir-2145 206 26 591 69 821 94 
mmu-mir-2146 489 65 353 22 515 45 
 
a. Names of miRNA entries are according to miRBase v14.0 and v15.0. Names in red are probably 
mis-annotated miRNAs. Names in blue are the dead miRNA entries removed from miRBase v15.0. 
Names in black are normal miRNAs. 
b. “Mismatch” refers to the mismatch existed in the alignment of library reads to miRNA sequences. 
“Mismatch0” means no mismatch. “Mismatch1” means one nucleotide mismatch. The read 
numbers with one nucleotide mismatch are shown in grey. 
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Table 2.11 Probably mis-annotated murine miRNA genes that match to other ncRNAs 
or do not match in murine genome. 
 
 
miRNA Sequence matched RNA 
(fully matched) 
mmu-mir-689 CGUCCCCGCUCGGCGGGGUCC 
murine 28S rRNA 
mmu-mir-2132 GGCGGGUGUUGACGCGAUG 
mmu-mir-2134 GUCUUGGGAAACGGGGUGC 
mmu-mir-2135 AGAGGUCUUGGGGCCGAAAC 
mmu-mir-2138 AAGGGAACGGGCUUGGCGGAAU 
mmu-mir-2140 AGGUGCAGAUCUUGGUGGU 
mmu-mir-2141 AGGAGGUGUCAGAAAAGUU 
mmu-mir-2146 GUGGAGAAGGGUUCCAUGUG 
mmu-mir-2133 GUCCCGCGGGGCCCGAAGCGUU murine 18S rRNA 
mmu-mir-2145 AGCAGGGUCGGGCCUGGUU murine 5S rRNA 
mmu-mir-696 GCGUGUGCUUGCUGUGGG 
murine 45S pre-rRNA mmu-mir-714 CGACGAGGGCCGGUCGGUCGC 
mmu-mir-715 CUCCGUGCACACCCCCGCGUG 
mmu-mir-720 AUCUCGCUGGGGCCUCCA murine tRNA-Thr(TGT)a 
mmu-mir-1937a AAUCCCGGACGAGCCCCCA 
murine tRNA-Pro(AGG)a 
mmu-mir-1937b AUCCCGGACGAGCCCCCA 
mmu-mir-1944 CUCUGUGCUGAAUGUCAAGUUCUGAUU murine Snord43 snoRNA 
(with one nucleotide mismatch or gap) 
mmu-mir-1274a UCAGGUCCCUGUUCAGGCGCCA murine tRNA-Lys(TTT)a 
mmu-mir-1937c AUCCCGGAAGAGCCCCCA murine tRNA-Pro(AGG)a 
mmu-mir-1939 UCGAUUCCCUGCCAAUGCAC murine tRNA-Gly(CCC)a 
mmu-mir-1957 CAGUGGUAGAGCAUAUGAC murine tRNA-Cys(GCA)a 
mmu-mir-1959 GGGGAUGUAGCUCAGUGGAG murine tRNA-Ala(AGC)a 
(not matched to murine genome) 
mmu-mir-590-5p GAGCUUAUUCAUAAAAGUGCAG 
 
mmu-mir-590-3p UAAUUUUAUGUAUAAGCUAGU 
 
a. There might be more than one tRNA sequences that match to this miRNA, due to the characteristics 
of tRNA sequences.. 
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Dicer1-/- and Dgcr8-/- mESCs libraries, normally ten-fold or even higher (Appendix 
Table III).This was similar to what Babiarz et al. have observed when miRBase v10.0 
was utilized. 131 murine miRNA sequences have no reads or extremely low 
numbered reads in all three libraries. This might be due to the tissue-specific 
expression of these miRNAs and were not followed up. 20 miRNA sequences have 
nearly no reads in Dicer1-/- library, but have much more reads in the Dgcr8-/- mESCs 
library than in the wt mESCs library. These included all of the mirtrons, snoRNA and 
tRNA-generated miRNAs known so far, and leave the interesting question to study the 
processing pathways of the rest of them. The remaining 38 miRNA sequences, which 
have abundant and similar read numbers in all three libraries, were the most 
suspicious candidates that could have been mis-annotated. Mir-451 was one of these 
Dicer1- and Dgcr8- independent sequences, but none of the rest sequences showed 
the similarity to its specific hairpin structure. 
To further test the hypothesis, the dead miRNA entries that have just been removed 
from the miRBase v15.0 due to mis-annotation were tested. Mmu-mir-2142, 
mmu-mir-2143 and mmu-mir-2144 were reported to be pieces of rRNA genes, while 
mmu-mir-685 was reported to be the piece of ncRNA RNase P. The examination of 
these four sequences in all three sequencing libraries resulted in similar read 
numbers (Table 2.10), indicating that the independencies from Dicer1 and Dgcr8 in 
production can be served as the useful evidence in defining whether the miRNA 
sequences have been mis-annotated, and were actually the degradation products of 
the other ncRNAs. 
First, rRNA-matched murine miRNA sequences were checked. Surprisingly, eight 
murine miRNAs were found to be matched to murine 28S rRNA sequence, one 
miRNAs matched to 18S rRNA sequence and one miRNA matched to 5S rRNA 
sequences (Table 2.11). All of these ten miRNA sequences showed independencies 
from Dicer1 and Dgcr8 with similar or higher read numbers in both knockout mESCs 
libraries than in the wt mESCs libraries (Table 2.10). Mouse rRNAs were known to be 
produced as a 45S rRNA long transcript (Perry, 1976). There were four more miRNAs 
found to be matched in the additional 45S rRNA regions (Table 2.11). However, 
different from the other three miRNAs, mmu-mir-712 showed largely reduced read 
number in Dicer1-/- mESCs library, implying that it might be an interesting miRNA 
derived from an alternative pathway (Table 2.10). Of note, mmu-mir-689, 
mmu-mir-696, mmu-mir-714 and mmu-mir-715 have been challenged for the 
annotation of miRNA genes in another Dicer knockout models (Calabrese et al., 
2007). 
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Next, tRNA gene sequences were examined. The tRNA sequences might not be 
efficiently annotated in the small RNA sequencing libraries, due to the fact that, the 
mature tRNAs are modified with the addition of a “CCA” tail (Xiong and Steitz, 2006), 
but this feature was not reflected in most of the tRNA databases and might also be 
ignored when the genomic sequence is utilized. Indeed, three murine miRNA 
sequences were found to be matched to the tRNA sequences with “CCA” in addition 
(Table 2.11). All of them showed both Dicer1 and Dgcr8 independencies (Table 2.10).  
Moreover, additional five murine miRNA sequences were found that they have one 
mismatch to the tRNA sequences (Table 2.11). The detailed analysis in the 
sequencing libraries revealed that, the perfect match to these miRNA sequences were 
much less than the sequences with one mismatch (Table 2.10), which turned out to be 
perfectly matched to the related tRNAs (data not shown), and both read numbers are 
dispensable of Dicer1 and Dgcr8. The speculation was that, although the error rate of 
about 1% in NGS is not much higher than the traditional Sanger Sequencing, the 
ability to produce huge volume of data by NGS is accompanied by the production of 
many sequences with errors. On the other hand, the principle behind many NGS data 
annotation programs was first to align the read sequences to the perfectly matched 
genome loci. It is not surprising when these short sequences with errors were able to 
find some hits elsewhere in the genome. Furthermore, the hairpin folding condition 
was stringent enough. These might be reasons for the possible mis-annotation of 
these miRNA sequences. Since the identification of novel miRNA genes by NGS 
nowadays does not require further Northern Blotting validation as necessity during the 
registration to the miRNA database, and it is also difficult to clarify the processing 
pathways of the low-abundant miRNAs. The actual sequences of identified miRNAs 
were not very well controlled. 
Then, the miRNA sequences were searched for matching to the other ncRNAs, and 
two murine miRNAs were found (Table 2.11). Among them, mmu-mir-664, matched to 
one H/ACA snoRNA, got much lower read number in Dicer1-/- mESCs library, than the 
Dgcr8-/- and wt mESCs libraries, implying a similar processing pathway to the 
mmu-mir-1839 from H/ACA 45 snoRNA. Mmu-mir-1944, which is matched to Snord43 
snoRNA and abnormally long of 27 nt, and has high read numbers in all three libraries 
(Table 2.10), is probably mis-annotated. 
Interestingly, mmu-mir-1971, which is especially short with only 18 nt was also noticed. 
It might be the truncated form of mmu-mir-1981 with one mismatch generated during 
sequencing procedures (Figure 2.19). Mmu-mir-1971 itself nearly got no reads from 
all three libraries (Table 2.10). 
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Furthermore, the sequence of mmu-mir-590, which was supposed as an ortholog of 
hsa-mir-590, got no hit at all in the current assembly of murine genome from GenBank. 
Nor does the miRBase provide any genomic information of this miRNA gene, as it 
does for most of the other miRNA genes (Table 2.11). 
Taken together, there are 24 murine miRNA genes that have to be carefully looked 
over and re-considered for their definition as miRNA genes. In addition, when 
analyzing closely at individual read sequence, the sequences matched to these 
suspicious miRNA genes always showed diversity of start, termini and length, with a 
length preferably shorter than 20 nt of “tRNA-derived” mis-annotated miRNAs or 
around 25 nt of other “ncRNA-derived” mis-annotated miRNAs (data not shown). This 
is obviously distinguished from the classical miRNAs, which showed a distinct pattern 
of start and termini, with the length mainly around 20 to 22 nt. 
 
2.4.2 Examination of human miRNA genes 
Although there is no human Dicer or Dgcr8 knockout samples available so far, the 
large homology between human genome and murine genome leads to the possibility 
of utilizing these mESCs small RNA libraries for the examination of human miRNAs as 
well. For this purpose, the three libraries were re-analysed again using the reference 
of human miRNAs from miRBase v15.0 (Appendix Table IV), and meanwhile 
searched for the identity of human miRNAs to human ncRNA sequences.  
As a result, eleven human miRNA sequences were found matched perfectly to diverse 
human ncRNA sequences, together with six miRNA sequences harbouring one 
mismatch to ncRNA sequencess (Table 2.13). Most of these mis-annotated miRNAs 
showed independencies from Dicer1 and Dgcr8 in production, while the rest got no 
read from all three libraries (Table 2.12).  
Of note, two miRNA genes were also found to perfectly match human mitochondrial 
genome sequence (Table 2.13). Hsa-mir-1973 is aligned to the mitochondrial 16S 
rRNA and showed independencies from Dicer1 and Dgcr8 in the read numbers, while 
hsa-mir-4284 is aligned to the mitochondrial Phe tRNA gene and has no read in all 
three murine libraries. 
Figure 2.19 Alignment of the murine miRNA which is a possible truncated form of an 
abundant miRNA. One probably mis-annotated murine miRNA is aligned with its 
corresponding miRNA. 
 
 
 
  RESULT 
48 
 
 
Table 2.12 Read numbers of mentioned human miRNA entries in three small RNA 
libraries. 
 
miRNAa 
wt Dicer1-/- Dgcr8-/- 
mismatch0b mismatch1b mismatch0 mismatch1 mismatch0 mismatch1 
hsa-mir-106b* 168 41 0 1 0 0 
hsa-mir-107 631 91 0 0 0 1 
hsa-mir-145 317 36 35 3 18 4 
hsa-mir-185 643 123 0 0 0 0 
hsa-mir-23a 8307 960 84 4 70 5 
hsa-mir-720 866 119 1465 86 1996 210 
hsa-mir-766 0 0 0 0 0 0 
hsa-mir-935 24 2 0 0 0 0 
hsa-mir-1246 8 11 26 6 27 7 
hsa-mir-1247 6 1 2 0 0 0 
hsa-mir-1248 64 12 173 4 258 18 
hsa-mir-1249 12 1 0 1 0 3 
hsa-mir-1260 5 698 1 3314 2 3862 
hsa-mir-1260b 143 11 723 29 719 56 
hsa-mir-1274a 101 21 515 22 289 41 
hsa-mir-1274b 660 95 1807 110 1724 191 
hsa-mir-1280 12 15 27 85 94 128 
hsa-mir-1290 0 21 0 34 0 54 
hsa-mir-1291 0 0 0 0 0 0 
hsa-mir-1308 1555 5658 10237 21398 5165 20376 
hsa-mir-1826 376 313 625 176 616 194 
hsa-mir-1973 6 2 3 0 16 5 
hsa-mir-1975 0 0 0 0 0 0 
hsa-mir-1979 27 301 151 1670 180 1284 
hsa-mir-3074 9 0 0 0 0 0 
hsa-mir-3182 0 18 0 81 0 67 
hsa-mir-3195 0 8 0 1 0 6 
hsa-mir-4284 0 0 0 0 0 0 
hsa-mir-4286 250 108 482 187 554 229 
hsa-mir-4289 1 14 0 0 0 0 
hsa-mir-4306 0 11 0 0 0 0 
hsa-mir-4317 0 7 0 0 0 0 
hsa-mir-4318 0 22 0 0 0 0 
hsa-mir-4323 0 0 0 0 0 0 
hsa-mir-4328 0 4 0 0 0 1 
a. Names of miRNA entries, according to miRBase v15.0. Names in red are probably mis-annotated 
miRNAs. Names in black are normal miRNAs. 
b. “Mismatch” refers to the mismatch existed in the alignment of library reads to miRNA sequences. 
“Mismatch0” means no mismatch. “Mismatch1” means one nucleotide mismatch. The read numbers 
with one nucleotide mismatch are shown in grey. 
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Table 2.13 Probably mis-annotated human miRNA genes that match to other 
ncRNAs. 
 
 
miRNA Sequence matched RNA 
(fully matched) 
hsa-mir-720 UCUCGCUGGGGCCUCCA human tRNA-Thr(TGT)a 
hsa-mir-1274a GUCCCUGUUCAGGCGCCA human tRNA-Lys(TTT)a 
hsa-mir-1274b UCCCUGUUCGGGCGCCA human tRNA-Lys(TTT)a 
hsa-mir-1280 UCCCACCGCUGCCACCC human tRNA-Leu(AAG)a 
hsa-mir-1308 GCAUGGGUGGUUCAGUGG human tRNA-Gly(GCC)a 
hsa-mir-4286 ACCCCACUCCUGGUACC human tRNA-Leu(TAA)a 
hsa-mir-1246 AAUGGAUUUUUGGAGCAGG human U2 snRNA 
hsa-mir-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA human H/ACA box 81 snoRNA 
hsa-mir-1291 UGGCCCUGACUGAAGACCAGCAGU human H/ACA box 34 snoRNA 
hsa-mir-1975 CCCCCACAACCGCGCUUGACUAGCU human RNY5 scRNA 
hsa-mir-1979 CUCCCACUGCUUCACUUGACUA human RNY3 scRNA 
hsa-mir-1973 ACCGUGCAAAGGUAGCAUA human mitochondrial 16S rRNA 
hsa-mir-4284 GGGCUCACAUCACCCCAU human mitochondrial tRNA-Phe 
(with one nucleotide mismatch or gap) 
hsa-mir-1826 AUUGAUCAUCGACACUUCGAACGCAAU human 5.8S rRNA 
hsa-mir-3195 CGCGCCGGGCCCGGGUU human 28S rRNA 
hsa-mir-1260 AUCCCACCUCUGCCACCA human tRNA-Leu(AGG)a 
hsa-mir-1260b AUCCCACCACUGCCACCAU human tRNA-Leu(AGG)a 
hsa-mir-3182 GCUUCUGUAGUGUAGUC human tRNA-Val(CAC)a 
hsa-mir-1290 UGGAUUUUUGGAUCAGGGA human U2-snRNA-related 
 
a. There might be more than one tRNA sequences that match to this miRNA, due to the characteristics 
of tRNA sequences. 
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Moreover, six human miRNA genes were found to be the possible truncated form of 
the abundantly expressed human miRNAs, with one mismatch or one gap (Figure 
2.20). These six miRNA sequences, however, are all abnormally short with the length 
of only 17 to 19, which does not seem to qualify them as normal miRNA genes. 
As a result, 25 human miRNA genes have been probably mis-annotated. 
At last, among the huge information emerged during the analysis, four human miRNA 
sequences were found to get significant read numbers in the wt mESCs library, but 
largely reduced numbers in both Dicer1-/- and Dgcr8-/- mESCs libraries (Table 2.12). 
The orthologs of these miRNAs in murine genome have not been reported before. 
The loci of these sequences were searched in murine genome, and their flanking 
sequences were all shown to form nice hairpin structures (Table 2.14). Among them, 
the hairpin of mmu-mir-3074 turned out to be the reverse complementary transcript of 
the pre-miRNA mmu-mir-24-1, which is the same case as hsa-mir-3074 and 
hsa-mir-24-1. Thus, there are four novel murine miRNA candidates identified. 
 
2.4.3 Summary of examination of mis-annotated miRNAs in miRBase 
Taken together, 24 murine miRNA genes and 25 human miRNA genes in the current 
version of miRBase are probably mis-annotated. Most of them might actually be the 
degradation products of other ncRNAs. The rapid development of the sequencing 
technologies has promoted the studies in miRNA field, especially the identification of 
novel miRNA genes. However, this analysis has raised the question whether all of the 
miRNA genes in the current database have been correctly annotated. People should  
 
Figure 2.20 Alignment of human miRNAs which are possible truncated form of 
abundant miRNAs. Six probably mis-annotated human miRNAs are aligned with their 
corresponding miRNAs. 
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be careful when defining a novel miRNA gene according to NGS data. Meanwhile, the 
database might take more responsibility during the acceptance of novel miRNA genes. 
More strict evidence other than NGS data might also be necessary. 
 
Table 2.14  Novel murine miRNA candidates of known human miRNA orthologs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Names of the putative new miRNA sequences are according to their orthologs in human miRNAs 
retrieved from miRBase (http://www.mirbase.org). 
b. RNA secondary structure prediction and free energy calculation have been done using mFOLD
version 3.2. The miRNA sequences are underlined. The actual size of the stem-loop has not been 
experimentally determined. 
c. The genomic locations of murine miRNAs are referring to the positions in murine chromosomes 
according to the assembly from NCBI (http://www.ncbi.nlm.nih.gov/mapview/). 
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3.  DISCUSSION 
3.1  Advantages of developed software for NGS data analysis 
The advent of NGS technologies has started a new era in the analysis of genome as 
well as gene expression profiles. Its amazing ability of producing enormous amount of 
short sequences at fast speed and low cost has inspired biologists with various 
applications in many research areas, including studies in the small RNA field. 
However, the obstacles stand between the huge set of data and the significant useful 
information. The specific characteristics of NGS data – the large number and the short 
length of the reads – demanded alternative methods for processing and alignment, 
other than those being commonly applied in Sanger sequencing. This will remain as 
the biggest challenge, before the potential of NGS can be fully evaluated and utilized 
(McPherson, 2009). 
In this study, we decided to use NGS to investigate the miRNAs important for 
γ-herpesvirus infection, which had not been carried out before. The short lengths of 
NGS reads were ideal for the studies of miRNAs, and would reserve as much 
sequence information as possible for further analysis. However, at the time when this 
project started, there was no analysis tool publicly available for NGS data. So an 
automated software has been designed and developed for the analysis of NGS data 
used in this study (Figure 2.2).  
With the development of NGS applications, a couple of data processing programs 
were developed during the recent two years (Fahlgren et al., 2009; Friedlander et al., 
2008; Hackenberg et al., 2009; Pantano et al., 2010; Wang et al., 2009a). Compared 
to these complicated programs, the software used in this study still shows some 
advantages. 
First of all, the stand-alone software is easy to handle. Most of the other accessible 
programs only provide online versions. The large size of NGS data files has made 
them difficult for data transferring. The stand-alone software can directly process the 
data and save the results on the personal computers. Furthermore, the small program 
size and no need for installation make it easily sharing among the users to analyse 
desired NGS data. 
Second, this automated software has comprised much flexibility in the analysis of 
NGS data. Customized miRNA database and genome sequences can be applied as 
desired. This feature can not only keep pace with the newest version of the miRNA 
database from miRBase, but also enable the flexibility in the analyses of the 
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sequences corresponding to different viral genomes in this study, which is still not 
possible in the other programs. Compared to the pre-set settings of the other online 
programs, these basic but powerful functions of this software have realized all the 
demanded analyses in this study. Meanwhile, the parameters for the quality of 
sequence alignment can also be adjusted as desired, so that the results have been 
generated in the well-controlled processes. 
Third, this software uses slightly different strategies than most of the other programs 
in the analysis of small RNA NGS data (Figure 2.1). While the other programs first 
align all the sequences to the whole genomes, and define the miRNA abundance 
according to the reads corresponding to the gene loci, the software used in this study 
first aligns the sequences against the miRNA database, and directly defines the 
miRNA read numbers. The purpose behind was to facilitate the analysis of the huge 
dataset on the personal computers, by minimizing the size of target database. As a 
result, it was possible to analyse a single NGS library within several days, without the 
demand for a specialized powerful computer system. The experiences gained during 
NGS data analysis revealed that, a small RNA library of good quality contained at 
least 80% of the sequences generated from known miRNA genes. So the direct 
alignment to the miRNA database is effective and time-saving. 
Fourth, the use of this software can avoid the mistakes derived from the alignment to 
the whole genome. As shown in Result 2.4, a number of miRNA genes have been 
probably mis-annotated, some of which might derive from ncRNA pieces or truncated 
miRNAs with one mismatch. The design of this software can provide the results of 
alignment to miRNA or ncRNA databases with desired number of mismatched 
nucleotides. The exclusion of these reads with mismatches will avoid the improper 
annotation of miRNA genes.  
Meanwhile, all the information, including read numbers, read length, gene annotations 
and mismatch numbers, are all reserved in the result files, providing the possibility for 
the further analysis of interest, for instance, the analysis of variations in the 5 prime 
and 3 prime of miRNA reads.  
As illustrated by the small RNA libraries applied to NGS that are involved in the study 
of this thesis, the development of this software led to the convenient and powerful 
analysis of NGS data. And it will benefit further NGS libraries of interest in the small 
RNA research. 
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3.2  Identification of novel gammaherpesvirus miRNAs 
The identification of the novel gene category of miRNAs was the profoundly significant 
issue in biological study during the past decade. These small regulatory non-coding 
RNA genes, processed from imperfect pairing hairpin precursors, were first identified 
in the little model organism of worm (Lee et al., 1993; Wightman et al., 1993). Several 
years later, the study of miRNAs explosively expanded into various species of 
invertebrates, vertebrates, as well as plants. Consequently, also viruses were 
analysed and the question whether virus can also encode miRNA genes was 
successfully addressed for the first time in 2004 (Pfeffer et al., 2004). In their study, 
small RNA cloning in the EBV/B95.8 infected B lymphoma cell line resulted in the 
identification of five EBV miRNAs in total. However, the deletion region carried in the 
genome of EBV/B95.8 has resulted in the underestimation of miRNA gene numbers in 
EBV genome. 
Later on, the identification of viral miRNAs has been successfully carried out in a 
number of γ-herpesviruses, by classical small RNA cloning, or computational 
prediction (Cai et al., 2005; Cai et al., 2006; Grundhoff et al., 2006; Pfeffer et al., 
2005), leading to the characterization of a number of miRNA clusters existing in the 
γ-herpesvirus genomes. As the investigations began to focus on the functions of viral 
miRNAs, the advent of NGS technologies with more sensitive and powerful 
sequencing ability allowed the possibility to re-examine the viral genomes for the 
previously ignored miRNA genes. 
When the study of this thesis started, there was no report of NGS application to 
γ-herpesviruses related models. So the small RNA libraries were constructed from 
several EBV and MHV-68 related samples and analysed by 454 sequencing. As a 
result, two novel EBV miRNA precursors and six novel MHV-68 miRNA precursors 
have been successfully identified in this study. Some of these miRNAs showed 
significant expression levels with high read numbers in the sequencing libraries and 
clear bands in the Northern blotting, indicating the effectiveness of NGS in novel 
miRNA identification compared to the classical small RNA cloning and sequencing 
method. Of note, the identification of novel EBV miRNAs in this study was performed 
with the amount-restricted NPC samples from the patients. Almost all EBV miRNAs 
from the BART region, including the two novel EBV miRNAs, were readily detected in 
the sequencing libraries, highlighting the great capability of NGS in handling low 
quantity samples. 
During the analysis, 454 sequencing has produced enormous amount of reads 
including both viral and cellular sequences. Among the huge information, the 
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identification of novel miRNA genes has been carefully carried out and strictly 
controlled, so as to avoid the possible mistakes in the gene annotations, as illustrated 
in Result 2.4. The sequences, other than the known miRNA genes, have been 
seriously checked for their genome loci and sequence uniformity. The sequences that 
matched to other ncRNAs, and showed the diversity in start, termini and length were 
considered as degradation products from ncRNAs, and ignored in the analysis of 
novel miRNA candidates. Only those sequences, which had a distinct pattern of 
accumulative sequences with 20 to 23 nt, were analysed with their flanking 
sequences from the genome for the folding of the hairpin structure. Most of the 
identified novel miRNAs were successfully validated by means of Northern blotting or 
qRT-PCR. These rules were strictly applied to the identification work of EBV and 
MHV-68 miRNAs, as well as the cellular miRNAs from the human genome.  
Interestingly, several reports that were released at a similar time or later than this 
study have confirmed the characterized novel miRNA genes, but no further novel 
miRNA gene in EBV and MHV-68 has been identified or suggested (Reese et al., 
2010; Walz et al., 2010). These were very supportive evidence that the miRNA gene 
sets of EBV and MHV-68 have probably been completed. 
As consequences, the characterization of novel miRNA genes as well as the 
completion of miRNA gene sets will promote the studies of miRNA functions in EBV 
and MHV-68 infection and pathogenesis processes. 
 
3.3  Genome organization and evolutionary conservation of 
gammaherpesvirus miRNAs 
The first report of miRNA genes in EBV genome has answered the question, whether 
or not the small size of viral genome is capable of encoding miRNA genes as well 
(Pfeffer et al., 2004). Five years thereafter, more than 200 viral miRNA genes have so 
far been identified. Intriguingly, all of these viral miRNA genes were identified in the 
genomes of dsDNA viruses, the majority of which were herpesviruses (Skalsky and 
Cullen, 2010). No miRNA gene has been found in RNA virus yet. There might be 
several speculations for this interesting observation. RNA viruses, comprising 70% of 
all viruses, show much higher mutation rates than do the DNA viruses because of the 
error rate of the enzymes involved in RNA replication (Baron et al., 1991). This might 
interfere with the existence of specifically structured miRNA precursor genes in the 
RNA virus genome. In contrast, the relative stability of dsDNA virus genomes was able 
to reserve miRNA genes during evolution. Meanwhile, the unique ability of dsDNA 
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viruses, particularly the herpesviruses, to establish the long-term, latent infections, 
means that these viruses need to block the protective host innate or adaptive immune 
responses while minimizing the expression of potentially antigenic viral proteins. As a 
result, the tiny miRNA genes with regulatory functions could be an effective device to 
overcome these obstacles. Furthermore, the accessibility of these particular nuclear 
DNA viruses to the nuclear miRNA-processing machinery enables the biogenesis of 
the viral miRNAs. Of note, there is no viral protein characterized to be involved in the 
viral miRNA generation or regulatory pathways, depicting a solely cellular 
environment which the dsDNA viral miRNAs have nicely incorporated and utilized. 
The group of γ-herpesviruses have been mostly studied for viral miRNAs, with more 
than 100 miRNA genes identified so far from five model γ-herpesviruses infecting 
human, primates and mouse (Table 1.1). Interestingly, miRNA genes in the 
γ-herpesvirus genomes are all organized as clusters. For instance, EBV miRNAs, 
including the two novel miRNAs identified in this study, were clustered in BHRF1 and 
BART regions, respectively. The three BHRF1 miRNA genes were exclusively 
detectable during the latency III-infected lymphoblast and induced lytic replication (Cai 
et al., 2006; Xing and Kieff, 2007), and were absent in the NPC samples, too. The 
BART transcript, of which the protein product has been seeking for long but always 
failed, was then revealed to harbor 22 miRNA genes, grouped in two sub-clusters. 
The BART miRNAs were demonstrated to be produced from a long transcript, while 
the processing of pre-miRNAs from the primary transcript occurs prior to completion 
of the splicing reaction (Edwards et al., 2008). Similarly, MHV-68 miRNAs were also 
clustered in the first 6 kbp region of the genome. The completion of MHV-68 miRNA 
gene set and the detailed analysis of the unique vtRNA-miRNA-miRNA structures in 
this study have elucidated its specific organization. The feature that two miRNAs 
locate closely adjacent in the genome with only several nucleotides in between was 
nearly never seen in the other species. Meanwhile, these vtRNA-miRNA-miRNA 
pieces were probably transcribed as separate transcripts of approximately 200 nt, 
under the regulation of RNA polymerase III promoter (Bogerd et al., 2010). The 
compactness of the viral miRNA gene organization, illustrated by the little intergenic 
sequences and the shared promoter regions, has nicely reflected the restricted size of 
viral genomes for the goodness during evolution. 
On the other hand, γ-herpesviruses miRNAs showed much diversity in their 
sequences. There are a considerable number of miRNA genes that are highly 
conserved among animals or plants. These are normally abundantly expressed 
miRNAs with important regulatory functions, indicating the indispensible roles of 
miRNA genes during evolution. However, the homology among γ-herpesviruses 
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miRNAs is very limited. The genomes of the γ-herpesviruses shared some similarities 
in the organization of ORFs (Simas and Efstathiou, 1998), but the overall identity of 
their genome sequences is not high. Recently, a global analysis has been performed 
among all the known and computationally predicted miRNA genes from the 
γ-herpesviruses (Walz et al., 2010). Surprisingly, only two pairs of viral genomes 
produced viral miRNAs with homology. One pair was EBV and rLCV, which shared 
60% identity in the genome sequences. All of the three EBV BHRF1 miRNA 
precursors, and 19 of the 22 BART miRNA precursors, including the ebv-mir-BART21 
identified in this study, found their orthologs in rLCV genome, while the other 13 rLCV 
miRNA precursors were not conserved. Another pair was rhesus rhadinovirus (RRV) 
and the closely related Japanese macaque herpesvirus (JMHV). They shared at least 
nine conserved miRNA precursors. The analysis of MHV-68 miRNA genes in this 
study has also confirmed the limitation in the sequence homology (Figure 2.12). Only 
one MHV-68 miRNA was found to have the same seed sequence as a KSHV miRNA, 
however, the little identity in the remaining nucleotides do not qualify them as 
orthologs. The limited conservations among γ-herpesvirus miRNA sequences implied 
their later and independent derivation processes during evolution of the viruses, which 
might be an interesting and significant aspect in studying the overall origination of 
miRNA genes. 
 
3.4  EBV and tumorigenesis 
EBV infection is benign and uneventful in the majority of humans, nevertheless, its 
presence in a spectrum of malignancies, varying from the T cell and B cell lymphomas 
in the immune system to the epithelial carcinomas in the nasopharynx and stomach, 
implies its role in the tumorigenesis processes (Kutok and Wang, 2006).  
The transforming events initiated by EBV have been studied through different aspects. 
Now the upcoming roles of miRNA regulation might be another significant component 
of this puzzle. 
A couple of cellular miRNAs have been revealed to be induced by EBV in the 
lymphoid malignancies, such as mir-146a and mir-155 (Cameron et al., 2008b; Gatto 
et al., 2008; Rahadiani et al., 2008). In this study, the NPC samples analyzed by NGS 
provided the opportunity to systematically depict the miRNA regulation for the first 
time in the EBV-related epithelial carcinomas. 
Like other tumours, the NPC samples were characterized by distinct miRNA 
expression profiles. In particular, hsa-mir-23a/b, hsa-mir-200c, and hsa-mir-27a/b 
were significantly upregulated, whereas hsa-mir-320, hsa-mir-17-5p, and hsa-mir-652 
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were downregulated in the NPC samples compared to the healthy control tissues 
(Figure 2.8). Bioinformatic predictions suggested that hsa-mir-23a and hsa-mir-23b, 
which are the most abundant miRNAs in the NPC samples, may regulate the tumour 
suppressors ITGB1 (integrin-beta1), LIG4 (ATP-dependent DNA ligase IV), and SAFB 
(scaffold attachment factor B). It was tempting to speculate that other upregulated 
miRNAs might target tumour suppressors as well. Indeed, it was exemplified in this 
study that, the expression of hsa-mir-15a and hsa-mir-16 were elevated in the NPC 
samples, and both miRNAs can target BRCA1, a tumour suppressor gene important 
for breast carcinoma (Wang, 2007). Interestingly, miR-15a and miR-16 have been 
implicated in cancers before. In B cell lymphocytic leukemia, miR-15a and miR-16 
expression is downregulated, and it has been suggested that both miRNAs target the 
oncogene bcl-2 (B cell lymphoma 2) (Cimmino et al., 2005). The dual role of the 
miRNAs indicated the complexity and tissue specificity in the miRNA functions. On the 
other hand, miR-15 and miR-16 induction and BRCA1 downregulation were observed 
similarly in MHV-68 infected NIH 3T3 cells (Figure 2.18). Notably, there was a report 
that NIH 3T3 cells, when ectopically expressed an RNA transcript that was antisense 
to the BRCA1 mRNA and thus inhibited the expression level of BRCA1 protein, 
showed accelerated and anchorage-independent growth as well as tumorigenecity in 
nude mice (Rao et al., 1996). Taken together, this suggested a common feature 
during the γ-herpesviruses infection which might contribute to the transformation of 
host tissues. 
In addition, the expression levels of EBV encoding miRNAs were also well depicted in 
this study. Almost all miRNAs from the BART cluster were readily detected in the NPC 
samples. Several BART miRNAs, including the newly identified ebv-mir-BART21 and 
ebv-mir-BART22, were abundantly expressed (Figure 2.7), suggesting that these 
miRNAs may have important functions in maintaining the virus in NPC tissues. Of 
note, no miRNA originating from the BHRF1 region was found in the data sets, in line 
with the observation of the EBV-positive gastric cancer samples (Kim do et al., 2007), 
while in contrast to the situation in the latency III-infected B cell lymphoblasts (Cai et 
al., 2006; Xing and Kieff, 2007). The differences in the EBV latency stages and 
corresponding miRNA expression sets might further inspire the studies of 
tumorigenesis processes in EBV-related epithelial carcinomas and lymphomas. 
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3.5  MHV-68 miRNA expression signatures 
In this study, NGS was also applied to cell lines infected with MHV-68, which is a 
powerful model virus infecting murine cells, to globally investigate the viral and cellular 
miRNA expression patterns. 
Almost all MHV-68 miRNAs were detectable in the two infected cell lines that have 
been sequenced (Table 2.7). Overall, the persistently infected S11 cells showed a 
much higher MHV-68 miRNA expression level than the lytically infected NIH 3T3 cells 
(Figure 2.11). Mghv-mir-M1-1, mghv-mir-M1-8 and mghv-mir-M1-9 were the three 
most abundant miRNAs in both cell lines. Mghv-mir-M1-5* was more abundant than 
mghv-mir-M1-5 in infected NIH 3T3 cells, while in S11 cells, mghv-mir-M1-5 was 
expressed at a higher level. Such different MHV-68 miRNA expression patterns might 
be suggestive for distinct functions during lytic and persistent/latent infection.  
By Northern blotting, the expression of three (mghv-mir-M1-10, mghv-mir-M1-12 and 
mghv-mir-M1-14) of the six novel MHV-68 miRNAs were well demonstrated. Although 
found with a comparable read number in NGS data sets, mghv-mir-M1-13 was hardly 
detectable by Northern blotting. This might be due to its low GC content. However, the 
expression of mghv-mir-M1-13 was shown by a more sensitive stem-loop qRT-PCR. 
This is consistent with a recent report that reverse ligation-mediated RT-PCR 
(RLM-RT-PCR) is able to detect mature MHV-68 miRNAs with at least 100-fold higher 
sensitivity than Northern blotting (Diebel et al., 2010). The expression of 
mghv-mir-M1-11 and mghv-mir-M1-15 with extremely low read numbers in NGS data 
was too low to be detected by either Northern Blotting or stem-loop qRT-PCR. 
MHV-68 miRNAs are among the minor portion of miRNAs that are under the 
regulation of RNA Polymerase III. It has been recently shown that the generation of 
MHV-68 miRNAs is dependent on the A/B boxes in the vtRNA sequences as well as 
the presence of tRNase Z and Dicer, but not on Drosha (Bogerd et al., 2010; Diebel et 
al., 2010). By infecting the Dicer-deficient MEFs with MHV-68, it was confirmed that 
MHV-68 miRNAs are processed by a Dicer-dependent pathway (Figure 2.16). 
Importantly, while Bogerd et al. (Bogerd et al., 2010) showed Dicer-dependency by 
siRNA-mediated knockdown of Dicer in human (HeLa) cells transfected with an 
MHV-68 miRNA expression plasmid, this study demonstrated it by infection of 
authentic host cells (Dicer-/- and Dicer+/+ MEFs) with MHV-68. 
The vtRNAs were identified and characterized more than ten years ago and were 
shown to be non-amino-acetylated (Bowden et al., 1997). However, their function still 
remains unknown. With the characterization of MHV-68 miRNA organization, it might 
be speculated that the vtRNA sequences remained as remnants during evolution, and 
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serve now as the promoter sequences for the generation of MHV-68 miRNAs. How 
the differential expression of MHV-68 miRNAs is regulated, and the significance of the 
existence of the vtRNA-miRNA-miRNA structures, will be interesting to further 
investigate. 
MHV-68 miRNAs were shown to be efficiently associating with the RISC complexes 
by immunoprecipitation using a monoclonal anti-mouse Ago2 antibody, implying that 
they are functional as cellular miRNAs (Figure 2.15 A). However, the functions of 
MHV-68 miRNAs are still to be explored. By matching the seed sequences of MHV-68 
miRNAs, they are predicted to target both viral and cellular proteins. The abundance 
of MHV-68 miRNAs might also suggest that they could function by occupying the 
cellular RISC machinery, thus interfering with the normal cellular miRNA pathways. 
The attenuated but not lethal phenotype of a spontaneous MHV-68 mutant virus 
lacking the first 9.5 kbp of the genome, including all vtRNAs and miRNAs, indicated 
that the vtRNAs and miRNAs are not absolutely essential for lytic replication and for 
the establishment and maintenance of latency (Clambey et al., 2002). 
Apart from MHV-68 miRNAs, the small RNA libraries also allowed the analysis of the 
expression signatures of cellular miRNAs in non-infected versus infected NIH 3T3 
cells (Figure 2.17). The upregulation of mmu-mir-15b and mmu-mir-16, and the 
downregulation of their correlated target protein BRCA1 were further validated.  
Altogether, NGS application of small RNAs expressed in lytically infected NIH 3T3 
cells and in persistently infected S11 cells provided the first comprehensive overview 
of both MHV-68 and cellular miRNA expression in infected cells, and completely 
defined the miRNA coding potential of MHV-68. These data would aid to fully explore 
the functions of γ-herpesvirus miRNAs. 
 
3.6  Further application of NGS in miRNA studies 
The application of NGS technologies in miRNA studies has been exemplified in 
various reports, including the study of this thesis. Its advantages of producing 
enormous amount of short reads with low cost and fast speed, not only possess the 
powerful and sensitive sequencing capability that is able to reserve as much 
sequence information as possible from little amount of samples, but also provide the 
possibility to analyse the miRNA expression levels represented by sequence 
frequencies in the libraries at the same time. The identification of novel miRNA genes 
and the profiling of cellular miRNA expressions performed in this thesis all relied and 
were benefited from these advanced technologies. However, several problems came 
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into sight and waited for some better solutions, before NGS would exert more 
significant functions.  
First, the identification of novel miRNA genes by NGS has led to the possible 
mis-annotations of some miRNA genes in the database, as illustrated in Result 2.4. 
This problem was noticed when a miRNA gene was observed to be strongly induced 
during MHV-68 infection in NIH 3T3 cells. Later on, the close examination revealed 
that this so-called miRNA gene was actually a piece of rRNA. It was not surprising that 
rRNA degradation product accumulated during the virus infection.  
Thus, the interference of the mis-annotated miRNA genes during research has driven 
the systematic examination of ncRNA-matched human and murine miRNAs. The 
result was surprising. More than 20 miRNA genes were found to be suspiciously 
mis-annotated in both human and murine miRNA sets, constituting more than 2% of 
the miRNA genes in the current version of miRBase release. Almost all of these 
mis-annotated miRNA genes derived from NGS projects. The direct alignment of the 
reads to the genome sequence, together with the subsequent folding of the 
suggestive novel miRNA genes, which were performed automatically by NGS data 
processing programs, might be the reason for the generation of these mis-annotated 
miRNA genes. A standardized and well-controlled program, which can reasonably 
meet the needs during small RNA NGS data analysis and be popularly shared among 
the investigators in miRNA field, might be beneficial to avoid such problems. The 
difficulties of validating low abundant miRNAs by any method led to the registration of 
these mis-annotated miRNA genes in the database without careful control. To solve 
these problems in the future, more strict criteria, such as the validation of novel 
miRNA expression from the suggested precursor sequence in artificial vectors, might 
be necessary. 
Second, the miRNA profiling, which has been performed by many NGS projects 
nowadays, is only semi-quantitative. The many steps during the sample preparation, 
especially the primer ligation, reverse transcription and sample amplification steps, 
not only make the absolute quantification impossible, but introduce the biases to the 
samples that might further disturb the interpretation of the sequencing results as well. 
This might be the reason that some sequencing results cannot be validated by other 
method. Meanwhile, there also exists the difference of the results among different 
NGS platforms. Recently, a systematic study has been performed under well control 
to compare the results from microarrays, NGS platform and qRT-PCR method (Git et 
al., 2010). The study suggested serious consideration of the differences in the results 
generated from these common methods applied in miRNA profilings. Furthermore, the 
lack of a proper internal normalization control among the small RNA data makes the 
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miRNA absolute quantification impossible, too. The application of the synthetic small 
RNA samples might be a solution, however, the correlations might vary according the 
miRNA concentration (Fahlgren et al., 2009; Willenbrock et al., 2009). 
As consequences, the development of the direct RNA sequencing method, namingly 
RNA-seq, which does not demand the conversion of RNAs to cDNAs and sample 
amplification, was very attractive and regarded as the solutions to the second problem 
mentioned above (Wang et al., 2009b). The direct depiction of the real RNA world 
would probably revolutionize studies in miRNA field. 
Taken together, the miRNA world, which has just been under the exploration for about 
ten years, still has many mysteries to be further investigated. The great potential of 
NGS technologies, largely promoting miRNA studies during the past five years, was 
well illustrated in this thesis by the identification of novel miRNA genes from 
γ-herpesviruses, and significant profilings of cellular miRNAs. NGS technologies will 
for sure continue to benefit the researches in miRNA field in the future, with 
improvements in the applications.  
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4.  MATERIALS & METHODS 
4.1  Materials 
4.1.1 Chemicals and enzymes 
Unless stated otherwise, all chemicals were purchased from Amersham Bioscience 
(Buckinghamshire,UK), Biorad (Hercules, USA), Merck (Darmstadt, Germany), 
Qiagen (Hilden, Germany), Roche (Penzberg, Germany), Roth (Karlsruhe, Germany) 
and Sigma-Aldrich (Munich, Germany). Radioactive chemicals were provided by 
Perkin Elmer (Waltham, USA). Enzymes were delivered from New England Biolabs 
(Ipswich, USA) and Fermentas (Burlington, Canada). 
 
4.1.2 Plasmid 
pMIR-TK-RNL  is referred in short as pMIR in this work. It is modified from 
the commercially available pMIR-REPORT plasmid by 
Ambion (Austin, USA) (Beitzinger et al., 2007). It encodes 
for the Phototinus pylaris luciferase (in this work termed 
firefly). The original CMV promoter was replaced by 
HSV-TK promoter which was PCR-cloned from pRL-TK 
plasmid (Promega, Madison, USA). A Renilla reniformis 
luciferase (in this work termed renilla) under the control of a 
SV40 promoter and a poly(A) site was PCR-amplified from 
pRL-SV40 plasimid (Promega, Madison, USA) and inserted 
into SspI site of pMIR-REPORT. The firefly coding 
sequence is flanked by a multiple cloning site (MCS) at its 
3’ end, allowing for the introduction of regulatory sequences 
into the 3’UTR. The plasmid carries an ampicillin 
resistance. 
 
4.1.3 Antibodies 
-HA Abcam (Cambridge, USA) 
-human Ago1 (4B8) monoclonal, rat hybridoma supernatant 
 (Beitzinger et al., 2007) 
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-human Ago2 (5D4)  monoclonal, rat hybridoma supernatant 
 (Beitzinger et al., 2007) 
-mouse Ago2 (6F4) monoclonal, rat hybridoma supernatant 
-human RmC (16D2) monoclonal, rat hybridoma supernatant  
-BRCA1 #MS110, Merck (Darmstadt, Germany) 
-β-actin Abcam (Cambridge, USA） 
-mouse IgG peroxidase conjugated, Sigma-Aldrich (Munich, Germany) 
 
4.1.4 Tissue samples 
NPC samples Biopsies were taken from the nasopharynx in an area 
where there was clinical evidence of tumor, and control 
tissues were taken from clinically normal mucosa from the 
opposite side of the nasopharynx in the same patient. 
 
4.1.5 Bacterial strains, virus stock and cell lines 
Bacterial strains: E. coli XL1 blue 
Virus stock: wildtype MHV-68 (clone G2.4), kindly provided by Dr. A. 
Nash (University of Edinburgh, Edinburgh, UK) 
Cell lines: Ag-8 
 BL41 
 BL41/B95.8 
 C666.1 
 Dicer+/+ MEF (Parameswaran et al., 2010) 
 Dicer-/- MEF (Parameswaran et al., 2010) 
 EREB2.5 
 HEK 
 Jijoye 
 MCF7 
 NIH 3T3 
 S11, kindly provided by Dr. J.P. Stewart (University of 
Liverpool, Liverpool, UK) 
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4.1.6 Cell culture media 
For the cultivation of BL41, BL41/95.8, EREB2.5, Jijoye cell lines: 
RPMI 1640 medium with L-glutamine (PAA, Pasching, Austria) 500mL 
fetal bovine serum (Biochrom, Berlin, Germany) 10% 
penicillin/streptomycin (PAA, Pasching, Austria) 1% 
 
For the cultivation of C666.1 cell line: 
RPMI 1640 medium with L-glutamine 500mL 
fetal bovine serum 10% 
penicillin/streptomycin 1% 
HEPES (Sigma-Aldrich) 25mM 
 
For the cultivation of Ag-8, S11 cell lines: 
RPMI 1640 medium with L-glutamine 500mL 
fetal bovine serum 10% 
penicillin/streptomycin 1% 
2-Mercaptoethanol (Sigma-Aldrich) 50μM 
 
For the cultivation of HEK, NIH 3T3 cell lines: 
DMEM medium with L-glutamine (PAA, Pasching, Austria) 500mL 
fetal bovine serum 10% 
penicillin/streptomycin 1% 
 
For the cultivation of Dicer+/+ MEF, Dicer-/- MEF cell lines: 
DMEM medium with L-glutamine 500mL 
fetal bovine serum 10% 
penicillin/streptomycin 1% 
HEPES 10mM 
 
For the cultivation of MCF7 cell lines: 
DMEM medium with L-glutamine 500mL 
fetal bovine serum 10% 
penicillin/streptomycin 1% 
bovine insulin (Sigma-Aldrich) 18μg/mL 
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4.1.7 Buffers and solutions 
LB (lysogeny broth) media 1% (w/v) Bacto Trypton 
 0.5% (w/v) NaCl 
 0.5% (w/v) Yeast extract 
 
Phosphate buffered saline 137 mM NaCl 
(PBS)   2.7 mM KCl 
 4.3 mM Na2HPO4 
 1.4 mM KH2PO4 
 adjust pH to 7.5 
 
HEPES 2x for Calcium 274 mM NaCl 
phosphate transfection 54.6 mM HEPES 
 1.5 mM Na2HPO4 
 adjust pH to 7.1 
 
Cell lysis buffer  150 mM KCl 
 25 mM  Tris pH 7.5 
 2 mM EDTA 
 1 mM NaF 
 0.5% NP-40 
 0.5mM ABESF (add freshly) 
 0.5mM DTT (add freshly) 
 
RIPA buffer-300 50 mM Tris pH7.5 
 300 mM NaCl 
 1%  Triton X 100 
 1% Sodium deoxycholate 
 0.1% SDS 
 
Protease K buffer, 2x 300 mM NaCl 
 200 mM Tris pH 7.5 
 25 mM EDTA 
 2% SDS 
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1x TBE buffer 89 mM Tris-BASE 
 89 mM  boric acid 
 2.5 mM EDTA 
 
DNA loading dye 5x 15 g Saccharose 
 50 ml H2O 
 0.025% Xylene cyanol 
 
20x SSC 3 M NaCl 
 0.3 M Sodium citrate 
 adjust pH to 7.0 
 
EDC cross-link solution 0.13 M 1-Methylimidazole (pH 8) 
 0.16 M EDC 
 
50x Denhardt’s solution 1% Albumin fraction V 
 1% Polyvinylpyrrolidon K30 
 1% Ficoll 400 
 
Hybridization solution 7.5 ml 20x SSC 
 21.0 ml 10% SDS 
 0.6 ml 1 M Na2HPO4 pH 7.2 
 0.6 ml 50x Denhardt’s solution 
 3 mg Salmon Sperm DNA   
 
Northern blotting wash solution I 25% 20x SSC 
 1% SDS 
 
Northern blotting wash solution II 5% 20x SSC 
 1% SDS 
 
RNA loading dye 1x 90% Formamide 
 0.025% Xylene cyanol 
 0.025% Bromophenol blue 
  in 1x TBE 
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Denaturing polyacrylamide gels for northern blotting 
15% 10% SequaGel Buffer (national 
diagnostics, Atlanta USA) 
 60% SequaGel Concentrate 
 30% SequaGel Diluent 
 0.1% APS 
 0.05% TEMED 
 
SDS running buffer 200 mM Glycin 
 25 mM Tris-BASE 
 0.1% (w/v) SDS 
 
Towbin-blotting buffer 40 mM Glycin 
 50 mM Tris-BASE 
 0.037% (w/v) SDS 
 20% Methanol 
 
Western blotting wash buffer 30 mM Tris-BASE 
 150 mM NaCl 
 0.25% Tween-20 
 adjust PH to 7.5 
 
Chemiluminescence 100 mM Tris pH 8.5 
detection 1.2 mM Luminol          in 10 ml 
 0.68% p-cumaric acid   in 150 µl 
  H2O2 (30%)       11 µl 
  mix all components before use 
 
Protein sample buffer 5x 400 mM Tris/HCl pH 6.8 
 5 mM EDTA 
 0.01% Bromphenol blue 
 50% Glycerin 
 1% (w/v) SDS 
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Polyacrylamide gels for SDS-PAGE 
5% stacking gel 5% Acrylamide 37,5:1 
 75 mM Tris pH 6.8 
 0.1 % SDS 
 0.1 % APS 
 0.05% TEMED 
 
10% separation gel 10% Acrylamide 37.5:1 
 400 mM Tris pH 8.0 
 0.1% SDS 
 0.1% APS 
 0.05% TEMED 
 
Renilla buffer 2.2 mM EDTA 
 220 mM K2PO4 pH 7.2 
 0.44 mg/ml BSA 
 1.1 M NaCl 
 1.3 mM NaN3 
 1.43 µM Coelenterazine (P.J.K.,  
  Kleinblitterdorf, Germany) 
  (add freshly) 
 
Firefly buffer 470 µM D-luciferin (P.J.K., 
  Kleinblitterdorf, Germany) 
 530 µM ATP (P.J.K., 
  Kleinblitterdorf, Germany) 
 270 µM Coenzyme A (P.J.K., 
  Kleinblitterdorf, Germany) 
 20 mM Tricine 
 5.34 mM MgSO4 pH 7.2 
 0.1 mM EDTA 
 33.3 mM DTT 
  (add freshly) 
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4.2  Methods 
4.2.1 Molecular biological methods 
4.2.1.1  General methods 
Any less detailed descriptions of molecular biological standard methods (DNA/RNA 
gel-electrophoresis, -extraction, -precipitation and the determination of concentrations 
of nucleic acids, PCR, etc.) were performed as described in Sambrook et al. 
(Sambrook et al., 1989) or according to the manufacturers' instructions, respectively. 
There, one can also find the composition of not listed buffers and solutions. 
The isolation of plasmid-DNA from E. coli was carried out by using Plasmid MiniKit I® 
(Omega BioTek, Darmstadt, Germany) or NucleoBond® XtraMidi-Kit (Macherey Nagel, 
Düren, Germany), respectively. For the elution of DNA fragments from agarose gels, 
the NucleoSpin®-Kit (Macherey Nagel, Düren, Germany) was used. 
 
4.2.1.2  Cloning of 3’UTRs from cDNA library into pMIR-TK-RNL 
pMIR-TK-RNL miRNA reporter plasmids which express the firefly luciferase ORF 
fused to a cleavage site complementary to a small RNA or a regulatory 3’UTR 
sequence and renilla luciferase as a transfection control were generated from 
pMIR-REPORT as described above (Beitzinger et al., 2007) 
3’UTRs were amplified by polymerase chain reaction (PCR). As template, cDNA 
library of HEK cells was used. PCR amplification was performed by the Phusion™ 
polymerase (Finnzymes, Espoo, Finland). PCR products were digested with 
restriction enzymes SacI and NaeI and cloned into MCS of the reporter plasmid 
pMIR-TK-RNL. 
The DNA oligos used as primers for PCR amplifications are as followed: 
(human) BRCA1-3’UTR:  
forward: 5’- GCTGAGCTCCTGCAGCCAGCCACAGGTACAGAGCC -3’ 
reverse: 5’- CGCTGCCGGCGAAGTGTTTGCTACCAAGTTTATTTGCAGTG -3’ 
 
4.2.1.3  RNA Extraction from tissue samples or cultured cells 
a) Total RNA extraction (mRNA and miRNAs) 
Extraction of RNA was performed following the TriFast® protocol (Peqlab, Erlangen, 
Germany). Briefly, tissue samples were frozen by liquid nitrogen and squeezed to 
powders by grinder. Grinded tissue samples or cultured cells were homogenized by 
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pipetting up and down several times in an appropriate amount of TriFast. Samples 
were incubated for a few minutes at room temperature to let nucleoprotein complexes 
dissociate. 200 µl chloroform per 1 ml TriFast were added. The samples were mixed 
for 20 seconds and centrifuged for 20 minutes at full speed and 4°C in a desk top 
centrifuge resulting in the dissociation of organic and aqueous phase. The upper 
phase (approx. 500 µl) was pipetted into a new sterile reaction tube containing 1 ml 
isopropanol for the precipitation of mRNA. If miRNA was desired, the upper phases 
were distributed into three tubes, which were further filled up with absolute ethanol. 
RNA was precipitated at -20°C overnight. After pelleting the RNA for 15 minutes by 
centrifugation at full speed at 4°C, isopropanol or absolute ethanol was removed 
thoroughly and the pellet washed with 80% ethanol. After pelleting and removing the 
ethanol, the RNA was air-dried for 5 minutes and was dissolved at 70°C in an 
appropriate amount of ddH2O. 
 
b) RNA exraction of immunopurified complexes and input samples 
Cells were usually lysed in 1ml lysis buffer per 15 cm plate. For input samples, usually 
100 µl lysate (generally 1/10 of lysate used for immunoprecipitation) was digested in 
200 µl 2x proteinase K buffer containing 40 mg Proteinase K. RNA from 
immunopurified samples was directly isolated from antibody coupled beads by adding 
200 µl 2x proteinase K buffer containing 40 mg Proteinase K. Proteinase K digestion 
was performed for 20 minutes at 65°C, followed by two times phenol/chloroform/iso- 
amylalcohol extractions. For subsequent RNA precipitation, the aqueous phase was 
mixed with three volumes (miRNAs) or two volumes (mRNAs) of absolute ethanol and 
incubated at -20°C. After pelleting the RNA for 30 minutes by centrifugation at 17’000g 
at 4°C, ethanol was removed thoroughly and the pellet was air-dried for 5 -10 minutes. 
RNA was dissolved at 70°C in an appropriate amount of ddH2O. 
 
4.2.1.4  Ago complex purification 
Desired cells were lysed in cell lysis buffer and centrifuged at 10,000 g for 10 min at 
4°C. For immunoprecipitation (IP) of endogenous Ago complexes, 100 µl Protein G 
Sepharose (GE Healthcare, Munich, Germany) was washed with PBS and incubated 
with 2ml of hybridoma supernatant of monoclonal antibody anti-human-Ago1(4B8), 
anti-human-Ago2(5D4), or anti-Rmc, respectively, at 4°C with gentle agitation 
overnight. After several wash steps with PBS, beads were incubated with cell lysates 
for 3 h at 4°C. After incubation, beads were washed five times using RIPA-300 buffer. 
RNA was isolated with 40 mg Proteinase K in 200 µl Proteinase K buffer followed by 
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phenol/chloroform/iso-amylalcohol extractions and ethanol precipitation. For the 
immunoprecipitation with purified monoclonal antibody anti-mouse-Ago2(6F4) and 
commercial antibody anti-HA, 10µg/ml of respective antibody was first mixed with cell 
lysates under constant rotation at 4°C for 3h. Protein G Sepharose beads were added 
to the lysates and the rotation continued for 1h. The washing of beads and 
precipitation of RNAs were performed as described above. 
 
4.2.1.5  RNA polyacrylamide gel electrophoresis 
For the detection of miRNA species, denaturing RNA polyacrylamide 
gel-electrophoresis was performed using the SequaGel® System Kit (National 
Diagnostics, Atlanta, USA). The acrylamide concentration was 15%. Before loading, 
the samples were provided with 2x dye and denatured for 5 min at 95°C. The gel was 
pre-run for 10-15 min at 10W. 1x TBE was used as running buffer. Samples were 
loaded after rinsing each pocket with buffer and the gel was run 28W. 
 
4.2.1.6  Northern blotting 
After adding formamide loading dye, the RNAs were separated by electrophoresis 
usually on a 15% denaturing polyacrylamide gel and transferred to Hybond-N 
membrane (Amersham Bioscience, Buckinghamshire, UK) by semidry blotting for 30 
min with 20 V. H2O was used to pre-wet three sheets of Whatman, the membrane and 
another three sheets of Whatman on top of the gel. After blotting was completed, the 
damp membrane was removed and placed with RNA side face up on top of a 
Whatman paper saturated in freshly prepared cross-linking EDC solution (Pall et al., 
2007). Wrapped in Saran, the membrane was incubated for 1 h at 50 °C. After 
cross-linking the membrane was rinsed in excess RNase-free distilled water and dried. 
Pre-hybridization was performed in hybridization solution for 1 h at 45°C, before a 
5'-32P-labeled probe (see below) was added for hybridization overnight at 45°C. 
Subsequently, the membrane was washed in 10-min intervals twice with wash 
solution I and once with wash solution II. Exposure to Kodak BioMax MS films was 
performed with an intensifying screen (Kodak, Stuttgart, Germany) at –80°C.  
For Northern probe preparation, 10 pmol of synthetic DNA-oligonucleotides (Metabion, 
Martinsried, Germany) reverse complementary to the appropriate miRNA were 
radio-labeled in a T4-Polynucleotide kinase (Fermentas, Burlington, Canada) reaction 
in the presence of [γ-32P]-ATP (Perkin Elmer, Waltham, USA) according to standard 
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protocols. Subsequently, the probe was purified by gel filtration using MicroSpin G-25 
columns (GE Healthcare, Munich, Germany). 
The following probes for Northern blotting were used: 
hsa-mir-16: 5’- CGCCAATATTTACGTGCTGCTA -3’ 
ebv-mir-BART1-5p: 5’- CACAGCACGTCACTTCCACTAAGA -3’ 
ebv-mir-BART4: 5‘- AGCACACCAGCAGCATCAGGTC -3‘ 
ebv-mir-BART21-5p: 5‘- GTTAGTTGCCTTCACTAGTGA -3‘ 
ebv-mir-BART21-3p: 5‘- AAACACCAGTGGGCACAACTAG -3’ 
ebv-mir-BART22: 5’- ACTACTAGACCATGACTTTGTA -3’ 
mmu-mir-15b: 5’- TGTAAACCATGATGTGCTGCTA -3‘ 
mmu-mir-16: 5’- CGCCAATATTTACGTGCTGCTA -3‘ 
mmu-mir-21: 5’- TCAACATCAGTCTGATAAGCTA -3‘ 
mghv-mir-M1-1: 5’- AAAGGAAGTACGGCCATTTCTA -3‘ 
mghv-mir-M1-8: 5’- GACCAAACCCCCAGTGAGTGCT -3‘ 
mghv-mir-M1-10: 5’- AAAGAACCTTCCGTGTAATCA -3‘ 
mghv-mir-M1-12: 5’- GCGTCGGGACCCGGGA -3‘ 
mghv-mir-M1-13: 5’- AAAGGGGTAGGACTCCCACACCAAA -3‘ 
mghv-mir-M1-14: 5’- AAAGAAGAGCTCACATGAGATA -3‘ 
tRNA-Met: 5’-TGGTAGCAGAGGATGGTTTCGATCCATCGACCTCTG -3‘ 
 
4.2.1.7  Reverse transcription and qRT-PCR of mRNA detection 
RNA was isolated as described above and dissolved in 12 μl H2O. RNA was first 
treated with DNaseI to remove DNA contaminations using the following reaction mix: 
12 μl RNA, 1.5 μl DNaseI buffer (Fermentas), 1 μl DNaseI (Fermentas) and 0.5 µl 
RiboLock (Fermentas). DNaseI digest was performed for 30 minutes at 37°C. 
Afterwards the enzyme was inactivated for 10 minutes at 70°C and reaction was 
cooled on ice. Then, cDNA synthesis was performed in a final 30 μl reaction using 
First Strand cDNA Synthesis-Kit from (Fermentas), according to the manufacturer’s 
protocol, using oligo(dT) as primers. 
Quantitative real-time reverse transcription-PCR (qRT-PCR) was performed using 
MESA Green qPCR Mastermix Plus for SYBR green assay with fluorescein 
(Eurogentec, Seraing, Belgium) and carried out on a MyiQ single-color real-time PCR 
detection system (Bio-Rad, Hercules, USA) with supplied software. The qRT-PCR 
reactions were set up as 25 μl reactions: 12.5 μl MESA GREEN qPCR kits for SYBR® 
Assay, 0.5 μl, forward RT-primer (10 μM), 0.5 μl reverse RT-primer (10 μM), 11.5  μl 
cDNA (1:5 or 1:10 diluted). The glyceraldehyde-3-phosphate dehydrogenase 
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(GAPDH) mRNA or 18S rRNA level was used for normalization. Error bars are derived 
from three individual measurements. 
The following pimers for mRNA qRT-PCR were used: 
(human)BRCA1, forward: 5’- TAAGCCAGAATCCAGAAGGC -3’ 
(human)BRCA1, reverse: 5’- GGGATGACCTTTCCACTCCT -3’ 
(human)GAPDH, forward: 5’- AATGGAAATCCCATCACCATCT -3’ 
(human) GAPDH, reverse: 5’- CACCCCACTTGATTTTGG -3’ 
(mouse)BRCA1-primer1, forward: 5’- TTGTGAGCGTTTGAATGAGG -3’ 
(mouse)BRCA1-primer1, reverse: 5’- CTGTCCTTCAAGGTGGCATT -3’ 
(mouse)BRCA1-primer2, forward: 5’- CAAGGCGAGAGCTAGAAGGA -3’ 
(mouse)BRCA1-primer2, reverse: 5’- AATGTGGGCTGGCTCTTTAG -3’ 
(mouse)18S rRNA, forward: 5’- CGGCTACCACATCCAAGGAA -3’ 
(mouse)18S rRNA, reverse: 5’- GCTGGAATTACCGCGGCT -3’ 
 
4.2.1.8  Reverse transcription and qRT-PCR of miRNA detection 
Mature miRNAs were modified and validated as described (Hurteau et al., 2006). 
Total RNA was extracted as described above. Poly(A) tail was added to 1.0 g RNA 
using Poly(A) Tailing Kit (Ambion, Austin, USA). The Adaptor-primer 
AACGAGACGACGACAGACTTTTTTTTTTTTTTTV was used in reverse transcription 
using First Strand cDNA synthesis Kit (Fermentas). qRT-PCR was performed using 
MESA Green qPCR Mastermix Plus for SYBR Assay with fluorescein (Eurogentec, 
Seraing, Belgium), and carried out on MyiQTM Single Color Real-Time PCR 
Detection System (Bio-Rad, Hercules, USA) with supplied software. GAPDH mRNA 
level was used for normalization. Error bars are derived from three individual 
measurements. 
The following pimers for poly(A)-tailed miRNA qRT-PCR were used: 
Universal PCR primer: 5‘- AACGAGACGACGACAGACTTT -3‘ 
ebv-BART1-5p: 5‘- TCTTAGTGGAAGTGACGTGCTGT -3‘ 
ebv-mir-BART21-5p: 5’- TCACTAGTGAAGGCAACTAAC -3’ 
ebv-mir-BART21-3p: 5’- CTAGTTGTGCCCACTGGTGTTT -3‘ 
ebv-mir-BART22: 5‘- TACAAAGTCATGGTCTAGTAGT -3‘ 
(human)GAPDH: 5‘- CCATCAATAAAGTACCCTGTGCTCAACC -3‘ 
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4.2.1.9  Reverse transcription and stem-loop qRT-PCR of miRNA detection 
Real-time quantification of miRNAs by stem-loop qRT-PCR was carried out as 
described (Chen et al., 2005). Total RNA was isolated using the miRneasy Kit (Qiagen, 
Hilden, Germany) according to manufacturer’s protocol. 1 µg of RNA was 
reverse-transcribed using Superscript II reverse transcriptase (Invitrogen, Carlsbad, 
USA). qPCR was performed using POWER SYBR GREEN MASTER MIX (Applied 
Biosystems, Darmstadt, Germany) on the 7300 platform (Applied Biosystems, 
Darmstadt, Germany). The 5.8S rRNA level was used for normalization. Error bars 
are derived from three individual measurements. 
The following primers for miRNA stem-loop qRT-PCR were used:  
(SLP = stem-loop RT primer; qP = qPCR primer) 
The universal primer: 5’- GTGCAGGGTCCGAGGT -3’ 
mmu-mir-191, SLP:  
5’-GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACCAGCTG-3’ 
mmu-mir-191, qP: 5’- CGGCAACGGAATCCCAAAAG -3’ 
mghv-mir-M1-1, SLP:  
5’-GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAAAGGA -3’ 
mghv-mir-M1-1, qP: 5’- CGGCTAGAAATGGCCGTACT -3’ 
mghv-mir-M1-13, SLP:  
5’-GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAAAGAA -3’ 
mghv-mir-M1-13, qP: 5’- CGCGTATCTCATGTGAGCTC -3’ 
(mouse)5.8S rRNA, SLP:  
5’-GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAGCGAC-3’ 
(mouse)5.8S rRNA, qP: 5’- GCCCGCCTGTCTGAGC -3’ 
 
4.2.1.10  Western blotting 
For western blotting, protein sample buffer was added to lysates. The proteins were 
analyzed by 10% SDS-PAGE followed by semidry western blotting using 1x Towbin 
blotting buffer onto a nitrocellulose membrane (GE Healthcare, Munich, Germany). 
The membrane was blocked by 5% milk in wash buffer. The primary antibodies were 
incubated with the membrane with recommended concentrations at 4°C under gentle 
shaking overnight. After three times 10 minutes washing with wash buffer, the 
secondary antibodies were incubated with the membrane with recommended 
concentrations at room temperature for 1h under gentle shaking. The membrane was 
washed again for three times with wash buffer, before the development by 
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chemiluminescence reagent. The signals were detected by ECL Hyperfilm (GE 
Healthcare, Munich, Germany). 
 
4.2.1.11  Generation of small RNA libraries for 454 sequencing 
Small RNA cloning was carried out by Vertis Biotechnology (Weihenstephan, 
Germany) and has been described earlier (Tarasov et al., 2007). Small RNA species 
were isolated from the desired tissue samples or cells using the mirVana miRNA 
isolation kit (Applied Biosystems, Darmstadt, Germany). The small RNAs were 
separated on a denaturing 12.5% polyacrylamide gel stained with SYBR green II. 
After passive elution, RNAs with a length of 15 to 30 bases were concentrated by 
ethanol precipitation and dissolved in water. Next, RNAs were poly(A) tailed using 
poly(A) polymerase. An adaptor was ligated to the 5’- phosphate of the miRNAs:    
(5’ end adaptor [43 nucleotides]: 
5’-GCCTCCCTCGCGCCATCAGCTNNNNGACCTTGGCTGTCACTCA -3’). NNNN 
represents a ‘‘barcode’’ sequence. Then, first strand cDNA synthesis was performed 
using an oligo(dT) linker primer [3’-end oligo(dT) linker primer (61 nt), 
5’-GCCTTGCCAGCCCGCTCAGACGAGACATCGCCCCGC(T)25-3’] and Moloney 
murine leukemia virus RNaseH reverse transcriptase. The resulting cDNAs were PCR 
amplified in 22 cycles, using the high-fidelity Phusion polymerase (Finnzymes, Espoo, 
Finland). Amplification products (120 to 135 bp) were confirmed by polyacrylamide gel 
electrophoresis (PAGE) analysis. All cDNA pools in one project were mixed in equal 
amounts and subjected to gel fractionation. The 120 to 135 bp fraction was 
electro-eluted from 6% PAA gels. After isolation with Nucleospin extract II (Macherey 
Nagel, Düren, Germany), cDNA pools were dissolved in 5 mM Tris-HCl, pH 8.5, at a 
concentration of 10 ng/l and used in single-molecule sequencing. Massively parallel 
sequencing was performed by 454 Life Sciences (Branford, USA), using a Genome 
Sequencer 20 system. The complete sequencing data is submitted and available at 
the Gene Expression Omnibus. 
The barcodes used in sequencing and GEO accession number of the libraries are: 
Result 2.2:  
EBV-infected NPC samples and control tissues (GEO accession number GSE14738) 
NPC-1: barcode CAAT 
Control-1: barcode ATCG 
NPC-2: barcode ACTA 
Control-2: barcode AGGT 
 
  MATERIALS & METHODS 
77 
 
Result 2.3:  
MHV-68 infected cells (GEO accession number GSE22938) 
uninfected NIH 3T3 cells: barcode ACTA 
infected NIH 3T3 cells: barcode AGGT 
S11 cells: barcode ATCG 
TPA induced S11 cells: barcode CAAT 
 
4.2.2 Cellular biological methods 
4.2.2.1  Culturing of mammalian cells 
Mammalian cell lines were cultured in different medium as mentioned above (4.1.6). 
The cells are cultured at 37°C in an atmosphere containing 5% CO2. Adherent cell 
lines Dicer+/+ MEF, Dicer-/- MEF, HEK, MCF7 and NIH 3T3 cells were grown in culture 
plates of different sizes. Non-adherent cell lines BL41, BL41/95.8, EREB2.5, Jijoye, 
AG-8 and S11 were grown in culture flasks of different sizes. Adherent cell line C666.1 
was grown in flask collagen I (Biocoat BD, Franklin Lakes, USA). To split the adherent 
cells, after medium was aspirated off, cells were washed once with PBS (pH 7.5) and 
detached by Trypsin-EDTA (PAA, Pasching, Austria) treatment, with the exception of 
C666.1 which was detached by Acutase (PAA, Pasching, Austria). 
 
4.2.2.2  Virus infection and lytic cycle induction 
NIH 3T3 cells, MEFs and Ag-8 cells were infected with wildtype MHV-68 at an MOI of 
1. The original stock of MHV-68 (clone G2.4) was obtained from Dr. A. Nash 
(University of Edinburgh, Edinburgh, UK). Working stocks of virus were prepared as 
previously described (Adler et al., 2000). Cells were harvest 48h after infection. 
MHV-68 constantly infected S11 cells were treated with TPA (20 ng/ml) for 48h to 
induce the lytic cycle. 
 
4.2.2.3  2’OMe- miRNA inhibitor transfection 
If not used for luciferase assays, 2’ O-Methylated miRNA inhibitors were transfected 
with Lipofectamine RNAiMax (Invitrogen, Carlsbad, USA) according to the 
manufacturer’s protocol 2 days prior to the harvest of the cells.  
The following 2’ OMe miRNA inhibitors were used:  
hsa-mir-15a: 5’- TGTAAACCATTATGTGCTGCTA -3‘                            
hsa-mir-16: 5’- CGCCAATATTTACGTGCTGCTA -3‘ 
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hsa-let-7a: 5’- AACTATACAACCTACTACCTCA -3’ 
ebv-mir-BHRF1-1: 5’- AACTCCGGGGCTGATCAGGTTA -3’ 
 
4.2.2.4  Cotransfection of 2’ OMe- inhibitors and luciferase reporter constructs 
The day before transfection, cells were plated sub-confluently on a 48-well plate. 
Co-transfection for luciferase assays were performed with 100 ng pMIR-TK-RNL 
3'UTR and 20 pmol 2'OMe-miRNA-inhibitor per 2x104 cells in a 96-well plate using 
Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer’s 
protocol. 
 
4.2.2.5  Luciferase assay 
Luciferase activity was measured 48h post transfection using a dual luciferase 
reporter system as described by the manufacturer (Promega, Madison, USA). Firefly 
luciferase expression was normalized to Renilla luciferase expression. Error bars are 
derived from four individual measurements.  
 
4.2.3 Computational methods 
4.2.3.1  Sequence analysis of 454 sequencing libraries 
Base calling and quality trimming of sequence chromatograms were done by the 
publicly available Phred software (Ewing and Green, 1998; Ewing et al., 1998). The 
adapter sequences and poly(A) tails were removed from the sequences. The 
remaining sequences that are longer than 15 nt were subjected to later analysis. 
Sequences were annotated according to miRBase (Griffiths-Jones, 2004), tRNA 
database (Chan and Lowe, 2009), non-coding RNA database (Szymanski et al., 2003), 
EBV (AJ507799) and MHV68 (NC_001826.2)  genome sequence from GenBank. 
The automated analysis of the sequences in the libraries was carried out by VBA 
programming in Microsoft Excel, or the developed stand-alone program. 
The retrieved sequences other than the known miRNAs were then subjected to a 
search for putative novel miRNA sequences. Genomic regions containing inserts with 
100 nt flanks were retrieved from GenBank to calculate RNA secondary structures by 
mFOLD (Zuker, 2003). Only regions that folded into hairpins and contained an insert 
in one of the hairpin arms were considered as putative novel miRNA sequences. 
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The relative abundance of miRNAs was calculated as the percentage of individual 
miRNA read numbers in total miRNA read numbers from each library. The heatmap of 
the expression profiles were generated using Mayday platform (Battke et al., 2010). 
 
4.2.3.2  Programming method 
The stand-alone software designed and developed in this project for the analysis of 
NGS data was using BASIC language by the RealBasic Program 
(https://www.realsoftware.com). The software was developed and compiled for the 
Operating System of Mac, but is also possible to be converted to the version fitting for 
Windows or Linux Operating system. 
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ABBREVIATIONS 
 
 
3’ UTR 3’ untranslated region 
5’ UTR 5’ untranslated region 
Ago Argonaute 
BALF5 BamHI fragment A containing the fifth leftward ORF 
BART BamHI fragment A rightward transcript 
BHRF1 BamHI fragment H rightward open reading frame 1 
bp base pair 
BRCA1 breast cancer 1  
cDNA complementary DNA 
CRT cyclic reversible termination 
DNA deoxyribonucleic acid 
dNTP 2’-deoxyribonucleoside triphosphate 
ds double-stranded 
EBV Epstein-Barr virus 
GA Genome Analyzer 
GEO Gene Expression Omnibus 
hAgo human Argonaute 
hsa Homo sapiens 
IP immunoprecipitation 
kbp kilo base pair 
KSHV Kaposi's sarcoma-associated herpesvirus 
mAgo murine Argonaute 
MCS multiple cloning sites 
MDV Marek's disease virus 
MEF mouse embryonic fibroblast 
mESC mouse embryonic stem cell 
mghv mouse gammaherpesvirus 68 (= Murid herpesvirus 4) 
MHV-68 mouse gammaherpesvirus 68 (= Murid herpesvirus 4) 
miRNA microRNA 
mmu Mus musculus 
ncRNA non-coding RNA 
NGS next generation sequencing 
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NPC nasopharyngeal carcinoma 
nt nucleotides 
ORF open reading frame 
P-bodies processing bodies 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
Pol polymerase 
pre-miRNA precursor microRNA 
pri-miRNA primary microRNA 
PTP PicoTitrePlate 
qRT-PCR quantitative real time polymerase chain reaction 
RISC RNA induced silencing complex 
rLCV Rhesus lymphocryptovirus 
RNA ribonucleic acid 
rRNA ribosomal RNA 
scRNA small cytoplasmic RNA 
SD standard deviation 
snoRNA small nucleolar RNA 
snRNA small nuclear RNA 
ss single-stranded 
stRNA small temporal RNA 
TPA 12-O-tetradecanoylphorbol-13-acetate 
tRNA transfer RNA 
wt wild type 
vtRNA viral transfer RNA 
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Figure 1.1  Model of miRNA-guided post-transcriptional regulation of gene expression. 
Figure 1.2   Working principles of 454 sequencing. 
Figure 1.3   Working principles of Solexa sequencing. 
Figure 2.1   Flow chart of NGS data analysis procedures. 
Figure 2.2  Interactive platforms of developed software for NGS data analysis. 
Figure 2.3  Schematic locations of putative novel miRNAs in BART miRNA cluster of EBV 
genome. 
Figure 2.4  Expression analysis of novel EBV miRNAs by Northern blotting. 
Figure 2.5  Verification of novel EBV miRNA expressions in several NPC samples by 
qRT-PCR. 
Figure 2.6   MiRNA composition in NPC samples. 
Figure 2.7  Relative abundance of EBV miRNAs in the NPC-1 and NPC-2 libraries. 
Figure 2.8   Cellular miRNA expressions in NPC and control tissue. 
Figure 2.9  Expressions of hsa-mir-15a and hsa-mir-16 are upregulated in two NPC 
samples compared to healthy tissues. 
Figure 2.10   Hsa-mir-15a and hsa-mir-16 target BRCA1 mRNA. 
Figure 2.11  Comprehensive analysis of small RNA libraries by 454 sequencing constructed 
from NIH 3T3 and S11 cells. 
Figure 2.12  Seed sequence homology among MHV-68 miRNAs and murine or other 
herpesvirus miRNAs. 
Figure 2.13  MHV-68 miRNAs are located directly after vtRNA sequences. 
Figure 2.14   Unique vtRNA-miRNA-miRNA structures in MHV-678 genome. 
Figure 2.15   Validation of novel MHV-68 miRNAs. 
Figure 2.16   MHV-68 miRNAs are generated in a Dicer-dependent pathway. 
Figure 2.17  Cellular miRNA profiling of uninfected or MHV-68 infected NIH 3T3 cells and of 
untreated or TPA-treated S11 cells. 
Figure 2.18  miR-15/16 upregulation was observed in MHV-68 infected NIH 3T3 cells. 
Figure 2.19  Alignment of the murine miRNA which is a possible truncated form of an 
abundant miRNA. 
Figure 2.20  Alignment of human miRNAs which are possible truncated form of abundant 
miRNAs. 
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Table 1.1  Numbers of miRNA precursors in herpesviruses. 
Table 2.1   Sequence distribution of small RNA libraries from NPC samples. 
Table 2.2   Novel candidate miRNAs of novel precursors identified from NPC samples. 
Table 2.3   Numbers of novel EBV miRNA reads in the libraries. 
Table 2.4   Novel candidate human miRNAs of novel precursors identified from NPC 
samples. 
Table 2.5   Numbers of novel human miRNA reads in the libraries. 
Table 2.6   Sequence distribution of small RNA libraries from MHV-68 infected cell lines. 
Table 2.7   MiRNA read numbers of known and novel viral precursors from MHV-68 
infected samples. 
Table 2.8   Novel candidate MHV-68 miRNAs of novel precursors identified from MHV-68 
infected samples. 
Table 2.9   Sequences and read numbers of murine novel star miRNAs in the sequencing 
libraries. 
Table 2.10  Read numbers of mentioned murine miRNA entries in three small RNA libraries. 
Table 2.11  Probably mis-annotated murine miRNA genes that match to other ncRNAs or do 
not match in murine genome. 
Table 2.12  Read numbers of mentioned human miRNA entries in three small RNA libraries. 
Table 2.13  Probably mis-annotated human miRNA genes that match to other ncRNAs. 
Table 2.14   Novel murine miRNA candidates of known human miRNA orthologs. 
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APPENDIX 
 
Appendix Table I 
 
Read numbers and analysis of individual miRNA in 454 sequencing libraries of NPC 
and control samples. 
 
  
Read number Percentage Read number Percentage 
NPC-1 control-1 NPC-1 control-1 NPC-2 control-2 NPC-2 control-2 
total miRNA 20330 1287 100.0% 100.0% 6194 1476 100.0% 100.0% 
hsa-let-7a 295 13 1.5% 1.0% 48 13 0.8% 0.9% 
hsa-let-7a* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-let-7a/c 38 1 0.2% 0.1% 3 2 0.0% 0.1% 
hsa-let-7b 287 34 1.4% 2.6% 262 74 4.2% 5.0% 
hsa-let-7c 128 10 0.6% 0.8% 30 10 0.5% 0.7% 
hsa-let-7d 65 1 0.3% 0.1% 11 1 0.2% 0.1% 
hsa-let-7d* 14 2 0.1% 0.2% 7 1 0.1% 0.1% 
hsa-let-7e 49 4 0.2% 0.3% 11 5 0.2% 0.3% 
hsa-let-7f 45 1 0.2% 0.1% 8 1 0.1% 0.1% 
hsa-let-7f-1* 1 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-let-7f-2* 10 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-let-7g 56 0 0.3% 0.0% 5 2 0.1% 0.1% 
hsa-let-7i 9 0 0.0% 0.0% 3 0 0.0% 0.0% 
hsa-let-7i* 7 0 0.0% 0.0% 4 3 0.1% 0.2% 
hsa-mir-7 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-7-1* 9 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-9* 1 1 0.0% 0.1% 0 1 0.0% 0.1% 
hsa-mir-10a 0 1 0.0% 0.1% 0 1 0.0% 0.1% 
hsa-mir-10b* 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-15a 552 24 2.7% 1.9% 44 4 0.7% 0.3% 
hsa-mir-15b 684 34 3.4% 2.6% 43 26 0.7% 1.8% 
hsa-mir-16 498 19 2.4% 1.5% 31 4 0.5% 0.3% 
hsa-mir-16-2* 1 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-17 328 54 1.6% 4.2% 27 58 0.4% 3.9% 
hsa-mir-17* 34 7 0.2% 0.5% 39 19 0.6% 1.3% 
hsa-mir-19b 0 4 0.0% 0.3% 0 1 0.0% 0.1% 
hsa-mir-20a 27 2 0.1% 0.2% 6 2 0.1% 0.1% 
hsa-mir-20b 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-21 146 3 0.7% 0.2% 17 0 0.3% 0.0% 
  APPENDIX 
93 
 
hsa-mir-21* 9 1 0.0% 0.1% 2 0 0.0% 0.0% 
hsa-mir-22 70 15 0.3% 1.2% 97 30 1.6% 2.0% 
hsa-mir-22* 44 1 0.2% 0.1% 14 8 0.2% 0.5% 
hsa-mir-23a 3422 66 16.8% 5.1% 294 30 4.7% 2.0% 
hsa-mir-23a/b 1007 31 5.0% 2.4% 82 23 1.3% 1.6% 
hsa-mir-23b 819 24 4.0% 1.9% 87 15 1.4% 1.0% 
hsa-mir-23b* 1 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-24 65 8 0.3% 0.6% 93 25 1.5% 1.7% 
hsa-mir-24-1* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-24-2* 1 0 0.0% 0.0% 1 1 0.0% 0.1% 
hsa-mir-25 1215 87 6.0% 6.8% 285 72 4.6% 4.9% 
hsa-mir-25* 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-26a 188 4 0.9% 0.3% 15 5 0.2% 0.3% 
hsa-mir-26b 316 4 1.6% 0.3% 14 8 0.2% 0.5% 
hsa-mir-27a 563 7 2.8% 0.5% 57 2 0.9% 0.1% 
hsa-mir-27a/b 66 5 0.3% 0.4% 5 3 0.1% 0.2% 
hsa-mir-27b 839 41 4.1% 3.2% 263 25 4.2% 1.7% 
hsa-mir-27b* 0 0 0.0% 0.0% 1 2 0.0% 0.1% 
hsa-mir-28-3p 25 2 0.1% 0.2% 5 1 0.1% 0.1% 
hsa-mir-28-5p 23 0 0.1% 0.0% 8 2 0.1% 0.1% 
hsa-mir-29a 52 1 0.3% 0.1% 10 0 0.2% 0.0% 
hsa-mir-29b 17 2 0.1% 0.2% 4 1 0.1% 0.1% 
hsa-mir-29b-2* 0 0 0.0% 0.0% 2 1 0.0% 0.1% 
hsa-mir-29c 32 0 0.2% 0.0% 9 1 0.1% 0.1% 
hsa-mir-29c* 1 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-30a 3 0 0.0% 0.0% 4 0 0.1% 0.0% 
hsa-mir-30a* 6 1 0.0% 0.1% 11 1 0.2% 0.1% 
hsa-mir-30a/e* 1 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-30b 9 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-30c 7 1 0.0% 0.1% 1 0 0.0% 0.0% 
hsa-mir-30c-2* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-30d 4 1 0.0% 0.1% 0 1 0.0% 0.1% 
hsa-mir-30e 5 1 0.0% 0.1% 1 1 0.0% 0.1% 
hsa-mir-30e* 39 1 0.2% 0.1% 0 0 0.0% 0.0% 
hsa-mir-31* 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-32 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-33a* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-34a 23 2 0.1% 0.2% 31 3 0.5% 0.2% 
hsa-mir-34b 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-34b* 0 0 0.0% 0.0% 4 0 0.1% 0.0% 
hsa-mir-34c-3p 5 1 0.0% 0.1% 3 0 0.0% 0.0% 
hsa-mir-34c-5p 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-92a 52 5 0.3% 0.4% 14 4 0.2% 0.3% 
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hsa-mir-92a-1* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-92b 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-92b* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-93 46 8 0.2% 0.6% 6 5 0.1% 0.3% 
hsa-mir-93* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-96 3 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-96* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-98 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-99a 13 1 0.1% 0.1% 2 0 0.0% 0.0% 
hsa-mir-99a* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-99b 8 1 0.0% 0.1% 8 2 0.1% 0.1% 
hsa-mir-99b* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-100 4 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-101 13 3 0.1% 0.2% 1 1 0.0% 0.1% 
hsa-mir-103 272 17 1.3% 1.3% 53 17 0.9% 1.2% 
hsa-mir-103-2* 12 1 0.1% 0.1% 15 1 0.2% 0.1% 
hsa-mir-103/107 72 3 0.4% 0.2% 18 1 0.3% 0.1% 
hsa-mir-106a 1 0 0.0% 0.0% 5 0 0.1% 0.0% 
hsa-mir-106b 364 25 1.8% 1.9% 30 21 0.5% 1.4% 
hsa-mir-106b* 7 5 0.0% 0.4% 14 5 0.2% 0.3% 
hsa-mir-107 5 1 0.0% 0.1% 1 0 0.0% 0.0% 
hsa-mir-122a 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-124 0 1 0.0% 0.1% 1 0 0.0% 0.0% 
hsa-mir-125a-3p 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-125a-5p 31 1 0.2% 0.1% 16 8 0.3% 0.5% 
hsa-mir-125b 74 15 0.4% 1.2% 40 16 0.6% 1.1% 
hsa-mir-126 92 3 0.5% 0.2% 45 15 0.7% 1.0% 
hsa-mir-126* 0 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-127-3p 0 0 0.0% 0.0% 2 1 0.0% 0.1% 
hsa-mir-128a 47 1 0.2% 0.1% 5 1 0.1% 0.1% 
hsa-mir-130a 3 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-130b 3 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-132 14 2 0.1% 0.2% 8 1 0.1% 0.1% 
hsa-mir-134 0 7 0.0% 0.5% 3 7 0.0% 0.5% 
hsa-mir-135b 4 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-135b* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-138 7 0 0.0% 0.0% 9 3 0.1% 0.2% 
hsa-mir-138-1* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-139-3p 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-139-5p 13 2 0.1% 0.2% 3 0 0.0% 0.0% 
hsa-mir-140-3p 68 5 0.3% 0.4% 25 5 0.4% 0.3% 
hsa-mir-140-5p 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-141 21 0 0.1% 0.0% 0 0 0.0% 0.0% 
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hsa-mir-142-3p 16 1 0.1% 0.1% 7 0 0.1% 0.0% 
hsa-mir-142-5p 14 1 0.1% 0.1% 2 0 0.0% 0.0% 
hsa-mir-143 5 0 0.0% 0.0% 3 0 0.0% 0.0% 
hsa-mir-144 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-145 7 0 0.0% 0.0% 1 1 0.0% 0.1% 
hsa-mir-146a 24 1 0.1% 0.1% 7 0 0.1% 0.0% 
hsa-mir-146a/b 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-146b-5p 7 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-146b-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-148a 13 1 0.1% 0.1% 6 0 0.1% 0.0% 
hsa-mir-148b 3 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-149 3 0 0.0% 0.0% 7 1 0.1% 0.1% 
hsa-mir-150 39 0 0.2% 0.0% 7 4 0.1% 0.3% 
hsa-mir-150* 2 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-151-3p 36 5 0.2% 0.4% 22 9 0.4% 0.6% 
hsa-mir-151-5p 432 36 2.1% 2.8% 95 17 1.5% 1.2% 
hsa-mir-152 81 5 0.4% 0.4% 8 9 0.1% 0.6% 
hsa-mir-153 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-155 120 1 0.6% 0.1% 8 0 0.1% 0.0% 
hsa-mir-181a 13 1 0.1% 0.1% 1 1 0.0% 0.1% 
hsa-mir-181a-2* 5 1 0.0% 0.1% 6 0 0.1% 0.0% 
hsa-mir-181b 5 2 0.0% 0.2% 9 1 0.1% 0.1% 
hsa-mir-181c* 3 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-182 74 2 0.4% 0.2% 15 1 0.2% 0.1% 
hsa-mir-182* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-183 26 1 0.1% 0.1% 12 0 0.2% 0.0% 
hsa-mir-184 73 7 0.4% 0.5% 2 1 0.0% 0.1% 
hsa-mir-185 117 10 0.6% 0.8% 30 8 0.5% 0.5% 
hsa-mir-186 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-187 1 1 0.0% 0.1% 2 7 0.0% 0.5% 
hsa-mir-190 24 5 0.1% 0.4% 17 8 0.3% 0.5% 
hsa-mir-191 182 5 0.9% 0.4% 35 11 0.6% 0.7% 
hsa-mir-192 10 0 0.0% 0.0% 2 1 0.0% 0.1% 
hsa-mir-192* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-193a-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-193a-5p 0 0 0.0% 0.0% 1 1 0.0% 0.1% 
hsa-mir-193b 0 0 0.0% 0.0% 11 1 0.2% 0.1% 
hsa-mir-194 9 0 0.0% 0.0% 1 1 0.0% 0.1% 
hsa-mir-195 50 1 0.2% 0.1% 3 0 0.0% 0.0% 
hsa-mir-196a 0 6 0.0% 0.5% 2 5 0.0% 0.3% 
hsa-mir-196b* 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-199a-3p 646 51 3.2% 4.0% 68 53 1.1% 3.6% 
hsa-mir-199a-5p 102 9 0.5% 0.7% 33 19 0.5% 1.3% 
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hsa-mir-199b-5p 16 0 0.1% 0.0% 1 0 0.0% 0.0% 
hsa-mir-200a 4 0 0.0% 0.0% 8 1 0.1% 0.1% 
hsa-mir-200a* 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-200b 530 31 2.6% 2.4% 137 28 2.2% 1.9% 
hsa-mir-200b* 9 0 0.0% 0.0% 6 1 0.1% 0.1% 
hsa-mir-200c 1498 40 7.4% 3.1% 127 6 2.1% 0.4% 
hsa-mir-203 1 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-205 69 6 0.3% 0.5% 58 1 0.9% 0.1% 
hsa-mir-205* 15 3 0.1% 0.2% 9 5 0.1% 0.3% 
hsa-mir-206 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-210 114 12 0.6% 0.9% 309 40 5.0% 2.7% 
hsa-mir-212 4 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-214 27 9 0.1% 0.7% 11 7 0.2% 0.5% 
hsa-mir-218 14 10 0.1% 0.8% 18 4 0.3% 0.3% 
hsa-mir-221 184 39 0.9% 3.0% 193 83 3.1% 5.6% 
hsa-mir-221* 7 0 0.0% 0.0% 1 1 0.0% 0.1% 
hsa-mir-222 92 9 0.5% 0.7% 73 17 1.2% 1.2% 
hsa-mir-223 14 0 0.1% 0.0% 4 0 0.1% 0.0% 
hsa-mir-223* 4 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-224 17 1 0.1% 0.1% 9 1 0.1% 0.1% 
hsa-mir-224* 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-296-3p 2 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-296-5p 0 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-301a/b 6 1 0.0% 0.1% 0 1 0.0% 0.1% 
hsa-mir-320 353 114 1.7% 8.9% 555 272 9.0% 18.4% 
hsa-mir-323-3p 0 1 0.0% 0.1% 0 1 0.0% 0.1% 
hsa-mir-324-3p 9 1 0.0% 0.1% 4 3 0.1% 0.2% 
hsa-mir-324-5p 7 0 0.0% 0.0% 4 3 0.1% 0.2% 
hsa-mir-328 0 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-330-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-331-3p 1 0 0.0% 0.0% 3 0 0.0% 0.0% 
hsa-mir-331-5p 1 0 0.0% 0.0% 3 0 0.0% 0.0% 
hsa-mir-338-3p 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-339-3p 1 0 0.0% 0.0% 3 0 0.0% 0.0% 
hsa-mir-339-5p 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-340 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-342-3p 5 2 0.0% 0.2% 3 0 0.0% 0.0% 
hsa-mir-345 28 5 0.1% 0.4% 36 10 0.6% 0.7% 
hsa-mir-361-3p 10 1 0.0% 0.1% 2 3 0.0% 0.2% 
hsa-mir-361-5p 51 1 0.3% 0.1% 0 2 0.0% 0.1% 
hsa-mir-362-5p 1 0 0.0% 0.0% 1 1 0.0% 0.1% 
hsa-mir-363 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-365 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
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hsa-mir-365-2* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-370 0 0 0.0% 0.0% 2 1 0.0% 0.1% 
hsa-mir-374a 37 0 0.2% 0.0% 2 0 0.0% 0.0% 
hsa-mir-375 0 0 0.0% 0.0% 3 3 0.0% 0.2% 
hsa-mir-376a 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-378 43 26 0.2% 2.0% 211 86 3.4% 5.8% 
hsa-mir-378* 11 0 0.1% 0.0% 27 13 0.4% 0.9% 
hsa-mir-409-3p 0 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-410 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-423-3p 7 0 0.0% 0.0% 9 4 0.1% 0.3% 
hsa-mir-423-5p 8 4 0.0% 0.3% 2 0 0.0% 0.0% 
hsa-mir-424 34 7 0.2% 0.5% 1 1 0.0% 0.1% 
hsa-mir-425 6 1 0.0% 0.1% 5 2 0.1% 0.1% 
hsa-mir-429 1 0 0.0% 0.0% 0 1 0.0% 0.1% 
hsa-mir-432 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-433 0 7 0.0% 0.5% 1 8 0.0% 0.5% 
hsa-mir-449a 3 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-449b 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-449b* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-450a 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-451 3 5 0.0% 0.4% 16 0 0.3% 0.0% 
hsa-mir-452 1 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-455-3p 82 3 0.4% 0.2% 32 1 0.5% 0.1% 
hsa-mir-455-5p 2 0 0.0% 0.0% 6 1 0.1% 0.1% 
hsa-mir-484 12 2 0.1% 0.2% 8 4 0.1% 0.3% 
hsa-mir-486-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-486-5p 26 66 0.1% 5.1% 105 11 1.7% 0.7% 
hsa-mir-487b 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-497 71 0 0.3% 0.0% 7 0 0.1% 0.0% 
hsa-mir-500 4 0 0.0% 0.0% 3 1 0.0% 0.1% 
hsa-mir-500* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-503 7 1 0.0% 0.1% 1 0 0.0% 0.0% 
hsa-mir-505 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-505* 2 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-517a 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-532-3p 30 3 0.1% 0.2% 17 3 0.3% 0.2% 
hsa-mir-532-5p 17 0 0.1% 0.0% 0 3 0.0% 0.2% 
hsa-mir-551b 4 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-551b* 4 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-574-3p 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-574-5p 6 2 0.0% 0.2% 10 0 0.2% 0.0% 
hsa-mir-584 2 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-590-3p 4 0 0.0% 0.0% 0 0 0.0% 0.0% 
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hsa-mir-598 10 1 0.0% 0.1% 1 0 0.0% 0.0% 
hsa-mir-607 0 1 0.0% 0.1% 0 0 0.0% 0.0% 
hsa-mir-615-3p 8 3 0.0% 0.2% 2 5 0.0% 0.3% 
hsa-mir-624 2 0 0.0% 0.0% 2 0 0.0% 0.0% 
hsa-mir-628-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-629 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-652 97 31 0.5% 2.4% 42 21 0.7% 1.4% 
hsa-mir-660 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-744 3 3 0.0% 0.2% 13 2 0.2% 0.1% 
hsa-mir-758 0 0 0.0% 0.0% 1 3 0.0% 0.2% 
hsa-mir-766 12 4 0.1% 0.3% 2 3 0.0% 0.2% 
hsa-mir-768-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-768-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-769-3p 1 0 0.0% 0.0% 1 0 0.0% 0.0% 
hsa-mir-769-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
hsa-mir-874 15 0 0.1% 0.0% 11 8 0.2% 0.5% 
hsa-mir-942 8 0 0.0% 0.0% 6 3 0.1% 0.2% 
hsa-mir-1301 15 1 0.1% 0.1% 5 0 0.1% 0.0% 
hsa-mir-1307 22 8 0.1% 0.6% 79 22 1.3% 1.5% 
hsa-mir-2110 3 1 0.0% 0.1% 2 3 0.0% 0.2% 
ebv-mir-BART1-3p 8 0 0.0% 0.0% 4 0 0.1% 0.0% 
ebv-mir-BART1-5p 136 6 0.7% 0.5% 169 0 2.7% 0.0% 
ebv-mir-BART2-5p 6 0 0.0% 0.0% 1 0 0.0% 0.0% 
ebv-mir-BART3 6 0 0.0% 0.0% 3 0 0.0% 0.0% 
ebv-mir-BART3* 2 0 0.0% 0.0% 7 0 0.1% 0.0% 
ebv-mir-BART4 38 7 0.2% 0.5% 424 0 6.8% 0.0% 
ebv-mir-BART4* 6 0 0.0% 0.0% 9 0 0.1% 0.0% 
ebv-mir-BART5 18 0 0.1% 0.0% 4 0 0.1% 0.0% 
ebv-mir-BART5* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
ebv-mir-BART6-3p 27 0 0.1% 0.0% 73 0 1.2% 0.0% 
ebv-mir-BART6-5p 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
ebv-mir-BART7 292 5 1.4% 0.4% 37 0 0.6% 0.0% 
ebv-mir-BART8 1 0 0.0% 0.0% 2 0 0.0% 0.0% 
ebv-mir-BART8* 18 1 0.1% 0.1% 24 0 0.4% 0.0% 
ebv-mir-BART9 36 0 0.2% 0.0% 22 0 0.4% 0.0% 
ebv-mir-BART10 14 0 0.1% 0.0% 2 0 0.0% 0.0% 
ebv-mir-BART11-3p 9 1 0.0% 0.1% 56 0 0.9% 0.0% 
ebv-mir-BART11-5p 21 1 0.1% 0.1% 13 0 0.2% 0.0% 
ebv-mir-BART12 13 1 0.1% 0.1% 64 0 1.0% 0.0% 
ebv-mir-BART13 10 1 0.0% 0.1% 6 0 0.1% 0.0% 
ebv-mir-BART14 11 1 0.1% 0.1% 10 0 0.2% 0.0% 
ebv-mir-BART14* 3 0 0.0% 0.0% 6 0 0.1% 0.0% 
ebv-mir-BART15 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
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ebv-mir-BART16 36 2 0.2% 0.2% 23 0 0.4% 0.0% 
ebv-mir-BART17-3p 23 0 0.1% 0.0% 34 0 0.5% 0.0% 
ebv-mir-BART17-5p 26 0 0.1% 0.0% 16 0 0.3% 0.0% 
ebv-mir-BART18-5p 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
ebv-mir-BART19-3p 6 1 0.0% 0.1% 85 0 1.4% 0.0% 
ebv-mir-BART20-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
ebv-mir-BART20-5p 0 0 0.0% 0.0% 0 0 0.0% 0.0% 
ebv-mir-BART21-3P 10 1 0.0% 0.1% 6 0 0.1% 0.0% 
ebv-mir-BART21-5P 19 1 0.1% 0.1% 7 0 0.1% 0.0% 
ebv-mir-BART22 201 1 1.0% 0.1% 81 0 1.3% 0.0% 
 
 
The libraries were analysed in the reference of miRBase v11.0. The human and EBV miRNAs 
that are not present here have no reads in all four libraries.  
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Appendix Table II 
 
Read numbers and analysis of individual murine miRNA in 454 sequencing libraries of 
MHV-68 infected cell lines. 
 
 
Read Number Percentage Read Number Percentage 
NIH 3T3- NIH 3T3+ NIH 3T3- NIH 3T3+ S11- S11+ S11- S11+ 
total miRNA 50069 47011 100% 100% 30055 39037 100% 100% 
mmu-let-7a 74 109 0.1% 0.2% 37 138 0.1% 0.3% 
mmu-let-7a* 21 8 0.0% 0.0% 4 5 0.0% 0.0% 
mmu-let-7a-2* 1 1 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-let-7b 155 199 0.3% 0.4% 0 0 0.0% 0.0% 
mmu-let-7b* 7 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-let-7c 280 382 0.6% 0.8% 58 127 0.1% 0.3% 
mmu-let-7c-1* 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-let-7d 35 44 0.1% 0.1% 14 68 0.0% 0.1% 
mmu-let-7d* 29 15 0.1% 0.0% 9 25 0.0% 0.1% 
mmu-let-7e 78 138 0.2% 0.3% 0 0 0.0% 0.0% 
mmu-let-7e* 7 15 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-let-7f 161 357 0.3% 0.8% 146 504 0.3% 1.1% 
mmu-let-7f* 7 10 0.0% 0.0% 3 1 0.0% 0.0% 
mmu-let-7f-2* 6 2 0.0% 0.0% 5 5 0.0% 0.0% 
mmu-let-7g 117 131 0.2% 0.3% 219 711 0.4% 1.5% 
mmu-let-7g* 3 1 0.0% 0.0% 5 5 0.0% 0.0% 
mmu-let-7i 743 326 1.5% 0.7% 30 80 0.1% 0.2% 
mmu-let-7i* 71 8 0.1% 0.0% 3 6 0.0% 0.0% 
mmu-mir-7a 36 35 0.1% 0.1% 46 100 0.1% 0.2% 
mmu-mir-7a* 11 12 0.0% 0.0% 10 27 0.0% 0.1% 
mmu-mir-9 55 60 0.1% 0.1% 444 374 0.9% 0.8% 
mmu-mir-9* 10 10 0.0% 0.0% 103 106 0.2% 0.2% 
mmu-mir-10a 0 11 0.0% 0.0% 4 5 0.0% 0.0% 
mmu-mir-10a* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-10b 73 11 0.1% 0.0% 62 119 0.1% 0.3% 
mmu-mir-10b* 6 0 0.0% 0.0% 3 5 0.0% 0.0% 
mmu-mir-15a 509 433 1.0% 0.9% 552 542 1.1% 1.2% 
mmu-mir-15a* 26 4 0.1% 0.0% 9 9 0.0% 0.0% 
mmu-mir-15b 807 1872 1.6% 4.0% 1165 1284 2.3% 2.7% 
mmu-mir-15b* 16 4 0.0% 0.0% 4 12 0.0% 0.0% 
mmu-mir-16 2823 5705 5.6% 12.1% 5135 5708 10.3% 12.1% 
mmu-mir-16* 1 1 0.0% 0.0% 0 4 0.0% 0.0% 
mmu-mir-16-2* 27 24 0.1% 0.1% 16 24 0.0% 0.1% 
mmu-mir-17 1205 1060 2.4% 2.3% 278 361 0.6% 0.8% 
mmu-mir-17* 138 43 0.3% 0.1% 35 66 0.1% 0.1% 
mmu-mir-18a 185 88 0.4% 0.2% 13 27 0.0% 0.1% 
mmu-mir-18a* 5 3 0.0% 0.0% 7 9 0.0% 0.0% 
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mmu-mir-18b 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-19a 25 2 0.0% 0.0% 12 12 0.0% 0.0% 
mmu-mir-19b 370 126 0.7% 0.3% 142 199 0.3% 0.4% 
mmu-mir-19b-1* 2 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-20a 593 625 1.2% 1.3% 177 296 0.4% 0.6% 
mmu-mir-20a* 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-20b* 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-21 2904 1665 5.8% 3.5% 2372 3427 4.7% 7.3% 
mmu-mir-21* 34 9 0.1% 0.0% 13 31 0.0% 0.1% 
mmu-mir-22 1566 826 3.1% 1.8% 57 112 0.1% 0.2% 
mmu-mir-22* 142 83 0.3% 0.2% 12 25 0.0% 0.1% 
mmu-mir-23a 2836 3270 5.7% 7.0% 417 460 0.8% 1.0% 
mmu-mir-23a* 0 0 0.0% 0.0% 3 0 0.0% 0.0% 
mmu-mir-23b 385 524 0.8% 1.1% 246 231 0.5% 0.5% 
mmu-mir-24 529 1100 1.1% 2.3% 129 178 0.3% 0.4% 
mmu-mir-24-2* 44 23 0.1% 0.0% 4 6 0.0% 0.0% 
mmu-mir-25 478 558 1.0% 1.2% 301 304 0.6% 0.6% 
mmu-mir-25* 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-26a 815 1295 1.6% 2.8% 194 222 0.4% 0.5% 
mmu-mir-26a-2* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-26b 133 314 0.3% 0.7% 217 612 0.4% 1.3% 
mmu-mir-26b* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-27a 1843 1617 3.7% 3.4% 310 351 0.6% 0.7% 
mmu-mir-27a* 5 3 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-27b 622 670 1.2% 1.4% 603 588 1.2% 1.3% 
mmu-mir-27b* 2 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-28 110 111 0.2% 0.2% 2 4 0.0% 0.0% 
mmu-mir-28* 90 46 0.2% 0.1% 1 1 0.0% 0.0% 
mmu-mir-29a 918 910 1.8% 1.9% 296 434 0.6% 0.9% 
mmu-mir-29a* 9 7 0.0% 0.0% 2 1 0.0% 0.0% 
mmu-mir-29b 116 44 0.2% 0.1% 40 50 0.1% 0.1% 
mmu-mir-29b* 0 3 0.0% 0.0% 4 2 0.0% 0.0% 
mmu-mir-29b-2* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-29c 25 26 0.0% 0.1% 35 26 0.1% 0.1% 
mmu-mir-30a 146 237 0.3% 0.5% 0 0 0.0% 0.0% 
mmu-mir-30a* 39 102 0.1% 0.2% 2 2 0.0% 0.0% 
mmu-mir-30b 234 239 0.5% 0.5% 193 224 0.4% 0.5% 
mmu-mir-30b* 2 3 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-30c 231 416 0.5% 0.9% 87 104 0.2% 0.2% 
mmu-mir-30c-1* 0 1 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-30c-2* 0 5 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-30d 61 112 0.1% 0.2% 39 80 0.1% 0.2% 
mmu-mir-30d* 7 2 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-30e 231 210 0.5% 0.4% 159 177 0.3% 0.4% 
mmu-mir-30e* 23 23 0.0% 0.0% 17 14 0.0% 0.0% 
mmu-mir-31 1294 1005 2.6% 2.1% 0 0 0.0% 0.0% 
mmu-mir-31* 720 354 1.4% 0.8% 0 0 0.0% 0.0% 
mmu-mir-32 23 7 0.0% 0.0% 7 16 0.0% 0.0% 
  APPENDIX 
102 
 
mmu-mir-32* 2 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-33 8 4 0.0% 0.0% 0 4 0.0% 0.0% 
mmu-mir-33* 6 4 0.0% 0.0% 7 13 0.0% 0.0% 
mmu-mir-34a 162 137 0.3% 0.3% 306 461 0.6% 1.0% 
mmu-mir-34a* 11 2 0.0% 0.0% 22 33 0.0% 0.1% 
mmu-mir-34b-3p 42 70 0.1% 0.1% 15 23 0.0% 0.0% 
mmu-mir-34b-5p 77 46 0.2% 0.1% 48 63 0.1% 0.1% 
mmu-mir-34c 182 137 0.4% 0.3% 73 118 0.1% 0.3% 
mmu-mir-34c* 41 33 0.1% 0.1% 18 15 0.0% 0.0% 
mmu-mir-92a 264 395 0.5% 0.8% 104 211 0.2% 0.4% 
mmu-mir-92a-1* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-92b 0 0 0.0% 0.0% 0 4 0.0% 0.0% 
mmu-mir-93 423 626 0.8% 1.3% 218 291 0.4% 0.6% 
mmu-mir-93* 5 7 0.0% 0.0% 2 5 0.0% 0.0% 
mmu-mir-96 21 6 0.0% 0.0% 45 41 0.1% 0.1% 
mmu-mir-96* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-98 14 19 0.0% 0.0% 5 10 0.0% 0.0% 
mmu-mir-98* 9 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-99a 5 13 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-99b 124 472 0.2% 1.0% 0 0 0.0% 0.0% 
mmu-mir-99b* 17 4 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-100 46 19 0.1% 0.0% 7 9 0.0% 0.0% 
mmu-mir-100* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-101a 79 34 0.2% 0.1% 18 8 0.0% 0.0% 
mmu-mir-101b 275 213 0.5% 0.5% 214 245 0.4% 0.5% 
mmu-mir-103 934 673 1.9% 1.4% 268 300 0.5% 0.6% 
mmu-mir-103-1* 0 5 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-103-2* 16 7 0.0% 0.0% 3 6 0.0% 0.0% 
mmu-mir-106b 587 578 1.2% 1.2% 333 357 0.7% 0.8% 
mmu-mir-106b* 20 39 0.0% 0.1% 10 15 0.0% 0.0% 
mmu-mir-107 51 72 0.1% 0.2% 15 20 0.0% 0.0% 
mmu-mir-107* 2 2 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-122 0 0 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-124 1 5 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-125a-3p 10 8 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-125a-5p 145 483 0.3% 1.0% 1 3 0.0% 0.0% 
mmu-mir-125b* 1 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-125b-3p 6 9 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-125b-5p 613 955 1.2% 2.0% 17 21 0.0% 0.0% 
mmu-mir-126-3p 1 0 0.0% 0.0% 4 11 0.0% 0.0% 
mmu-mir-126-5p 1 0 0.0% 0.0% 6 2 0.0% 0.0% 
mmu-mir-127 38 30 0.1% 0.1% 0 0 0.0% 0.0% 
mmu-mir-127* 6 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-128 16 11 0.0% 0.0% 10 13 0.0% 0.0% 
mmu-mir-129-3p 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-129-5p 2 6 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-130a 492 218 1.0% 0.5% 0 0 0.0% 0.0% 
mmu-mir-130b 25 24 0.0% 0.1% 72 126 0.1% 0.3% 
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mmu-mir-130b* 0 1 0.0% 0.0% 5 4 0.0% 0.0% 
mmu-mir-132 2 6 0.0% 0.0% 9 30 0.0% 0.1% 
mmu-mir-132* 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-134 65 7 0.1% 0.0% 0 4 0.0% 0.0% 
mmu-mir-134* 2 5 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-135a 2 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-135b 1 4 0.0% 0.0% 3 1 0.0% 0.0% 
mmu-mir-136 16 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-136* 6 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-138 6 4 0.0% 0.0% 4 3 0.0% 0.0% 
mmu-mir-139-5p 1 1 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-140 33 52 0.1% 0.1% 14 13 0.0% 0.0% 
mmu-mir-140* 245 352 0.5% 0.7% 54 103 0.1% 0.2% 
mmu-mir-141 0 0 0.0% 0.0% 2 4 0.0% 0.0% 
mmu-mir-142-3p 1 0 0.0% 0.0% 705 1171 1.4% 2.5% 
mmu-mir-142-5p 0 0 0.0% 0.0% 243 446 0.5% 0.9% 
mmu-mir-143 92 35 0.2% 0.1% 0 0 0.0% 0.0% 
mmu-mir-143* 7 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-145 364 247 0.7% 0.5% 0 1 0.0% 0.0% 
mmu-mir-145* 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-146a 6 2 0.0% 0.0% 263 301 0.5% 0.6% 
mmu-mir-146b 164 22 0.3% 0.0% 175 331 0.3% 0.7% 
mmu-mir-146b* 0 0 0.0% 0.0% 1 9 0.0% 0.0% 
mmu-mir-148a 6 0 0.0% 0.0% 112 108 0.2% 0.2% 
mmu-mir-148b 14 7 0.0% 0.0% 3 3 0.0% 0.0% 
mmu-mir-149 12 20 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-150 0 1 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-151-3p 44 40 0.1% 0.1% 16 23 0.0% 0.0% 
mmu-mir-151-5p 165 170 0.3% 0.4% 66 118 0.1% 0.3% 
mmu-mir-152 381 207 0.8% 0.4% 16 15 0.0% 0.0% 
mmu-mir-152* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-153 0 0 0.0% 0.0% 2 9 0.0% 0.0% 
mmu-mir-154 19 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-154* 2 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-155 1059 242 2.1% 0.5% 8672 10835 17.3% 23.0% 
mmu-mir-155* 0 0 0.0% 0.0% 3 6 0.0% 0.0% 
mmu-mir-181a 13 12 0.0% 0.0% 13 17 0.0% 0.0% 
mmu-mir-181b 27 33 0.1% 0.1% 3 9 0.0% 0.0% 
mmu-mir-181b-1* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-181c 18 6 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-181c* 5 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-181d 15 14 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-182 37 82 0.1% 0.2% 164 273 0.3% 0.6% 
mmu-mir-182* 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-183 42 77 0.1% 0.2% 53 111 0.1% 0.2% 
mmu-mir-183* 2 6 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-185 181 83 0.4% 0.2% 61 78 0.1% 0.2% 
mmu-mir-186 48 19 0.1% 0.0% 11 18 0.0% 0.0% 
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mmu-mir-186* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-187 6 11 0.0% 0.0% 4 18 0.0% 0.0% 
mmu-mir-188-3p 1 4 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-188-5p 9 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-190 33 51 0.1% 0.1% 9 12 0.0% 0.0% 
mmu-mir-190* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-190b 4 1 0.0% 0.0% 4 6 0.0% 0.0% 
mmu-mir-191 182 237 0.4% 0.5% 1245 1522 2.5% 3.2% 
mmu-mir-191* 0 0 0.0% 0.0% 3 1 0.0% 0.0% 
mmu-mir-192 0 1 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-193 43 9 0.1% 0.0% 0 2 0.0% 0.0% 
mmu-mir-193* 0 3 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-193b 12 13 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-194 7 4 0.0% 0.0% 10 23 0.0% 0.0% 
mmu-mir-195 270 201 0.5% 0.4% 38 28 0.1% 0.1% 
mmu-mir-195 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-196a 4 89 0.0% 0.2% 54 77 0.1% 0.2% 
mmu-mir-196a* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-196a-1* 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-196b 1 8 0.0% 0.0% 2 8 0.0% 0.0% 
mmu-mir-196b* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-197 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-199a-3p 4027 3621 8.0% 7.7% 2 0 0.0% 0.0% 
mmu-mir-199a-5p 1555 1082 3.1% 2.3% 0 0 0.0% 0.0% 
mmu-mir-199b* 326 141 0.7% 0.3% 0 0 0.0% 0.0% 
mmu-mir-200b 0 1 0.0% 0.0% 3 1 0.0% 0.0% 
mmu-mir-200c 0 2 0.0% 0.0% 25 27 0.0% 0.1% 
mmu-mir-201 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-203 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-206 19 50 0.0% 0.1% 0 0 0.0% 0.0% 
mmu-mir-207 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-210 250 8 0.5% 0.0% 0 2 0.0% 0.0% 
mmu-mir-210* 7 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-211 1 0 0.0% 0.0% 11 12 0.0% 0.0% 
mmu-mir-212 1 0 0.0% 0.0% 4 8 0.0% 0.0% 
mmu-mir-214 366 266 0.7% 0.6% 0 0 0.0% 0.0% 
mmu-mir-214* 12 10 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-216a 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-216b 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-217* 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-218 2476 1649 4.9% 3.5% 102 94 0.2% 0.2% 
mmu-mir-218-1* 4 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-219 8 10 0.0% 0.0% 8 11 0.0% 0.0% 
mmu-mir-221 783 434 1.6% 0.9% 0 0 0.0% 0.0% 
mmu-mir-221* 8 6 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-222 141 73 0.3% 0.2% 0 0 0.0% 0.0% 
mmu-mir-222* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-224 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
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mmu-mir-291a-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-292-3p 5 0 0.0% 0.0% 3 1 0.0% 0.0% 
mmu-mir-292-5p 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-296-3p 20 2 0.0% 0.0% 3 18 0.0% 0.0% 
mmu-mir-296-5p 1 1 0.0% 0.0% 2 4 0.0% 0.0% 
mmu-mir-297a 90 16 0.2% 0.0% 0 2 0.0% 0.0% 
mmu-mir-297b-3p 3 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-297b-5p 7 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-297c 33 7 0.1% 0.0% 0 1 0.0% 0.0% 
mmu-mir-298 7 0 0.0% 0.0% 3 6 0.0% 0.0% 
mmu-mir-299 24 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-299* 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-300 77 9 0.2% 0.0% 1 1 0.0% 0.0% 
mmu-mir-300* 5 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-301a 215 180 0.4% 0.4% 44 61 0.1% 0.1% 
mmu-mir-301a* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-301b 11 6 0.0% 0.0% 11 11 0.0% 0.0% 
mmu-mir-302a 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-320 178 104 0.4% 0.2% 19 59 0.0% 0.1% 
mmu-mir-322 485 376 1.0% 0.8% 6 15 0.0% 0.0% 
mmu-mir-322* 23 26 0.0% 0.1% 0 1 0.0% 0.0% 
mmu-mir-323-3p 1 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-323-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-324-3p 31 36 0.1% 0.1% 6 5 0.0% 0.0% 
mmu-mir-324-5p 20 28 0.0% 0.1% 4 3 0.0% 0.0% 
mmu-mir-325 0 0 0.0% 0.0% 7 2 0.0% 0.0% 
mmu-mir-325* 0 0 0.0% 0.0% 8 2 0.0% 0.0% 
mmu-mir-326 2 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-327 0 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-328 2 6 0.0% 0.0% 12 5 0.0% 0.0% 
mmu-mir-329 20 7 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-329* 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-330 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-330* 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-331-3p 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-331-5p 1 5 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-337-3p 21 8 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-337-5p 11 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-339-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-339-5p 6 1 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-340-3p 3 2 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-340-5p 8 7 0.0% 0.0% 16 13 0.0% 0.0% 
mmu-mir-341 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-342-3p 36 25 0.1% 0.1% 22 44 0.0% 0.1% 
mmu-mir-342-5p 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-344 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-345-3p 7 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-345-5p 18 13 0.0% 0.0% 1 8 0.0% 0.0% 
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mmu-mir-346 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-350 140 71 0.3% 0.2% 60 68 0.1% 0.1% 
mmu-mir-350* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-351 159 211 0.3% 0.4% 1 0 0.0% 0.0% 
mmu-mir-351* 2 6 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-361 120 148 0.2% 0.3% 112 118 0.2% 0.3% 
mmu-mir-361* 1 2 0.0% 0.0% 2 2 0.0% 0.0% 
mmu-mir-362-3p 36 24 0.1% 0.1% 24 24 0.0% 0.1% 
mmu-mir-362-5p 30 14 0.1% 0.0% 8 16 0.0% 0.0% 
mmu-mir-365 28 80 0.1% 0.2% 0 1 0.0% 0.0% 
mmu-mir-369-3p 18 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-370 1 0 0.0% 0.0% 2 2 0.0% 0.0% 
mmu-mir-370* 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-374 286 242 0.6% 0.5% 213 180 0.4% 0.4% 
mmu-mir-374* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-376a 11 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-376a* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-376b 79 20 0.2% 0.0% 0 0 0.0% 0.0% 
mmu-mir-376b* 0 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-376c 9 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-377 10 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-378 403 140 0.8% 0.3% 109 193 0.2% 0.4% 
mmu-mir-378* 28 21 0.1% 0.0% 7 6 0.0% 0.0% 
mmu-mir-379 22 14 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-379* 2 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-380-3p 12 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-380-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-381 35 1 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-382 3 5 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-382* 3 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-384-5p 0 0 0.0% 0.0% 7 4 0.0% 0.0% 
mmu-mir-409-3p 12 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-410 80 43 0.2% 0.1% 0 0 0.0% 0.0% 
mmu-mir-410* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-411 19 9 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-411* 30 14 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-421 50 52 0.1% 0.1% 7 9 0.0% 0.0% 
mmu-mir-423-3p 12 12 0.0% 0.0% 9 11 0.0% 0.0% 
mmu-mir-423-5p 7 4 0.0% 0.0% 4 5 0.0% 0.0% 
mmu-mir-425 46 34 0.1% 0.1% 134 147 0.3% 0.3% 
mmu-mir-425* 1 0 0.0% 0.0% 4 0 0.0% 0.0% 
mmu-mir-431 9 14 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-431* 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-433 17 7 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-433* 0 0 0.0% 0.0% 2 2 0.0% 0.0% 
mmu-mir-434-3p 26 11 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-434-5p 6 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-449a 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
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mmu-mir-450a-3p 4 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-450a-5p 60 29 0.1% 0.1% 0 3 0.0% 0.0% 
mmu-mir-450b-3p 7 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-450b-5p 5 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-452 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-455 6 13 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-455* 8 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-465b-5p 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466a-3p 12 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466a-5p 44 3 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466b-5p 47 11 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466c-5p 83 19 0.2% 0.0% 2 0 0.0% 0.0% 
mmu-mir-466d-3p 3 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466d-5p 1 0 0.0% 0.0% 2 4 0.0% 0.0% 
mmu-mir-466e-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466f 12 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466f-3p 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466f-5p 8 1 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-466g 14 4 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466h 9 4 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466h-3p 1 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466i 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466i-5p 0 0 0.0% 0.0% 2 3 0.0% 0.0% 
mmu-mir-466j 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-466k 69 9 0.1% 0.0% 0 1 0.0% 0.0% 
mmu-mir-466l-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-467a 112 62 0.2% 0.1% 0 0 0.0% 0.0% 
mmu-mir-467a* 7 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-467b 2 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-467b* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-467c 44 35 0.1% 0.1% 0 0 0.0% 0.0% 
mmu-mir-467d 7 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-467e 58 27 0.1% 0.1% 0 0 0.0% 0.0% 
mmu-mir-467f 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-468 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-470 1 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-483 8 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-483* 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-484 57 56 0.1% 0.1% 25 33 0.0% 0.1% 
mmu-mir-485 2 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-485* 2 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-486 1 1 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-487b 8 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-493* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-494 20 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-495 16 9 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-496 9 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-497 231 113 0.5% 0.2% 9 9 0.0% 0.0% 
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mmu-mir-497* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-499 2 0 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-500 16 13 0.0% 0.0% 15 26 0.0% 0.1% 
mmu-mir-500* 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-501-3p 6 13 0.0% 0.0% 2 4 0.0% 0.0% 
mmu-mir-501-5p 8 6 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-503 37 25 0.1% 0.1% 1 6 0.0% 0.0% 
mmu-mir-503* 0 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-511 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-532-3p 5 10 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-532-5p 77 29 0.2% 0.1% 29 16 0.1% 0.0% 
mmu-mir-540-3p 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-540-5p 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-541 117 10 0.2% 0.0% 0 9 0.0% 0.0% 
mmu-mir-542-3p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-543 10 9 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-543* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-547 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-574-3p 4 17 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-574-5p 48 37 0.1% 0.1% 4 10 0.0% 0.0% 
mmu-mir-582-3p 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-582-5p 2 5 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-598 4 11 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-615-3p 6 9 0.0% 0.0% 3 4 0.0% 0.0% 
mmu-mir-615-5p 4 0 0.0% 0.0% 2 3 0.0% 0.0% 
mmu-mir-652 137 271 0.3% 0.6% 32 67 0.1% 0.1% 
mmu-mir-652* 3 0 0.0% 0.0% 2 0 0.0% 0.0% 
mmu-mir-654-3p 1 0 0.0% 0.0% 5 9 0.0% 0.0% 
mmu-mir-664 0 13 0.0% 0.0% 9 13 0.0% 0.0% 
mmu-mir-664* 1 4 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-665 13 4 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-666-3p 3 0 0.0% 0.0% 1 3 0.0% 0.0% 
mmu-mir-666-5p 5 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-668 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-669a 376 113 0.8% 0.2% 0 0 0.0% 0.0% 
mmu-mir-669a-1* 22 6 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669b 204 44 0.4% 0.1% 0 0 0.0% 0.0% 
mmu-mir-669c 29 24 0.1% 0.1% 2 0 0.0% 0.0% 
mmu-mir-669d 99 12 0.2% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669d* 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669e 28 5 0.1% 0.0% 0 2 0.0% 0.0% 
mmu-mir-669f 1 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669f-5p 7 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669g 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-669h-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669l 50 17 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-669o 35 8 0.1% 0.0% 0 0 0.0% 0.0% 
mmu-mir-670 0 7 0.0% 0.0% 0 0 0.0% 0.0% 
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mmu-mir-670* 0 3 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-671-3p 0 1 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-671-5p 54 12 0.1% 0.0% 5 7 0.0% 0.0% 
mmu-mir-673-3p 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-673-5p 5 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-674 100 26 0.2% 0.1% 13 15 0.0% 0.0% 
mmu-mir-674* 30 19 0.1% 0.0% 2 0 0.0% 0.0% 
mmu-mir-676 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-677 1 0 0.0% 0.0% 5 14 0.0% 0.0% 
mmu-mir-677* 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-679 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-689 1 0 0.0% 0.0% 2 1 0.0% 0.0% 
mmu-mir-690 2 0 0.0% 0.0% 1 3 0.0% 0.0% 
mmu-mir-696 0 0 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-700 2 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-700* 2 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-703 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-705 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-707 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-708 10 11 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-708* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-709 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-710 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-711 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-712 0 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-712* 1 0 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-718 0 1 0.0% 0.0% 2 0 0.0% 0.0% 
mmu-mir-720 9 10 0.0% 0.0% 13 15 0.0% 0.0% 
mmu-mir-743a 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-744 42 48 0.1% 0.1% 2 10 0.0% 0.0% 
mmu-mir-744* 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-758 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-760 0 2 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-762 3 0 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-763 2 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-764-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-770-3p 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-770-5p 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-804 1 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-805 36 62 0.1% 0.1% 70 63 0.1% 0.1% 
mmu-mir-805* 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-872 18 24 0.0% 0.1% 4 4 0.0% 0.0% 
mmu-mir-872* 21 23 0.0% 0.0% 2 5 0.0% 0.0% 
mmu-mir-874 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-877 2 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-879* 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-881 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-883b-5p 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
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mmu-mir-1187 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1188 4 1 0.0% 0.0% 3 3 0.0% 0.0% 
mmu-mir-1190 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1191 3 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1195 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1196 0 0 0.0% 0.0% 2 0 0.0% 0.0% 
mmu-mir-1198 19 17 0.0% 0.0% 11 15 0.0% 0.0% 
mmu-mir-1224 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1274a 171 108 0.3% 0.2% 59 56 0.1% 0.1% 
mmu-mir-1306 1 1 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-1839-3p 3 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1839-5p 23 15 0.0% 0.0% 7 14 0.0% 0.0% 
mmu-mir-1893 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1895 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1896 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1897-3p 0 0 0.0% 0.0% 0 4 0.0% 0.0% 
mmu-mir-1904 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1906 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-1927 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-1930 0 0 0.0% 0.0% 1 3 0.0% 0.0% 
mmu-mir-1933-5p 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1935 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1937a 6 21 0.0% 0.0% 5 14 0.0% 0.0% 
mmu-mir-1937b 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1937c 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1939 46 255 0.1% 0.5% 60 65 0.1% 0.1% 
mmu-mir-1940 0 0 0.0% 0.0% 2 3 0.0% 0.0% 
mmu-mir-1941-3p 3 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1941-5p 0 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1944 83 16 0.2% 0.0% 16 18 0.0% 0.0% 
mmu-mir-1944* 1 1 0.0% 0.0% 3 9 0.0% 0.0% 
mmu-mir-1946a 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-1947 0 0 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-1948 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-1948* 1 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1949 0 1 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-1955 1 1 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1957 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1959 0 1 0.0% 0.0% 2 5 0.0% 0.0% 
mmu-mir-1961 0 0 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-1965 0 0 0.0% 0.0% 1 0 0.0% 0.0% 
mmu-mir-1967 1 0 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1968 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-1981 4 6 0.0% 0.0% 1 3 0.0% 0.0% 
mmu-mir-1981* 1 2 0.0% 0.0% 0 0 0.0% 0.0% 
mmu-mir-1982* 0 1 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-1983 0 4 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-2132 1 0 0.0% 0.0% 0 7 0.0% 0.0% 
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mmu-mir-2133 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-2133-1* 6 1 0.0% 0.0% 7 12 0.0% 0.0% 
mmu-mir-2133-2* 0 0 0.0% 0.0% 1 2 0.0% 0.0% 
mmu-mir-2134 0 0 0.0% 0.0% 3 11 0.0% 0.0% 
mmu-mir-2134-1* 0 0 0.0% 0.0% 1 1 0.0% 0.0% 
mmu-mir-2134-4* 0 0 0.0% 0.0% 0 2 0.0% 0.0% 
mmu-mir-2135 5 2 0.0% 0.0% 7 9 0.0% 0.0% 
mmu-mir-2135-1* 2 0 0.0% 0.0% 2 10 0.0% 0.0% 
mmu-mir-2137 0 0 0.0% 0.0% 1 4 0.0% 0.0% 
mmu-mir-2138 0 0 0.0% 0.0% 3 3 0.0% 0.0% 
mmu-mir-2138* 0 0 0.0% 0.0% 0 3 0.0% 0.0% 
mmu-mir-2140 0 0 0.0% 0.0% 1 3 0.0% 0.0% 
mmu-mir-2141 0 0 0.0% 0.0% 5 4 0.0% 0.0% 
mmu-mir-2142 23 207 0.0% 0.4% 90 184 0.2% 0.4% 
mmu-mir-2143 3 2 0.0% 0.0% 2 8 0.0% 0.0% 
mmu-mir-2143-3* 0 0 0.0% 0.0% 0 1 0.0% 0.0% 
mmu-mir-2144 0 0 0.0% 0.0% 4 0 0.0% 0.0% 
mmu-mir-2144* 0 0 0.0% 0.0% 3 14 0.0% 0.0% 
mmu-mir-2145 0 1 0.0% 0.0% 10 45 0.0% 0.1% 
mmu-mir-2146 1 0 0.0% 0.0% 2 6 0.0% 0.0% 
mmu-mir-2183 0 0 0.0% 0.0% 9 18 0.0% 0.0% 
 
The libraries were analysed in the reference of miRBase v14.0. The murine miRNAs that are 
not present here have no reads in all four libraries.  
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Appendix Table III 
 
Read numbers of individual murine miRNA in Solexa sequencing libraries of wt, 
Dicer1-/- and Dgcr8-/- mESCs. 
 
 
wt Dicer1-/- Dgcr8-/- 
mismatch0 mismatch1 mismatch0 mismatch1 mismatch0 mismatch1 
total miRNA 2610803 340757 18198 12351 116462 30508 
mmu-let-7a 967 110 102 5 30 2 
mmu-let-7a* 9 10 0 0 0 0 
mmu-let-7b 73 39 11 0 11 1 
mmu-let-7b* 0 1 0 0 0 0 
mmu-let-7c 1802 167 24 1 2 0 
mmu-let-7d 383 46 18 2 6 2 
mmu-let-7d* 1 0 0 0 1 0 
mmu-let-7e 635 70 9 2 6 2 
mmu-let-7f 725 52 107 6 42 0 
mmu-let-7f* 0 1 0 1 0 0 
mmu-let-7g 455 47 7 1 10 0 
mmu-let-7g* 2 0 0 0 0 0 
mmu-let-7i 153 17 20 1 13 1 
mmu-let-7i* 5 1 0 0 1 0 
mmu-mir-1 84 10 2 0 7 0 
mmu-mir-1-2-as 1 1 0 1 0 0 
mmu-mir-7a 25777 2330 108 3 0 0 
mmu-mir-7a* 155 21 3 1 0 0 
mmu-mir-7b 202 31 1 0 0 0 
mmu-mir-9 794 79 4 1 0 0 
mmu-mir-9* 111 19 0 0 2 0 
mmu-mir-10a 5 0 6 0 0 0 
mmu-mir-10b 0 1 0 0 0 0 
mmu-mir-10b* 1 0 0 0 0 0 
mmu-mir-15a 4357 461 25 1 5 2 
mmu-mir-15a* 70 18 0 0 0 0 
mmu-mir-15b 7640 649 47 0 2 0 
mmu-mir-15b* 216 26 1 0 0 0 
mmu-mir-16 23030 2333 237 13 21 1 
mmu-mir-16* 158 32 6 0 0 0 
mmu-mir-17 39624 6214 10 1 4 1 
mmu-mir-17* 242 33 5 0 0 0 
mmu-mir-18a 22525 2622 10 1 3 0 
mmu-mir-18a* 515 55 1 0 0 0 
mmu-mir-18b 2835 271 10 0 0 0 
mmu-mir-19a 6866 810 3 0 0 0 
mmu-mir-19a* 118 8 0 0 0 0 
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mmu-mir-19b 36048 4886 8 1 7 1 
mmu-mir-20a 48483 6528 68 5 5 1 
mmu-mir-20a* 91 22 1 0 0 0 
mmu-mir-20b 27029 3857 10 0 0 0 
mmu-mir-20b* 809 74 0 0 0 0 
mmu-mir-21 67968 5876 850 35 139 11 
mmu-mir-21* 466 51 47 3 1 0 
mmu-mir-23a 6751 788 33 3 14 2 
mmu-mir-23b 5820 657 62 1 70 3 
mmu-mir-24 28902 3982 150 14 111 16 
mmu-mir-24-1* 72 11 0 0 0 0 
mmu-mir-24-2* 522 69 13 0 2 1 
mmu-mir-25 4752 510 3 1 3 1 
mmu-mir-26a 13317 1440 61 7 32 5 
mmu-mir-26b 6507 500 47 2 14 0 
mmu-mir-26b* 40 1 0 0 0 0 
mmu-mir-27a 11531 1533 22 6 23 4 
mmu-mir-27a* 576 53 13 0 0 0 
mmu-mir-27b 9681 1609 51 7 38 7 
mmu-mir-27b* 196 24 1 0 0 0 
mmu-mir-28 1425 140 1 0 0 0 
mmu-mir-28* 598 86 1 1 2 0 
mmu-mir-29a 1836 154 66 1 47 2 
mmu-mir-29a* 34 3 6 0 1 0 
mmu-mir-29b 1139 102 18 1 10 2 
mmu-mir-29b* 18 8 0 0 0 0 
mmu-mir-29c 390 45 1 0 0 0 
mmu-mir-29c* 9 2 0 0 0 0 
mmu-mir-30a 707 65 6 0 1 0 
mmu-mir-30a* 63 51 0 0 0 0 
mmu-mir-30b 1560 119 21 1 0 0 
mmu-mir-30b* 20 5 2 1 0 0 
mmu-mir-30c 3776 409 8 0 1 0 
mmu-mir-30c-1* 58 6 0 0 0 0 
mmu-mir-30c-2* 47 5 0 0 0 0 
mmu-mir-30d 881 91 14 1 3 0 
mmu-mir-30e 3769 351 19 1 0 0 
mmu-mir-30e* 74 96 1 1 0 0 
mmu-mir-31 223 18 1 0 0 0 
mmu-mir-31* 56 10 0 0 0 0 
mmu-mir-32 3582 399 4 2 0 0 
mmu-mir-33 4387 431 2 0 3 0 
mmu-mir-33* 36 9 0 0 0 0 
mmu-mir-34a 7188 679 104 3 8 0 
mmu-mir-34b-3p 48 6 1 0 0 0 
mmu-mir-34b-5p 220 29 5 0 0 0 
mmu-mir-34c 470 57 14 4 8 1 
mmu-mir-34c* 10 2 0 0 0 0 
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mmu-mir-92a 24729 2985 9 1 9 1 
mmu-mir-92a* 226 37 1 0 0 0 
mmu-mir-92b 551 101 0 0 0 0 
mmu-mir-93 20191 3159 15 3 4 1 
mmu-mir-93* 193 24 1 0 0 0 
mmu-mir-96 33575 2904 210 4 7 0 
mmu-mir-98 54 13 3 0 2 0 
mmu-mir-99a 2 0 3 1 8 1 
mmu-mir-99b 360 51 0 0 1 0 
mmu-mir-99b* 44 7 0 0 0 0 
mmu-mir-100 0 1 2 0 2 0 
mmu-mir-101a 2902 535 7 1 10 0 
mmu-mir-101a* 74 6 8 0 0 0 
mmu-mir-101b 5746 697 1 0 0 0 
mmu-mir-103 18627 2604 18 3 18 5 
mmu-mir-106a 21904 3759 5 1 0 0 
mmu-mir-106b 20134 2461 106 10 6 1 
mmu-mir-106b* 168 41 0 1 0 0 
mmu-mir-107 631 91 0 0 0 1 
mmu-mir-122 43 8 63 1 93 3 
mmu-mir-124 2482 351 0 0 0 0 
mmu-mir-124* 73 8 0 0 0 0 
mmu-mir-125a-3p 77 13 0 0 1 0 
mmu-mir-125a-5p 1503 196 8 3 5 1 
mmu-mir-125b-3p 14 4 1 5 1 0 
mmu-mir-125b-5p 275 33 71 6 54 7 
mmu-mir-126-3p 844 104 1 0 0 0 
mmu-mir-126-5p 212 21 1 0 0 0 
mmu-mir-127 12994 1908 13 1 13 1 
mmu-mir-127* 1336 155 5 1 0 0 
mmu-mir-128 957 138 0 0 1 0 
mmu-mir-129-3p 130 52 0 0 5 0 
mmu-mir-129-5p 66 6 0 0 1 0 
mmu-mir-130a 57203 6417 33 3 34 7 
mmu-mir-130b 13134 1495 2 0 3 0 
mmu-mir-130b* 1169 103 1 0 0 0 
mmu-mir-132 32 4 0 0 0 0 
mmu-mir-133a 11 0 2 0 5 0 
mmu-mir-133a* 2 1 0 0 0 0 
mmu-mir-134 1323 281 15 2 0 3 
mmu-mir-135a 60 66 0 0 0 0 
mmu-mir-135a* 1 0 0 0 0 0 
mmu-mir-135b 13291 1672 56 4 0 0 
mmu-mir-136 12177 1156 37 4 7 0 
mmu-mir-136* 1123 84 2 0 4 0 
mmu-mir-137 10 0 0 0 0 0 
mmu-mir-138 169 30 1 0 0 0 
mmu-mir-139-3p 1 0 0 0 0 0 
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mmu-mir-139-5p 107 23 1 0 0 0 
mmu-mir-140 781 130 5 0 0 0 
mmu-mir-140* 710 85 1 0 1 2 
mmu-mir-141 3671 336 0 0 0 0 
mmu-mir-141* 76 9 2 0 0 0 
mmu-mir-142-3p 1523 255 7 0 7 0 
mmu-mir-142-5p 206 17 1 0 0 0 
mmu-mir-143 193 19 8 0 4 0 
mmu-mir-144 12 3 6 0 13 0 
mmu-mir-145 317 36 35 3 18 4 
mmu-mir-145* 9 1 0 0 0 0 
mmu-mir-146a 115 9 13 0 2 0 
mmu-mir-146b 126 10 0 0 0 0 
mmu-mir-146b* 3 0 0 0 0 0 
mmu-mir-147 70 3 0 0 0 0 
mmu-mir-148a 6761 679 24 0 28 1 
mmu-mir-148a* 80 7 7 1 0 0 
mmu-mir-148b 3287 358 9 0 9 0 
mmu-mir-149 320 35 0 0 0 0 
mmu-mir-150 1381 134 7 0 4 0 
mmu-mir-150* 5 1 0 0 0 0 
mmu-mir-151-3p 603 102 1 0 0 1 
mmu-mir-151-5p 2492 236 6 0 0 0 
mmu-mir-152 204 23 3 1 7 0 
mmu-mir-153 35 3 0 0 0 0 
mmu-mir-154 893 96 7 0 0 0 
mmu-mir-154* 7185 826 1 1 0 0 
mmu-mir-155 446 53 0 0 0 0 
mmu-mir-181a 46 13 14 0 6 0 
mmu-mir-181a-1* 0 3 0 0 0 0 
mmu-mir-181b 22 11 2 0 2 0 
mmu-mir-181c 1991 258 5 0 1 0 
mmu-mir-181d 2654 339 0 0 0 0 
mmu-mir-182 4140 612 49 3 0 0 
mmu-mir-183 9716 927 60 2 0 0 
mmu-mir-183* 838 113 3 1 0 0 
mmu-mir-184 2 0 0 0 0 0 
mmu-mir-185 643 123 0 0 0 0 
mmu-mir-186 2114 215 2 0 0 0 
mmu-mir-186* 60 19 1 0 0 0 
mmu-mir-187 83 57 0 0 0 0 
mmu-mir-188-3p 14 0 0 0 0 0 
mmu-mir-188-5p 191 31 1 0 0 0 
mmu-mir-190 841 85 3 0 1 0 
mmu-mir-190b 19 4 0 0 0 0 
mmu-mir-191 10843 1643 42 4 7 0 
mmu-mir-191* 104 17 0 0 1 0 
mmu-mir-192 134 17 7 0 0 0 
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mmu-mir-193 63 26 2 0 2 0 
mmu-mir-193* 17 2 1 1 0 1 
mmu-mir-194 156 13 0 0 0 0 
mmu-mir-195 1272 194 7 0 1 0 
mmu-mir-196a 55 8 7 0 0 1 
mmu-mir-196b 8 1 1 0 0 0 
mmu-mir-199a-3p 235 26 108 6 70 7 
mmu-mir-199a-5p 20 4 12 4 15 1 
mmu-mir-199b* 21 2 0 1 0 0 
mmu-mir-200a 4915 433 0 0 0 0 
mmu-mir-200a* 52 7 1 0 0 0 
mmu-mir-200b 4890 479 0 0 0 0 
mmu-mir-200b* 191 14 1 0 0 0 
mmu-mir-200c 4089 642 2 0 0 0 
mmu-mir-200c* 18 3 0 0 0 0 
mmu-mir-202-3p 0 1 0 0 0 0 
mmu-mir-202-5p 4 0 0 0 0 0 
mmu-mir-203 123 24 4 2 7 1 
mmu-mir-203* 4 0 0 0 0 0 
mmu-mir-204 9 0 0 0 0 0 
mmu-mir-205 1131 132 61 3 2 0 
mmu-mir-206 1 0 2 0 0 0 
mmu-mir-208a 9 1 0 0 0 0 
mmu-mir-208b 4 1 0 0 0 0 
mmu-mir-210 1722 414 1 0 0 0 
mmu-mir-211 9 1 0 0 0 0 
mmu-mir-212 18 3 0 0 0 0 
mmu-mir-214 0 0 0 0 1 0 
mmu-mir-214* 0 0 1 0 1 0 
mmu-mir-215 1 0 0 0 0 0 
mmu-mir-216b 3 0 0 0 0 0 
mmu-mir-218 159 9 0 0 0 0 
mmu-mir-218-1* 1 0 0 0 0 0 
mmu-mir-218-2* 1 0 0 0 0 0 
mmu-mir-219 160 8 0 0 1 0 
mmu-mir-22 6975 790 43 2 54 4 
mmu-mir-22* 257 19 4 0 1 0 
mmu-mir-221 617 135 29 4 17 2 
mmu-mir-222 789 76 15 1 21 2 
mmu-mir-223 1 0 0 0 1 0 
mmu-mir-224 64 5 1 0 0 0 
mmu-mir-290-3p 1307 243 14 3 2 2 
mmu-mir-290-5p 163878 22964 3325 223 19 1 
mmu-mir-291a-3p 166770 18652 103 13 17 0 
mmu-mir-291a-5p 51860 6735 110 15 8 0 
mmu-mir-291b-3p 15311 1646 0 0 0 0 
mmu-mir-291b-5p 7912 1530 9 0 1 0 
mmu-mir-292-3p 177466 25698 86 5 5 0 
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mmu-mir-292-5p 138375 26865 338 29 7 0 
mmu-mir-293 123699 14238 6 0 0 0 
mmu-mir-293* 30099 2715 204 8 0 0 
mmu-mir-294 260532 24171 7 1 90 3 
mmu-mir-294* 7412 1037 287 28 3 0 
mmu-mir-295 331261 39887 49 5 58 4 
mmu-mir-295* 12115 1575 430 15 3 0 
mmu-mir-296-3p 2122 568 16 3 2 2 
mmu-mir-296-5p 1301 237 1 0 0 0 
mmu-mir-297a 6510 702 1 0 0 1 
mmu-mir-297b-3p 412 111 0 0 0 0 
mmu-mir-297b-5p 222 35 1 0 0 0 
mmu-mir-297c 2482 239 4 0 0 0 
mmu-mir-298 1068 163 0 0 0 0 
mmu-mir-299 802 124 0 0 2 0 
mmu-mir-299* 1212 167 2 1 0 0 
mmu-mir-300 4604 743 2 0 2 1 
mmu-mir-300* 105 9 0 0 0 0 
mmu-mir-301a 7094 704 3 0 4 0 
mmu-mir-301b 3315 325 0 0 1 0 
mmu-mir-302a 2726 385 0 0 0 0 
mmu-mir-302a* 212 26 3 0 1 0 
mmu-mir-302b 3939 412 0 0 0 0 
mmu-mir-302b* 68 6 0 0 0 0 
mmu-mir-302c 663 87 0 0 0 0 
mmu-mir-302c* 36 1 0 0 0 0 
mmu-mir-302d 7055 755 0 0 0 0 
mmu-mir-320 3203 639 13 2 39629 5368 
mmu-mir-322 568 66 4 4 2 11 
mmu-mir-322* 4 0 0 0 0 0 
mmu-mir-323-3p 2267 274 0 0 0 0 
mmu-mir-323-5p 52 17 1 0 0 0 
mmu-mir-324-3p 111 18 0 0 0 0 
mmu-mir-324-5p 515 50 0 0 1 0 
mmu-mir-325 2 0 0 0 0 0 
mmu-mir-325* 1 0 0 0 0 0 
mmu-mir-326 27 3 0 0 0 0 
mmu-mir-328 52 8 0 0 0 0 
mmu-mir-329 455 58 0 0 0 0 
mmu-mir-330 173 20 5 0 0 0 
mmu-mir-330* 58 9 0 0 0 0 
mmu-mir-331-3p 147 39 1 0 0 0 
mmu-mir-331-5p 15 3 1 0 0 0 
mmu-mir-335-3p 1495 245 0 0 0 0 
mmu-mir-335-5p 1745 179 13 0 3 1 
mmu-mir-337-3p 845 104 3 0 1 0 
mmu-mir-337-5p 16 4 0 0 1 0 
mmu-mir-338-3p 45 9 0 0 0 0 
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mmu-mir-338-5p 4 0 0 0 0 0 
mmu-mir-339-3p 88 15 0 0 0 0 
mmu-mir-339-5p 571 148 38 4 36 5 
mmu-mir-340-3p 13 2 0 0 0 0 
mmu-mir-340-5p 989 74 9 0 0 0 
mmu-mir-341 255 53 0 0 0 0 
mmu-mir-342-3p 841 87 0 0 1 1 
mmu-mir-342-5p 101 12 1 0 0 0 
mmu-mir-344 67 8 0 0 196 11 
mmu-mir-345-3p 11 16 0 0 0 0 
mmu-mir-345-5p 187 45 0 0 0 0 
mmu-mir-346 8 0 0 0 0 0 
mmu-mir-350 458 39 0 0 0 0 
mmu-mir-351 29 7 1 0 0 0 
mmu-mir-361 1072 245 15 0 0 1 
mmu-mir-362-3p 168 21 0 1 0 0 
mmu-mir-362-5p 243 35 0 0 0 0 
mmu-mir-363 3905 446 0 0 1 0 
mmu-mir-365 158 17 6 1 1 0 
mmu-mir-367 1467 160 1 0 0 0 
mmu-mir-369-3p 5148 462 12 3 9 0 
mmu-mir-369-5p 714 69 10 0 0 0 
mmu-mir-370 962 223 0 0 0 0 
mmu-mir-374 1086 172 2 0 0 0 
mmu-mir-375 11 2 0 0 0 0 
mmu-mir-376a 4984 569 0 0 1 0 
mmu-mir-376a* 254 27 0 0 0 0 
mmu-mir-376b 6132 628 0 0 3 1 
mmu-mir-376b* 1083 100 8 0 5 0 
mmu-mir-376c 2287 248 0 0 1 0 
mmu-mir-376c* 21 5 0 0 0 0 
mmu-mir-377 1633 154 2 0 0 0 
mmu-mir-378 1980 205 5 1 6 1 
mmu-mir-378* 48 6 0 0 0 0 
mmu-mir-379 1625 129 1 0 1 0 
mmu-mir-380-3p 1980 256 1 0 2 0 
mmu-mir-380-5p 39 3 0 0 0 0 
mmu-mir-381 2074 254 0 1 1 0 
mmu-mir-382 1491 208 3 1 0 1 
mmu-mir-382* 28 7 0 0 0 0 
mmu-mir-384-3p 3 0 0 0 0 0 
mmu-mir-384-5p 4 0 0 0 0 0 
mmu-mir-409-3p 3809 618 1 2 1 0 
mmu-mir-409-5p 806 77 14 0 0 0 
mmu-mir-410 2552 253 2 0 3 2 
mmu-mir-411 2658 241 20 0 1 0 
mmu-mir-411* 3708 2680 0 1 0 0 
mmu-mir-412 28 2 0 0 0 0 
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mmu-mir-421 642 122 1 0 0 0 
mmu-mir-423-3p 882 134 1 0 0 0 
mmu-mir-423-5p 771 159 66 7 10 1 
mmu-mir-425 803 83 2 0 1 0 
mmu-mir-425* 67 16 1 0 0 0 
mmu-mir-429 3262 326 2 0 0 0 
mmu-mir-431 2392 301 5 2 2 0 
mmu-mir-431* 62 34 0 0 0 0 
mmu-mir-433 1851 210 2 0 3 0 
mmu-mir-433* 79 9 0 0 1 0 
mmu-mir-434-3p 3936 361 4 0 1 0 
mmu-mir-434-5p 1382 200 15 2 2 0 
mmu-mir-449a 57 7 0 0 0 0 
mmu-mir-449c 21 1 0 0 0 0 
mmu-mir-450a-3p 17 1 0 0 0 0 
mmu-mir-450a-5p 292 36 10 0 0 0 
mmu-mir-450b-3p 70 3 0 0 0 0 
mmu-mir-450b-5p 148 19 1 0 0 0 
mmu-mir-451 111 11 127 4 115 21 
mmu-mir-455 8 1 0 0 0 0 
mmu-mir-455* 17 0 0 0 0 0 
mmu-mir-463 2 0 0 0 0 0 
mmu-mir-463* 6 0 1 0 0 0 
mmu-mir-465a-3p 28 4 0 0 0 0 
mmu-mir-465a-5p 5 0 1 0 0 0 
mmu-mir-465b-5p 7 1 0 0 0 0 
mmu-mir-465c-5p 18 1 1 0 0 0 
mmu-mir-466a-3p 17151 2080 3 0 0 0 
mmu-mir-466a-5p 2618 298 19 2 0 0 
mmu-mir-466b-3-3p 157 21 0 0 0 0 
mmu-mir-466b-5p 1337 143 1 0 0 0 
mmu-mir-466c-5p 6991 673 51 2 0 0 
mmu-mir-466d-3p 2730 364 0 0 0 0 
mmu-mir-466d-5p 233 32 0 0 0 0 
mmu-mir-466e-5p 544 43 0 0 0 0 
mmu-mir-466f 1592 251 0 0 0 0 
mmu-mir-466f-3p 79 10 0 1 0 5 
mmu-mir-466f-5p 487 62 0 1 0 0 
mmu-mir-466g 151 963 0 1 0 0 
mmu-mir-466h 1345 661 0 0 0 0 
mmu-mir-466i 110 583 0 0 0 0 
mmu-mir-466j 314 144 6 4 0 0 
mmu-mir-466k 1173 833 1 1 0 0 
mmu-mir-466l 89 12 0 0 0 0 
mmu-mir-467a 17237 1752 132 7 0 0 
mmu-mir-467a-1* 4156 707 2 3 0 0 
mmu-mir-467b 1075 125 0 0 0 0 
mmu-mir-467b* 10 5 0 0 0 0 
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mmu-mir-467c 6161 690 75 3 0 0 
mmu-mir-467d 3401 377 18 1 0 0 
mmu-mir-467e 7995 682 28 0 0 0 
mmu-mir-467e* 160 17 0 0 0 0 
mmu-mir-467f 4 78 0 1 0 0 
mmu-mir-467g 2 53 0 0 0 1 
mmu-mir-467h 20 3549 0 0 0 0 
mmu-mir-470 8 1 1 0 0 0 
mmu-mir-470* 1 1 0 0 0 0 
mmu-mir-471 7 1 0 0 0 0 
mmu-mir-483 5 0 0 0 1 0 
mmu-mir-483* 4 0 0 0 0 0 
mmu-mir-484 2475 809 2 0 19480 4888 
mmu-mir-485 149 43 2 0 0 0 
mmu-mir-485* 1155 105 0 0 0 0 
mmu-mir-486 8 1 2 1 2 0 
mmu-mir-487b 1187 112 0 0 0 0 
mmu-mir-488 4 1 0 0 0 0 
mmu-mir-489 9 0 0 0 0 0 
mmu-mir-491 3 1 0 0 0 0 
mmu-mir-493 15 7 0 0 0 0 
mmu-mir-494 2909 393 2 0 5 0 
mmu-mir-495 4079 384 0 0 1 0 
mmu-mir-496 248 28 0 0 2 0 
mmu-mir-497 1493 103 0 0 1 0 
mmu-mir-499 176 15 35 2 7 0 
mmu-mir-500 393 65 0 0 2 0 
mmu-mir-501-3p 148 30 0 0 0 0 
mmu-mir-501-5p 143 21 28 2 0 0 
mmu-mir-503 121 26 1 0 0 0 
mmu-mir-503* 7 1 0 0 0 0 
mmu-mir-504 2 1 1 0 0 0 
mmu-mir-505 22 1 1 0 1 0 
mmu-mir-532-3p 84 8 1 0 0 0 
mmu-mir-532-5p 257 30 12 0 0 0 
mmu-mir-539 457 53 0 0 0 0 
mmu-mir-540-3p 994 113 0 0 0 0 
mmu-mir-540-5p 234 35 0 0 0 0 
mmu-mir-541 14331 1765 27 1 1 1 
mmu-mir-542-3p 114 20 0 2 1 0 
mmu-mir-542-5p 34 6 0 0 0 0 
mmu-mir-543 5765 638 2 0 1 0 
mmu-mir-544 39 77 0 0 0 0 
mmu-mir-574-3p 2 0 0 0 0 0 
mmu-mir-574-5p 39 25 0 32 3 49 
mmu-mir-582-5p 279 25 8 0 1 0 
mmu-mir-592 7 2 0 0 0 0 
mmu-mir-598 5 0 0 0 0 0 
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mmu-mir-615-3p 0 0 2 1 0 0 
mmu-mir-652 526 72 4 0 19 0 
mmu-mir-664 14 0 1 0 171 21 
mmu-mir-665 4997 685 0 0 0 0 
mmu-mir-666-3p 61 8 0 0 0 0 
mmu-mir-666-5p 270 52 0 0 2 0 
mmu-mir-667 136 60 0 0 0 0 
mmu-mir-668 34 12 0 0 42 11 
mmu-mir-669a 12505 2781 62 3 5 0 
mmu-mir-669b 4237 401 2 0 0 0 
mmu-mir-669c 7817 769 5 0 0 3 
mmu-mir-669d 2841 222 6 0 0 0 
mmu-mir-669e 756 67 0 0 0 0 
mmu-mir-669f 1165 716 1 0 0 1 
mmu-mir-669g 28 5 0 0 0 0 
mmu-mir-669h-3p 59 44 1 0 7 11 
mmu-mir-669h-5p 501 84 13 1 140 16 
mmu-mir-669i 22 93 0 0 15 6 
mmu-mir-669j 28 4 0 0 3 0 
mmu-mir-669k 32 13 0 0 1 1 
mmu-mir-669l 3868 306 0 0 0 0 
mmu-mir-669m 65 130 0 0 0 0 
mmu-mir-669n 20 150 0 4 0 0 
mmu-mir-669o 2169 204 3 0 0 0 
mmu-mir-670 4 1 0 0 0 0 
mmu-mir-671-3p 10 1 0 2 0 0 
mmu-mir-671-5p 159 65 2 1 0 0 
mmu-mir-672 1972 240 26 1 0 0 
mmu-mir-673-3p 22 3 0 0 0 0 
mmu-mir-673-5p 550 71 0 0 0 0 
mmu-mir-674 883 123 2 0 0 0 
mmu-mir-674* 635 98 0 0 0 0 
mmu-mir-676 76 14 1 0 0 0 
mmu-mir-676* 11 0 0 0 0 0 
mmu-mir-677 62 6 53 0 120 6 
mmu-mir-679 23 0 0 0 0 0 
mmu-mir-688 0 0 0 0 2 0 
mmu-mir-689 19 1 33 11 25 7 
mmu-mir-690 110 11 65 11 140 12 
mmu-mir-692 1 0 0 0 0 0 
mmu-mir-693-3p 1 1 0 0 0 0 
mmu-mir-696 2 1 1 1 4 2 
mmu-mir-700 29 12 0 0 0 0 
mmu-mir-701 3 1 0 0 0 0 
mmu-mir-702 35 9 0 0 601 33 
mmu-mir-703 2 0 2 0 5 0 
mmu-mir-704 3 0 0 0 13 3 
mmu-mir-705 0 0 1 1 0 0 
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mmu-mir-706 1 9 4 19 10 23 
mmu-mir-707 0 0 0 0 0 0 
mmu-mir-708 3106 304 3 0 3 1 
mmu-mir-708* 247 24 1 0 1 0 
mmu-mir-709 32 12 69 25 54 23 
mmu-mir-710 0 1 0 0 0 0 
mmu-mir-712 5 1 1 0 12 1 
mmu-mir-712* 658 66 40 3 306 18 
mmu-mir-713 0 0 0 1 0 0 
mmu-mir-714 3 1 12 0 3 0 
mmu-mir-715 4 2 2 0 2 0 
mmu-mir-717 0 0 0 0 0 0 
mmu-mir-718 0 0 0 0 0 0 
mmu-mir-719 0 0 0 0 0 0 
mmu-mir-720 861 118 1440 83 1975 196 
mmu-mir-721 0 2 0 0 0 0 
mmu-mir-741 13 1 0 0 0 0 
mmu-mir-743a 7 2 0 0 0 0 
mmu-mir-743b-3p 7 1 0 0 0 0 
mmu-mir-743b-5p 1 0 0 0 0 0 
mmu-mir-744 1569 236 5 0 0 0 
mmu-mir-744* 33 7 0 0 0 0 
mmu-mir-758 636 62 0 0 0 0 
mmu-mir-760 4 2 0 0 0 0 
mmu-mir-770-3p 13 6 1 0 0 0 
mmu-mir-770-5p 32 7 0 0 0 0 
mmu-mir-804 0 0 0 1 0 1 
mmu-mir-871 6 2 2 0 0 0 
mmu-mir-872 1144 102 5 0 0 0 
mmu-mir-872* 446 43 0 0 1 0 
mmu-mir-874 5 0 1 0 1 0 
mmu-mir-876-5p 1 0 0 0 0 0 
mmu-mir-877 25 4 0 0 419 35 
mmu-mir-877* 63 7 0 1 459 62 
mmu-mir-878-3p 8 0 0 0 0 0 
mmu-mir-878-5p 2 1 4 0 0 0 
mmu-mir-879 5 0 0 0 0 0 
mmu-mir-880 4 0 0 0 0 0 
mmu-mir-881 8 1 0 0 0 0 
mmu-mir-883a-3p 3 0 0 0 0 0 
mmu-mir-883b-5p 0 0 1 0 0 0 
mmu-mir-1186 1213 317 1 19 3496 866 
mmu-mir-1186b 1 7 2 7 2 2 
mmu-mir-1187 181 270 3 16 2 10 
mmu-mir-1188 28 11 0 0 0 0 
mmu-mir-1190 12 3 0 0 0 0 
mmu-mir-1191 27 3 0 0 0 0 
mmu-mir-1192 0 0 0 0 0 1 
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mmu-mir-1193 318 34 0 0 0 0 
mmu-mir-1194 0 4 0 2 1 15 
mmu-mir-1195 95 85 15 59 116 166 
mmu-mir-1196 2260 252 1 11 7928 641 
mmu-mir-1197 221 16 1 0 0 0 
mmu-mir-1198 143 44 3 1 0 0 
mmu-mir-1199 12 1 0 0 0 0 
mmu-mir-1224 0 1 0 0 0 0 
mmu-mir-1274a 67 575 305 1659 196 1678 
mmu-mir-1306 7 4 0 0 0 0 
mmu-mir-1839-3p 44 13 0 0 239 47 
mmu-mir-1839-5p 208 30 2 0 1642 149 
mmu-mir-1894-5p 0 0 0 0 1 0 
mmu-mir-1895 0 0 0 3 0 2 
mmu-mir-1930 7 1 0 0 0 0 
mmu-mir-1931 0 19 0 40 0 23 
mmu-mir-1934 5 1 0 0 0 0 
mmu-mir-1935 49 23 0 0 106 53 
mmu-mir-1937a 273 38 872 67 877 94 
mmu-mir-1937b 25 2 192 21 175 23 
mmu-mir-1937c 1 2 0 1 2 4 
mmu-mir-1939 0 111 0 422 0 437 
mmu-mir-193b 78 15 1 0 0 0 
mmu-mir-1940 0 0 0 0 3 0 
mmu-mir-1941-5p 1 0 0 0 0 0 
mmu-mir-1943 3 1 0 0 0 0 
mmu-mir-1944 343 31 657 30 867 67 
mmu-mir-1946a 6 25 19 36 8 35 
mmu-mir-1946b 1 24 2 24 3 13 
mmu-mir-1947 11 0 0 0 0 0 
mmu-mir-1949 28 5 67 5 62 6 
mmu-mir-1950 1 0 0 0 0 0 
mmu-mir-1952 0 0 0 1 0 0 
mmu-mir-1953 1 0 0 0 0 0 
mmu-mir-1954 3 0 0 0 0 0 
mmu-mir-1955 7 2 0 0 0 0 
mmu-mir-1956 0 0 0 0 2 0 
mmu-mir-1957 0 75 0 270 0 355 
mmu-mir-1959 116 143 169 261 221 355 
mmu-mir-1961 0 1 0 0 0 0 
mmu-mir-1964 3 4 0 0 0 0 
mmu-mir-1965 841 292 6 1 845 179 
mmu-mir-1968 26 8 0 0 0 0 
mmu-mir-1969 1 0 0 0 0 0 
mmu-mir-1971 0 5 0 0 1 254 
mmu-mir-1981 37 3 0 0 2770 110 
mmu-mir-1982* 1 0 0 0 5 0 
mmu-mir-1982.1 19 1 0 0 44 5 
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mmu-mir-1982.2 3 0 0 0 7 1 
mmu-mir-1983 1827 367 6 1 25413 4555 
mmu-mir-2132 90 31 256 62 536 147 
mmu-mir-2133 41 11 334 46 232 47 
mmu-mir-2134 27 3 12 3 40 6 
mmu-mir-2135 514 110 304 37 501 79 
mmu-mir-2137 6 4337 9 8038 12 8509 
mmu-mir-2138 827 133 1091 95 1172 196 
mmu-mir-2140 71 8 49 1 77 7 
mmu-mir-2141 1257 164 1174 68 1779 152 
mmu-mir-2145 206 26 591 69 821 94 
mmu-mir-2146 489 65 353 22 515 45 
mmu-mir-3072 73 14 0 0 0 0 
mmu-mir-3072* 19 3 0 0 0 0 
mmu-mir-3099 3 2 0 0 0 0 
mmu-mir-3470a 5 2 18 5 17 6 
mmu-mir-3470b 1 0 2 5 5 14 
mmu-mir-3471 1 0 2 1 0 2 
mmu-mir-3472 0 0 0 0 0 2 
mmu-mir-3473 29 27 58 82 76 50 
mmu-mir-3474 2 0 0 0 1 0 
mmu-mir-3475 5 3 0 0 0 1 
 
The libraries were analysed in the reference of miRBase v15.0. The murine miRNAs that are 
not present here have no reads in all three libraries.  
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Appendix Table IV 
 
Read numbers of individual human miRNA in Solexa sequencing libraries of wt, 
Dicer1-/- and Dgcr8-/- mESCs. 
 
 
wt Dicer1-/- Dgcr8-/- 
mismatch0 mismatch1 mismatch0 mismatch1 mismatch0 mismatch1 
total miRNA 889563 353066 20511 32411 73599 41158 
hsa-let-7a 967 115 102 6 30 2 
hsa-let-7a* 11 5 3 2 0 0 
hsa-let-7b 73 40 11 0 11 1 
hsa-let-7b* 0 1 0 0 0 0 
hsa-let-7c 1802 168 24 1 2 0 
hsa-let-7c* 0 0 0 0 0 0 
hsa-let-7d 383 43 18 1 6 2 
hsa-let-7d* 1 0 0 0 1 0 
hsa-let-7e 635 71 9 2 6 2 
hsa-let-7e* 21 1 1 0 0 0 
hsa-let-7f 725 53 107 6 42 0 
hsa-let-7f-1* 0 1 0 1 0 0 
hsa-let-7f-2* 3 1 0 0 0 0 
hsa-let-7g 455 42 7 1 10 0 
hsa-let-7g* 3 0 0 0 0 0 
hsa-let-7i 153 16 20 1 13 1 
hsa-let-7i* 5 1 0 0 1 0 
hsa-mir-1 84 10 2 0 7 0 
hsa-mir-7 25777 2534 108 4 0 0 
hsa-mir-7-1* 155 21 3 1 0 0 
hsa-mir-9 794 79 4 1 0 0 
hsa-mir-9* 111 19 0 0 2 0 
hsa-mir-10a 5 0 6 0 0 0 
hsa-mir-10b 0 1 0 0 0 0 
hsa-mir-10b* 1 0 0 0 0 0 
hsa-mir-15a 4357 463 25 1 5 2 
hsa-mir-15a* 0 71 0 0 0 0 
hsa-mir-15b 7640 647 47 0 2 0 
hsa-mir-15b* 216 26 1 0 0 0 
hsa-mir-16 23030 2404 237 13 21 1 
hsa-mir-16-1* 0 159 0 6 0 0 
hsa-mir-16-2* 0 106 0 1 0 0 
hsa-mir-17 39624 28380 10 6 4 1 
hsa-mir-17* 0 242 0 5 0 0 
hsa-mir-18a 22525 2649 10 3 3 0 
hsa-mir-18a* 494 76 1 0 0 0 
hsa-mir-18b 31 2801 0 8 0 0 
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hsa-mir-18b* 3 42 0 0 0 0 
hsa-mir-19a 6866 911 3 0 0 0 
hsa-mir-19a* 36 9 1 0 0 0 
hsa-mir-19b 36048 4785 8 1 7 1 
hsa-mir-19b-1* 355 64 12 0 0 0 
hsa-mir-19b-2* 0 3 0 0 0 0 
hsa-mir-20a 48483 6319 68 5 5 1 
hsa-mir-20a* 0 91 0 1 0 0 
hsa-mir-20b 27029 3920 10 0 0 0 
hsa-mir-21 67968 5876 850 35 139 11 
hsa-mir-21* 0 470 0 45 0 1 
hsa-mir-22 6975 790 43 2 54 4 
hsa-mir-22* 257 19 4 0 1 0 
hsa-mir-23a 8307 960 84 4 70 5 
hsa-mir-23a* 72 9 2 0 0 0 
hsa-mir-23b 4264 485 11 0 14 0 
hsa-mir-23b* 89 12 1 0 0 0 
hsa-mir-24 28902 3982 150 14 111 16 
hsa-mir-24-1* 44 9 0 0 0 0 
hsa-mir-24-2* 3 7 2 0 0 0 
hsa-mir-25 4752 533 3 1 3 1 
hsa-mir-25* 14 2 0 0 0 0 
hsa-mir-26a 13317 1440 61 7 32 5 
hsa-mir-26a-1* 1 0 0 0 0 0 
hsa-mir-26a-2* 0 28 0 0 0 0 
hsa-mir-26b 6507 500 47 2 14 0 
hsa-mir-26b* 40 1 0 0 0 0 
hsa-mir-27a 11682 1632 29 7 33 5 
hsa-mir-27a* 576 53 13 0 0 0 
hsa-mir-27b 9530 1510 44 6 28 6 
hsa-mir-27b* 196 24 1 0 0 0 
hsa-mir-28-3p 1 598 0 2 0 2 
hsa-mir-28-5p 1425 141 1 0 0 0 
hsa-mir-29a 1836 155 66 1 47 2 
hsa-mir-29a* 34 3 6 0 1 0 
hsa-mir-29b 1139 101 18 1 10 2 
hsa-mir-29b-1* 17 3 0 0 0 0 
hsa-mir-29b-2* 4 2 0 0 0 0 
hsa-mir-29c 390 45 1 0 0 0 
hsa-mir-29c* 9 2 0 0 0 0 
hsa-mir-30a 707 65 6 0 1 0 
hsa-mir-30a* 63 51 0 0 0 0 
hsa-mir-30b 1340 103 18 1 0 0 
hsa-mir-30b* 0 1 0 0 0 0 
hsa-mir-30c 3996 425 11 0 1 0 
hsa-mir-30c-1* 58 6 0 0 0 0 
hsa-mir-30c-2* 47 5 0 0 0 0 
hsa-mir-30d 881 94 14 1 3 0 
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hsa-mir-30d* 25 11 1 0 0 0 
hsa-mir-30e 3769 348 19 1 0 0 
hsa-mir-30e* 74 96 1 1 0 0 
hsa-mir-31 220 19 1 0 0 0 
hsa-mir-31* 51 7 0 0 0 0 
hsa-mir-32 3582 399 4 2 0 0 
hsa-mir-32* 175 15 0 0 0 0 
hsa-mir-33a 4387 431 2 0 3 0 
hsa-mir-33a* 36 9 0 0 0 0 
hsa-mir-33b 0 1 0 0 0 0 
hsa-mir-34a 7188 679 104 3 8 0 
hsa-mir-34a* 62 5 3 0 0 0 
hsa-mir-34b 5 1 0 0 0 0 
hsa-mir-34b* 0 46 0 0 0 2 
hsa-mir-34c-3p 0 10 0 0 0 0 
hsa-mir-34c-5p 470 57 14 4 8 1 
hsa-mir-92a 19136 8304 9 2 9 1 
hsa-mir-92b 551 108 0 0 0 0 
hsa-mir-92b* 0 12 0 0 0 0 
hsa-mir-93 20191 3159 15 3 4 1 
hsa-mir-93* 193 24 1 0 0 0 
hsa-mir-96 33575 2904 210 4 7 0 
hsa-mir-96* 1 20 0 4 0 0 
hsa-mir-98 54 13 3 0 2 0 
hsa-mir-99a 2 0 3 1 8 1 
hsa-mir-99a* 2 0 0 0 0 0 
hsa-mir-99b 360 51 0 0 1 0 
hsa-mir-99b* 44 7 0 0 0 0 
hsa-mir-100 0 1 2 0 2 0 
hsa-mir-101 2902 6281 7 2 10 0 
hsa-mir-101* 71 7 8 0 0 0 
hsa-mir-103 18627 2603 18 3 18 5 
hsa-mir-103-2* 26 6 0 0 0 0 
hsa-mir-105* 0 1 0 0 0 0 
hsa-mir-106a 93 106 0 0 0 0 
hsa-mir-106b 20134 2461 106 11 6 1 
hsa-mir-106b* 168 41 0 1 0 0 
hsa-mir-107 631 91 0 0 0 1 
hsa-mir-122 43 8 63 1 93 3 
hsa-mir-124 2482 351 0 0 0 0 
hsa-mir-124* 73 8 0 0 0 0 
hsa-mir-125a-3p 77 13 0 0 1 0 
hsa-mir-125a-5p 1503 196 8 3 5 1 
hsa-mir-125b 275 33 71 6 54 7 
hsa-mir-125b-1* 14 4 1 5 1 0 
hsa-mir-126 844 104 1 0 0 0 
hsa-mir-126* 212 21 1 0 0 0 
hsa-mir-127-3p 12994 1908 13 1 13 1 
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hsa-mir-127-5p 1336 155 5 1 0 0 
hsa-mir-128 957 138 0 0 1 0 
hsa-mir-129* 39 13 0 0 0 0 
hsa-mir-129-3p 118 23 0 0 5 0 
hsa-mir-129-5p 66 6 0 0 1 0 
hsa-mir-130a 57203 6417 33 3 34 7 
hsa-mir-130a* 1 0 0 0 0 0 
hsa-mir-130b 13134 1495 2 0 3 0 
hsa-mir-130b* 1155 96 1 0 0 0 
hsa-mir-132 32 4 0 0 0 0 
hsa-mir-132* 7 0 0 0 0 0 
hsa-mir-133a 11 0 2 0 5 0 
hsa-mir-134 1323 281 15 2 0 3 
hsa-mir-135a 60 66 0 0 0 0 
hsa-mir-135a* 1 0 0 0 0 0 
hsa-mir-135b 13291 1672 56 4 0 0 
hsa-mir-135b* 117 8 1 4 0 0 
hsa-mir-136 12218 1281 36 5 7 0 
hsa-mir-136* 1397 116 2 0 5 0 
hsa-mir-137 10 0 0 0 0 0 
hsa-mir-138 169 30 1 0 0 0 
hsa-mir-138-2* 8 1 0 0 0 0 
hsa-mir-139-3p 1 0 0 0 0 0 
hsa-mir-139-5p 107 23 1 0 0 0 
hsa-mir-140-3p 710 85 1 0 1 2 
hsa-mir-140-5p 781 130 5 0 0 0 
hsa-mir-141 3671 336 0 0 0 0 
hsa-mir-141* 0 76 0 2 0 0 
hsa-mir-142-3p 1523 255 7 0 7 0 
hsa-mir-142-5p 206 17 1 0 0 0 
hsa-mir-143 193 19 8 0 4 0 
hsa-mir-143* 15 0 1 0 0 0 
hsa-mir-144 12 3 6 0 13 0 
hsa-mir-145 317 36 35 3 18 4 
hsa-mir-145* 37 1 0 0 0 0 
hsa-mir-146a 115 9 13 0 2 0 
hsa-mir-146b-5p 126 10 0 0 0 0 
hsa-mir-147 0 2 0 0 0 0 
hsa-mir-147b 70 2 0 0 0 0 
hsa-mir-148a 6761 679 24 0 28 1 
hsa-mir-148a* 80 7 7 1 0 0 
hsa-mir-148b 3287 358 9 0 9 0 
hsa-mir-148b* 57 6 0 0 0 0 
hsa-mir-149 320 35 0 0 0 0 
hsa-mir-149* 0 0 0 1 0 2 
hsa-mir-150 1381 134 7 0 4 0 
hsa-mir-150* 0 5 0 0 0 0 
hsa-mir-151-3p 1 604 0 1 1 0 
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hsa-mir-151-5p 2492 235 6 0 0 0 
hsa-mir-152 204 23 3 1 7 0 
hsa-mir-153 35 3 0 0 0 0 
hsa-mir-154 893 96 7 0 0 0 
hsa-mir-154* 7185 826 1 1 0 0 
hsa-mir-155 0 446 0 0 0 0 
hsa-mir-181a 46 13 14 0 6 0 
hsa-mir-181b 22 11 2 0 2 0 
hsa-mir-181c 1991 258 5 0 1 0 
hsa-mir-181c* 73 12 0 1 0 0 
hsa-mir-181d 2654 339 0 0 0 0 
hsa-mir-182 1305 2831 21 27 0 0 
hsa-mir-182* 53 7 3 2 0 0 
hsa-mir-183 9716 927 60 2 0 0 
hsa-mir-183* 838 113 3 1 0 0 
hsa-mir-184 2 0 0 0 0 0 
hsa-mir-185 643 123 0 0 0 0 
hsa-mir-185* 11 3 0 0 0 0 
hsa-mir-186 2114 215 2 0 0 0 
hsa-mir-186* 1 59 0 1 0 0 
hsa-mir-187 83 57 0 0 0 0 
hsa-mir-187* 4 0 0 0 0 0 
hsa-mir-188-3p 14 0 0 0 0 0 
hsa-mir-188-5p 191 31 1 0 0 0 
hsa-mir-190 841 85 3 0 1 0 
hsa-mir-190b 19 4 0 0 0 0 
hsa-mir-191 10843 1643 42 4 7 0 
hsa-mir-191* 0 8 0 0 0 0 
hsa-mir-192 134 17 7 0 0 0 
hsa-mir-192* 2 0 0 0 0 0 
hsa-mir-193a-3p 63 31 2 0 2 0 
hsa-mir-193a-5p 0 17 1 1 0 0 
hsa-mir-193b 0 74 0 1 0 0 
hsa-mir-193b* 4 0 0 0 0 0 
hsa-mir-194 156 13 0 0 0 0 
hsa-mir-194* 3 0 0 0 0 0 
hsa-mir-195 1272 123 7 0 1 0 
hsa-mir-195* 5 3 0 0 0 0 
hsa-mir-196a 55 8 7 0 0 1 
hsa-mir-196b 8 1 1 0 0 0 
hsa-mir-199a-3p 235 26 108 6 70 7 
hsa-mir-199a-5p 20 24 12 4 15 1 
hsa-mir-199b-5p 1 1 0 0 0 0 
hsa-mir-200a 4915 433 0 0 0 0 
hsa-mir-200a* 52 7 1 0 0 0 
hsa-mir-200b 4890 519 0 0 0 0 
hsa-mir-200b* 191 14 1 0 0 0 
hsa-mir-200c 4089 642 2 0 0 0 
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hsa-mir-200c* 18 3 0 0 0 0 
hsa-mir-202* 4 0 0 0 0 0 
hsa-mir-203 123 24 4 2 7 1 
hsa-mir-204 9 9 0 0 0 0 
hsa-mir-205 1131 132 61 3 2 0 
hsa-mir-205* 7 12 0 1 0 0 
hsa-mir-206 1 0 2 0 0 0 
hsa-mir-208a 9 1 0 0 0 0 
hsa-mir-208b 4 1 0 0 0 0 
hsa-mir-210 1722 414 1 0 0 0 
hsa-mir-212 18 3 0 0 0 0 
hsa-mir-214 0 0 0 0 1 0 
hsa-mir-214* 0 0 1 0 1 0 
hsa-mir-215 0 1 0 0 0 0 
hsa-mir-216b 3 0 0 0 0 0 
hsa-mir-218 159 9 0 0 0 0 
hsa-mir-218-2* 1 0 0 0 0 0 
hsa-mir-219-1-3p 0 5 0 0 0 0 
hsa-mir-219-5p 160 8 0 0 1 0 
hsa-mir-221 617 135 29 4 17 2 
hsa-mir-221* 15 2 0 0 0 0 
hsa-mir-222 789 76 15 1 21 2 
hsa-mir-222* 4 0 0 0 0 0 
hsa-mir-223 1 0 0 0 1 0 
hsa-mir-224 0 64 0 1 0 0 
hsa-mir-224* 1 0 0 0 0 0 
hsa-mir-296-3p 2122 568 16 3 2 2 
hsa-mir-296-5p 1301 237 1 0 0 0 
hsa-mir-297 6469 3122 1 4 0 0 
hsa-mir-299-3p 0 803 0 0 0 2 
hsa-mir-299-5p 1212 167 2 1 0 0 
hsa-mir-301a 7094 4019 3 0 4 1 
hsa-mir-301b 1 9 0 0 0 0 
hsa-mir-302a 2726 379 0 0 0 0 
hsa-mir-302a* 0 223 0 3 0 1 
hsa-mir-302b 3939 408 0 0 0 0 
hsa-mir-302b* 0 0 0 0 0 1 
hsa-mir-302c 351 66 0 0 0 0 
hsa-mir-302c* 3 123 0 1 0 0 
hsa-mir-302d 7055 746 0 0 0 0 
hsa-mir-302d* 116 22 1 0 0 0 
hsa-mir-302e 26 149 0 0 0 0 
hsa-mir-302f 2 8 0 0 0 0 
hsa-mir-320a 3203 601 13 2 39629 5131 
hsa-mir-320b 25 12 0 1 93 50 
hsa-mir-320c 13 36 0 0 96 270 
hsa-mir-320d 3 0 1 0 40 91 
hsa-mir-320e 5 125 0 0 60 1949 
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hsa-mir-323-3p 2267 274 0 0 0 0 
hsa-mir-323-5p 52 17 1 0 0 0 
hsa-mir-323b-3p 0 1 0 0 0 0 
hsa-mir-324-3p 706 74 1 0 1 0 
hsa-mir-324-5p 515 50 0 0 1 0 
hsa-mir-326 27 3 0 0 0 0 
hsa-mir-328 52 8 0 0 0 0 
hsa-mir-330-3p 0 58 0 0 0 0 
hsa-mir-330-5p 173 20 5 0 0 0 
hsa-mir-331-3p 147 39 1 0 0 0 
hsa-mir-331-5p 15 3 1 0 0 0 
hsa-mir-335 1745 179 13 0 3 1 
hsa-mir-335* 1495 245 0 0 0 0 
hsa-mir-337-3p 19 1 0 0 0 1 
hsa-mir-338-3p 45 7 0 0 0 0 
hsa-mir-338-5p 4 0 0 0 0 0 
hsa-mir-339-3p 0 90 0 0 0 0 
hsa-mir-339-5p 571 148 38 4 36 5 
hsa-mir-340 989 74 9 0 0 0 
hsa-mir-340* 13 2 0 0 0 0 
hsa-mir-342-3p 841 87 0 0 1 1 
hsa-mir-342-5p 102 11 1 0 0 0 
hsa-mir-361-3p 51 8 0 0 1 0 
hsa-mir-361-5p 1072 245 15 0 0 1 
hsa-mir-362-3p 1 168 0 0 0 0 
hsa-mir-362-5p 60 194 0 0 0 0 
hsa-mir-363 3905 446 0 0 1 0 
hsa-mir-363* 0 3 0 0 0 0 
hsa-mir-365 158 17 6 1 1 0 
hsa-mir-367 1467 160 1 0 0 0 
hsa-mir-367* 0 13 0 4 0 0 
hsa-mir-369-3p 5148 462 12 3 9 0 
hsa-mir-369-5p 714 69 10 0 0 0 
hsa-mir-370 962 223 0 0 0 0 
hsa-mir-371-3p 0 106 0 0 0 0 
hsa-mir-371-5p 56 166273 0 3315 0 17 
hsa-mir-373* 1 104 0 1 0 0 
hsa-mir-374a 0 9 0 0 0 0 
hsa-mir-374b 1086 163 2 0 0 0 
hsa-mir-374b* 88 6 0 0 0 0 
hsa-mir-375 11 2 0 0 0 0 
hsa-mir-376a 39 5207 0 0 0 1 
hsa-mir-376a* 275 25 2 0 0 0 
hsa-mir-376b 0 48 0 0 0 0 
hsa-mir-376c 0 2290 0 2 0 7 
hsa-mir-377 1633 154 2 0 0 0 
hsa-mir-377* 113 16 3 0 0 0 
hsa-mir-378 1980 195 5 0 6 1 
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hsa-mir-378* 48 6 0 0 0 0 
hsa-mir-378b 7 4 1 0 0 0 
hsa-mir-378c 3 1 0 0 0 0 
hsa-mir-379 1625 129 1 0 1 0 
hsa-mir-379* 1032 329 1 0 0 0 
hsa-mir-380 1 1982 0 3 0 2 
hsa-mir-380* 1 2 0 0 0 0 
hsa-mir-381 2088 652 0 1 1 1 
hsa-mir-382 1491 208 3 1 0 1 
hsa-mir-384 0 4 0 0 0 0 
hsa-mir-409-3p 3809 618 1 2 1 0 
hsa-mir-409-5p 806 77 14 0 0 0 
hsa-mir-410 2552 253 2 0 3 2 
hsa-mir-411 2658 241 20 0 1 0 
hsa-mir-411* 3708 1582 0 0 0 0 
hsa-mir-412 35 5 1 0 0 0 
hsa-mir-421 642 122 1 0 0 0 
hsa-mir-423-3p 882 134 1 0 0 0 
hsa-mir-423-5p 771 159 66 7 10 1 
hsa-mir-424 119 485 6 4 12 1 
hsa-mir-425 803 83 2 0 1 0 
hsa-mir-425* 70 20 1 0 0 0 
hsa-mir-429 2 11 0 0 0 0 
hsa-mir-431 2392 301 5 2 2 0 
hsa-mir-431* 62 34 0 0 0 0 
hsa-mir-432 0 0 2 1 0 0 
hsa-mir-433 1851 210 2 0 3 0 
hsa-mir-449a 57 7 0 0 0 0 
hsa-mir-450a 292 36 10 0 0 0 
hsa-mir-450b-3p 0 4 0 0 0 0 
hsa-mir-450b-5p 0 149 0 1 0 0 
hsa-mir-451 111 11 127 4 115 21 
hsa-mir-452 11 1 0 0 0 0 
hsa-mir-455-3p 0 8 0 0 0 0 
hsa-mir-455-5p 17 0 0 0 0 0 
hsa-mir-483-3p 0 4 0 0 0 0 
hsa-mir-484 2475 809 2 0 19480 4888 
hsa-mir-485-3p 1653 285 0 0 0 0 
hsa-mir-485-5p 149 43 2 0 0 0 
hsa-mir-486-5p 8 1 2 1 2 0 
hsa-mir-487a 0 2 0 0 0 0 
hsa-mir-487b 1187 111 0 0 0 0 
hsa-mir-488 0 4 0 0 0 0 
hsa-mir-491-3p 0 0 0 0 0 1 
hsa-mir-491-5p 3 1 0 0 0 0 
hsa-mir-493* 94 7 0 0 0 0 
hsa-mir-494 2909 393 2 0 5 0 
hsa-mir-495 4079 384 0 0 1 0 
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hsa-mir-496 248 28 0 0 2 0 
hsa-mir-497 1213 78 0 0 1 0 
hsa-mir-497* 14 0 0 0 0 0 
hsa-mir-499-3p 5 0 0 0 0 1 
hsa-mir-499-5p 176 15 35 2 7 0 
hsa-mir-500 0 1 0 0 0 0 
hsa-mir-500* 0 4 0 0 0 0 
hsa-mir-501-3p 26 20 0 0 0 0 
hsa-mir-501-5p 13 135 4 24 0 0 
hsa-mir-502-3p 5 388 0 0 0 2 
hsa-mir-502-5p 0 25 0 0 0 0 
hsa-mir-503 1 120 0 1 0 0 
hsa-mir-504 2 1 1 0 0 0 
hsa-mir-505 12 10 1 0 1 0 
hsa-mir-505* 14 3 0 0 0 0 
hsa-mir-518a-3p 0 12 0 0 0 0 
hsa-mir-520a-3p 2 24 0 0 0 0 
hsa-mir-520d-3p 0 18 0 0 0 0 
hsa-mir-520e 2 2917 0 0 0 1 
hsa-mir-520g 13 337 0 1 0 0 
hsa-mir-521 0 5 0 0 0 0 
hsa-mir-526b* 0 1 0 0 0 0 
hsa-mir-532-3p 84 8 1 0 0 0 
hsa-mir-532-5p 257 30 12 0 0 0 
hsa-mir-539 457 53 0 0 0 0 
hsa-mir-541 0 0 0 0 0 3 
hsa-mir-542-3p 114 20 0 2 1 0 
hsa-mir-542-5p 2 3 0 0 0 0 
hsa-mir-543 5765 638 2 0 1 0 
hsa-mir-544 8 32 0 0 0 0 
hsa-mir-549 0 0 0 1 0 0 
hsa-mir-572 0 0 0 1 0 1 
hsa-mir-574-3p 2 2 0 0 0 0 
hsa-mir-574-5p 39 25 0 32 3 49 
hsa-mir-578 0 1 0 0 0 0 
hsa-mir-582-5p 277 110 6 1 1 0 
hsa-mir-592 7 2 0 0 0 0 
hsa-mir-598 0 1 0 0 0 0 
hsa-mir-615-3p 0 0 2 1 0 0 
hsa-mir-651 0 1 0 0 0 0 
hsa-mir-652 526 72 4 0 19 0 
hsa-mir-655 0 0 0 1 0 0 
hsa-mir-660 0 0 0 1 0 0 
hsa-mir-663b 0 0 0 1 0 0 
hsa-mir-664* 0 1 0 0 0 0 
hsa-mir-665 30 5073 0 0 0 0 
hsa-mir-668 38 10 0 0 44 11 
hsa-mir-670 0 4 0 0 0 0 
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hsa-mir-671-3p 10 1 0 2 0 0 
hsa-mir-671-5p 159 65 2 1 0 0 
hsa-mir-708 3106 304 3 0 3 1 
hsa-mir-708* 247 24 1 0 1 0 
hsa-mir-718 0 0 0 4 0 0 
hsa-mir-720 866 119 1465 86 1996 210 
hsa-mir-744 1569 236 5 0 0 0 
hsa-mir-744* 33 7 0 0 0 0 
hsa-mir-758 614 77 0 0 0 0 
hsa-mir-760 4 2 0 0 0 0 
hsa-mir-762 0 0 0 1 0 0 
hsa-mir-874 5 0 1 0 1 0 
hsa-mir-877 25 4 0 0 419 35 
hsa-mir-877* 59 27 0 1 525 226 
hsa-mir-885-5p 0 0 0 0 1 0 
hsa-mir-935 24 2 0 0 0 0 
hsa-mir-1197 221 16 1 0 0 0 
hsa-mir-1203 0 0 0 1 0 1 
hsa-mir-1225-5p 0 0 0 1 1 0 
hsa-mir-1244 1 0 0 0 0 0 
hsa-mir-1246 8 11 26 6 27 7 
hsa-mir-1247 6 1 2 0 0 0 
hsa-mir-1248 64 12 173 4 258 18 
hsa-mir-1249 12 1 0 1 0 3 
hsa-mir-1251 1 0 0 0 0 0 
hsa-mir-1259 0 0 0 0 0 1 
hsa-mir-1260 5 698 1 3314 2 3862 
hsa-mir-1260b 143 11 723 29 719 56 
hsa-mir-1261 0 99 0 226 0 359 
hsa-mir-1265 0 0 0 1 0 0 
hsa-mir-1266 0 0 0 2 0 0 
hsa-mir-1268 0 137 0 417 0 374 
hsa-mir-1274a 101 21 515 22 289 41 
hsa-mir-1274b 660 95 1807 110 1724 191 
hsa-mir-1280 12 15 27 85 94 128 
hsa-mir-1285 0 0 0 0 0 1 
hsa-mir-1290 0 21 0 34 0 54 
hsa-mir-1297 0 7 0 0 0 0 
hsa-mir-1298 2 0 0 0 0 0 
hsa-mir-1306 7 5 0 0 0 0 
hsa-mir-1307 0 0 0 0 0 0 
hsa-mir-1308 1555 5658 10237 21398 5165 20376 
hsa-mir-1322 0 0 2 0 0 0 
hsa-mir-1323 0 1 0 0 0 0 
hsa-mir-1469 0 60 1 422 0 377 
hsa-mir-1471 0 1 0 2 0 1 
hsa-mir-1826 376 313 625 176 616 194 
hsa-mir-1827 0 2 0 0 0 0 
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hsa-mir-1915 0 0 0 0 0 1 
hsa-mir-1973 6 2 3 0 16 5 
hsa-mir-1979 27 301 151 1670 180 1284 
hsa-mir-3065-5p 1 0 0 0 0 0 
hsa-mir-3074 9 0 0 0 0 0 
hsa-mir-3141 0 0 0 0 0 1 
hsa-mir-3142 0 0 0 1 0 3 
hsa-mir-3154 0 0 1 1 0 0 
hsa-mir-3168 0 158 1 325 2 392 
hsa-mir-3178 0 1 0 0 0 0 
hsa-mir-3182 0 18 0 81 0 67 
hsa-mir-3186-3p 0 1 0 0 0 0 
hsa-mir-3195 0 8 0 1 0 6 
hsa-mir-4286 250 108 482 187 554 229 
hsa-mir-4289 1 14 0 0 0 0 
hsa-mir-4291 1 18 0 0 0 0 
hsa-mir-4298 0 0 0 1 0 0 
hsa-mir-4305 0 1 0 0 0 0 
hsa-mir-4306 0 11 0 0 0 0 
hsa-mir-4317 0 7 0 0 0 0 
hsa-mir-4318 0 22 0 0 0 0 
hsa-mir-4328 0 4 0 0 0 1 
hsa-mir-4330 0 1 0 2 0 1 
 
The libraries were analysed in the reference of miRBase v15.0. The human miRNAs that are 
not present here have no reads in all three libraries.  
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